Accurate, Robust, and Automated Longitudinal and Cro

NeuroImage 17, 479-489 DOI: 10.1006/nimg.2002.1040

Citation Report

#	Article	IF	CITATIONS
1	Diffuse Axonal and Tissue Injury in Patients With Multiple Sclerosis With Low Cerebral Lesion Load and No Disability. Archives of Neurology, 2002, 59, 1565.	4.5	176
2	Fast robust automated brain extraction. Human Brain Mapping, 2002, 17, 143-155.	3.6	9,218
3	Enhancing Brain and Cognitive Function of Older Adults Through Fitness Training. Journal of Molecular Neuroscience, 2003, 20, 213-222.	2.3	97
4	MR evidence of structural and metabolic changes in brains of patients with Werner?s syndrome. Journal of Neurology, 2003, 250, 1169-1173.	3.6	13
5	Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions. Journal of Neurology, 2003, 250, 456-460.	3.6	56
6	Imaging neuronal and axonal degeneration in multiple sclerosis. Neurological Sciences, 2003, 24, s283-s286.	1.9	38
7	Quantitative image analysis: software systems in drug development trials. Drug Discovery Today, 2003, 8, 451-458.	6.4	22
8	Methodological considerations for measuring rates of brain atrophy. Journal of Magnetic Resonance Imaging, 2003, 18, 16-24.	3.4	80
9	Characterization and propagation of uncertainty in diffusion-weighted MR imaging. Magnetic Resonance in Medicine, 2003, 50, 1077-1088.	3.0	2,715
10	Biomechanical simulation of atrophy in MR images. , 2003, , .		5
10	Biomechanical simulation of atrophy in MR images. , 2003, , . Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177.	0.6	5
	Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI	0.6 4.2	
11	Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177. A functional magnetic resonance imaging study of patients with secondary progressive multiple		47
11 12	 Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177. A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. NeuroImage, 2003, 19, 1770-1777. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. Journal of Neurology, 	4.2	47 88
11 12 14	 Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177. A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. NeuroImage, 2003, 19, 1770-1777. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1371-1381. 	4.2 1.9	47 88 69
11 12 14 15	 Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177. A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. Neuroimage, 2003, 19, 1770-1777. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1371-1381. Evidence of early cortical atrophy in MS. Neurology, 2003, 60, 1157-1162. Clinical neurophysiology on the internet: www.neurophys.com. Journal of Neurology, Neurosurgery 	4.2 1.9 1.1	47 88 69 446
11 12 14 15 16	 Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177. A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. NeuroImage, 2003, 19, 1770-1777. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1371-1381. Evidence of early cortical atrophy in MS. Neurology, 2003, 60, 1157-1162. Clinical neurophysiology on the internet: www.neurophys.com. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1381-1381. Cord damage elicits brain functional reorganization after a single episode of myelitis. Neurology, 	4.2 1.9 1.1 1.9	47 88 69 446 0

#	Article	IF	CITATIONS
20	Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain, 2003, 126, 2750-2760.	7.6	162
21	Age-related Changes in Conventional, Magnetization Transfer, and Diffusion-Tensor MR Imaging Findings: Study with Whole-Brain Tissue Histogram Analysis1ÂÂ. Radiology, 2003, 227, 731-738.	7.3	134
22	Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Frontiers in Bioscience - Landmark, 2004, 9, 647.	3.0	70
23	Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment. Neurology, 2004, 63, 89-93.	1.1	293
24	Altered cerebellar functional connectivity mediates potential adaptive plasticity in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 840-846.	1.9	74
25	Chronic Back Pain Is Associated with Decreased Prefrontal and Thalamic Gray Matter Density. Journal of Neuroscience, 2004, 24, 10410-10415.	3.6	1,223
26	Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology, 2004, 62, 476-478.	1.1	118
27	Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology, 2004, 62, 591-600.	1.1	726
28	Controlling for premorbid brain size in imaging studies: T1-derived cranium scaling factor vs. T2-derived intracranial vault volume. Psychiatry Research - Neuroimaging, 2004, 131, 169-176.	1.8	22
29	Pathologic issues and new methodologies in the evaluation of non-Alzheimer dementias. Clinical Neuroscience Research, 2004, 3, 413-426.	0.8	3
30	The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. Journal of Neurology, 2004, 251, 432-439.	3.6	68
31	Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology, 2004, 39, 1613-1622.	7.3	87
32	Pathologic issues and new methodologies in the evaluation of non-Alzheimer dementias. Clinical Neuroscience Research, 2004, , .	0.8	0
33	Development & Aging. NeuroImage, 2004, 22, e451-e588.	4.2	0
34	High Altitude Cerebral Edema. High Altitude Medicine and Biology, 2004, 5, 136-146.	0.9	265
35	An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease. NeuroImage, 2004, 22, 134-143.	4.2	48
36	Correction of differential intensity inhomogeneity in longitudinal MR images. NeuroImage, 2004, 23, 75-83.	4.2	113
37	A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. NeuroImage, 2004, 23, 724-738.	4.2	1,105

ARTICLE IF CITATIONS # A meta-algorithm for brain extraction in MRI. NeuroImage, 2004, 23, 625-637. 4.2 98 38 Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. NeuroImage, 4.2 522 2004, 23, 708-716. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. NeuroImage, 40 4.2 147 2004, 23, 1168-1175. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage, 2004, 11,375 23, S208-S219. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of 42 multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2004, 364, 13.7 246 1489-1496. Brain atrophy, interferon beta, and treatment trials in multiple sclerosis. Lancet, The, 2004, 364, 13.7 1463-1464. Influence of Apolipoprotein E ϵ4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple 44 4.5 45 Sclerosis. Archives of Neurology, 2004, 61, 536. Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis. 4.5 36 Archives of Neurology, 2005, 62, 898-902. Magnetic Resonance Approaches to Brain Aging and Alzheimer Disease-associated Neuropathology. 1.2 30 46 Topics in Magnetic Resonance Imaging, 2005, 16, 439-452. Diffusion-Tensor Magnetic Resonance Imaging Detects Normal-Appearing White Matter Damage Unrelated to Short-term Disease Activity in Patients at the Earliest Clinical Stage of Multiple 4.5 101 Sclerosis. Archives of Neurology, 2005, 62, 803. Multiple Sclerosis Medical Image Analysis and Information Management. Journal of Neuroimaging, 22 48 2.0 2005, 15, 103S-117S. Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain 49 26 Atrophy Measurement in Multiple Sclerosis. Journal of Neuroimaging, 2005, 15, 27-36. Identifying lesions on structural brain imagesâ€"Validation of the method and application to 50 1.6 58 neuropsychological patients. Brain and Language, 2005, 94, 167-177. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. 1.8 271 BMC Neurology, 2005, 5, 23. White matter lesion progression, brain atrophy, and cognitive decline: The Austrian stroke prevention 52 357 5.3 study. Annals of Neurology, 2005, 58, 610-616. Excellent cognitive performance despite massive cerebral white matter changes. Neuroradiology, 2.2 2005, 47, 749-752. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease 54 1.1 48 evolution. Neurology, 2005, 65, 1626-1630. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. 1.1 Neurology, 2005, 65, 633-635.

#	Article	IF	CITATIONS
56	Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology, 2005, 65, 1126-1128.	1.1	72
57	Dehydration confounds the assessment of brain atrophy. Neurology, 2005, 64, 548-550.	1.1	157
58	The Effects of Early Lead Exposure on the Brains of Adult Rhesus Monkeys: A Volumetric MRI Study. Toxicological Sciences, 2005, 85, 963-975.	3.1	13
59	Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 578.	4.5	103
60	Risk factors for progression of brain atrophy in aging. Neurology, 2005, 64, 1704-1711.	1.1	355
61	Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain, 2005, 128, 1454-1460.	7.6	135
62	Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain, 2005, 128, 2732-2741.	7.6	518
63	Increased sensitivity in neuroimaging analyses using robust regression. Neurolmage, 2005, 26, 99-113.	4.2	256
64	A platform for distributed analysis of neuroimaging data on global grids. , 2005, , .		7
65	Brain volumes in healthy adults aged 40 years and over: a voxel-based morphometry study. Aging Clinical and Experimental Research, 2005, 17, 329-336.	2.9	54
66	Age-related alterations in white matter microstructure measured by diffusion tensor imaging. Neurobiology of Aging, 2005, 26, 1215-1227.	3.1	751
67	Structural Brain Imaging Evidence for Multiple Pathological Processes at Different Stages of Brain Development in Schizophrenia. Schizophrenia Bulletin, 2005, 31, 672-696.	4.3	479
68	Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images. IEEE Transactions on Medical Imaging, 2005, 24, 1548-1565.	8.9	335
69	Deformation-based mapping of volume change from serial brain MRI in the presence of local tissue contrast change. IEEE Transactions on Medical Imaging, 2006, 25, 626-639.	8.9	142
70	Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 355, 1124-1140.	27.0	996
71	Phenomenological Model of Diffuse Global and Regional Atrophy Using Finite-Element Methods. IEEE Transactions on Medical Imaging, 2006, 25, 1417-1430.	8.9	32
72	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 6-15.	1.3	203
73	A consistent relationship between local white matter architecture and functional specialisation in medial frontal cortex. NeuroImage, 2006, 30, 220-227.	4.2	53

#	Article	IF	CITATIONS
74	An fMRI study of the motor system in patients with neuropsychiatric systemic lupus erythematosus. NeuroImage, 2006, 30, 478-484.	4.2	37
75	Common MRI acquisition non-idealities significantly impact the output of the boundary shift integral method of measuring brain atrophy on serial MRI. NeuroImage, 2006, 30, 1196-1202.	4.2	42
76	Statistical parametric mapping of brain morphology: Sensitivity is dramatically increased by using brain-extracted images as inputs. Neurolmage, 2006, 30, 1187-1195.	4.2	56
77	Brain atrophy in long-term abstinent alcoholics who demonstrate impairment on a simulated gambling task. NeuroImage, 2006, 32, 1465-1471.	4.2	92
78	Predicting neuropsychological abnormalities in multiple sclerosis. Journal of the Neurological Sciences, 2006, 245, 67-72.	0.6	57
79	Neocortical volume decrease in relapsing–remitting multiple sclerosis with mild cognitive impairment. Journal of the Neurological Sciences, 2006, 245, 195-199.	0.6	30
80	Motor cortex maps articulatory features of speech sounds. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7865-7870.	7.1	555
81	Contributions of Cognitive Neuroscience to the Understanding of Behavior and Aging. , 2006, , 57-83.		18
82	An fMRI Analysis of Neural Activity during Perceived Zone-State Performance. Journal of Sport and Exercise Psychology, 2006, 28, 421-433.	1.2	10
83	Magnetization Transfer Magnetic Resonance Imaging and Clinical Changes in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2006, 63, 736.	4.5	33
84	Brain volume measurements in patients with human T-cell lymphotropic virus-1–associated tropical spastic paraparesis. Journal of NeuroVirology, 2006, 12, 349-355.	2.1	7
85	Diffuse structural and metabolic brain changes in Fabry disease. Journal of Neurology, 2006, 253, 434-440.	3.6	23
86	MRI quantification of gray and white matter damage in patients with early–onset multiple sclerosis. Journal of Neurology, 2006, 253, 903-907.	3.6	58
87	Cortical damage in brains of patients with adult-form of myotonic dystrophy type 1 and no or minimal MRI abnormalities. Journal of Neurology, 2006, 253, 1471-1477.	3.6	27
88	The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurology, The, 2006, 5, 158-170.	10.2	406
89	Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Movement Disorders, 2006, 21, 1317-1325.	3.9	306
90	Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2006, 23, 605-618.	3.4	103
91	Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Annals of Neurology, 2006, 59, 634-639.	5.3	69

#	Article	IF	CITATIONS
92	Aerobic Exercise Training Increases Brain Volume in Aging Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 1166-1170.	3.6	1,599
93	Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis. Neurological Research, 2006, 28, 275-279.	1.3	8
94	Heritability of MRI Lesion Volume in CADASIL. Stroke, 2006, 37, 2684-2689.	2.0	66
95	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain, 2006, 129, 2628-2634.	7.6	122
96	Manifestations of early brain recovery associated with abstinence from alcoholism. Brain, 2006, 130, 36-47.	7.6	169
97	Whole-Brain T1 Mapping in Multiple Sclerosis: Global Changes of Normal-appearing Gray and White Matter. Radiology, 2006, 240, 811-820.	7.3	162
98	Intracranial dermoid cyst rupture with subarachnoid and intraventricular fat dissemination. Neurology, 2006, 66, 1937-1937.	1.1	13
99	Diffusion tensor magnetic resonance imaging at 3.0 tesla shows subtle cerebral grey matter abnormalities in patients with migraine. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 686-689.	1.9	40
100	Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis. Archives of Neurology, 2006, 63, 1175.	4.5	157
101	Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. Neurology, 2006, 66, 535-539.	1.1	109
102	Brain volume changes in CADASIL. Neurology, 2006, 66, 1517-1522.	1.1	121
104	Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology, 2006, 66, 1935-1937.	1.1	94
105	Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain, 2007, 130, 1767-1776.	7.6	229
106	In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain, 2007, 130, 2211-2219.	7.6	141
107	Testosterone Treatment in Multiple Sclerosis. Archives of Neurology, 2007, 64, 683.	4.5	188
108	Connectivity of the human pedunculopontine nucleus region and diffusion tensor imaging in surgical targeting. Journal of Neurosurgery, 2007, 107, 814-820.	1.6	113
109	Structural magnetic resonance imaging-derived biomarkers for Alzheimer's disease. Biomarkers in Medicine, 2007, 1, 79-92.	1.4	4
110	Longitudinal Changes in Global Brain Volume between 79 and 409 Days after Traumatic Brain Injury: Relationship with Duration of Coma. Journal of Neurotrauma, 2007, 24, 766-771.	3.4	108

#	Article	IF	CITATIONS
111	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 722-730.	3.0	91
112	Whole-Brain Histogram and Voxel-Based Analyses of Diffusion Tensor Imaging in Patients with Leukoaraiosis: Correlation with Motor and Cognitive Impairment. American Journal of Neuroradiology, 2007, 28, 1313-1319.	2.4	84
113	Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology, 2007, 69, 1603-1609.	1.1	372
114	A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis. American Journal of Neuroradiology, 2007, 28, 1659-1661.	2.4	33
115	Assessing "occult" cervical cord damage in patients with neuropsychiatric systemic lupus erythematosus using diffusion tensor MRI. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 893-895.	1.9	7
116	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple Sclerosis Journal, 2007, 13, 1068-1070.	3.0	53
117	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2007, 64, 1157.	4.5	203
118	Preservation of gray matter volume in multiple sclerosis patients with the MetÂallele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Human Molecular Genetics, 2007, 16, 2659-2668.	2.9	93
119	Whole-Brain N-Acetylaspartate as a Surrogate Marker of Neuronal Damage in Diffuse Neurologic Disorders. American Journal of Neuroradiology, 2007, 28, 1843-1849.	2.4	97
120	Determinants of Cerebral Atrophy Rate at the Time of Diagnosis of Multiple Sclerosis. Archives of Neurology, 2007, 64, 190.	4.5	28
121	An Independent Meta-Analysis Using Summary Data for Clinical Response, Remission, and Discontinuation for Any Reason from the 6 Pivotal Phase III Randomized Clinical Trials of Duloxetine in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2007, 27, 219-221.	1.4	6
122	N-Acetyl Cysteine in the Treatment of Grooming Disorders. Journal of Clinical Psychopharmacology, 2007, 27, 227-229.	1.4	87
123	Time-Dependent Clearance Decrements of Fluvoxamine in Depressed Inpatients. Journal of Clinical Psychopharmacology, 2007, 27, 231-233.	1.4	1
124	An Open-Label Trial of Aripiprazole Augmentation for Treatment-Resistant Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology, 2007, 22, 207-210.	1.4	44
125	Changes in Hippocampal Volume in Patients With Post-Traumatic Stress Disorder After Sertraline Treatment. Journal of Clinical Psychopharmacology, 2007, 27, 233-235.	1.4	41
126	Smoking Cessation in Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 239-240.	1.4	1
127	Aripiprazole and Neuroleptic Malignant Syndrome. Journal of Clinical Psychopharmacology, 2007, 27, 212-214.	1.4	11
128	Cerebral activation patterns related to initiation and inhibition of hand movement. NeuroReport, 2007, 18, 1557-1560.	1.2	18

#	Article	IF	CITATIONS
129	Atypical Antipsychotic Drug-Induced Acute Laryngeal Dystonia. Journal of Clinical Psychopharmacology, 2007, 27, 206-207.	1.4	22
130	Adjuvant Levetiracetam in Adolescent Mania. Journal of Clinical Psychopharmacology, 2007, 27, 215-216.	1.4	8
131	Pancytopenia Associated With the Introduction of Oxcarbazepine. Journal of Clinical Psychopharmacology, 2007, 27, 217-218.	1.4	16
132	Manic Episode With Psychotic Symptoms Associated With High Dose of Disulfiram. Journal of Clinical Psychopharmacology, 2007, 27, 224-225.	1.4	17
133	Reply to Comments by Dr Babbar. Journal of Clinical Psychopharmacology, 2007, 27, 240.	1.4	0
134	Aripiprazole Augmentation of Tranylcypromine in Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2007, 27, 216-217.	1.4	9
135	Worsening of Obsessive-Compulsive Symptoms After Treatment With Aripiprazole. Journal of Clinical Psychopharmacology, 2007, 27, 237-238.	1.4	21
136	Exposure to Nitrous Oxide May Be Associated With High Homocysteine Plasma Levels and a Risk for Clinical Depression. Journal of Clinical Psychopharmacology, 2007, 27, 238-239.	1.4	3
137	Acute Nocturnal Akathisia Induced By Clozapine. Journal of Clinical Psychopharmacology, 2007, 27, 205.	1.4	8
138	A 6-Month Longitudinal Study of Early-Onset Tardive Dyskinesia. Journal of Clinical Psychopharmacology, 2007, 27, 210-212.	1.4	8
139	Cognitive Side Effects of Valproic Acid-Induced Hyperammonemia in Children With Epilepsy. Journal of Clinical Psychopharmacology, 2007, 27, 221-224.	1.4	20
140	Escitalopram for Compulsive Buying Disorder. Journal of Clinical Psychopharmacology, 2007, 27, 225-227.	1.4	97
141	Escitalopram-Associated Serotonin Toxicity. Journal of Clinical Psychopharmacology, 2007, 27, 229-230.	1.4	8
142	Amenorrhea After Sertraline Introduction in an Amisulpride-Treated Patient With Undiagnosed Polycystic Ovary Disease. Journal of Clinical Psychopharmacology, 2007, 27, 235-237.	1.4	4
143	Olanzapine-Associated Bilateral Eyelid Edema. Journal of Clinical Psychopharmacology, 2007, 22, 214-215.	1.4	12
144	Connectivity of an effective hypothalamic surgical target for cluster headache. Journal of Clinical Neuroscience, 2007, 14, 955-960.	1.5	77
145	Motor evoked potential: A reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clinical Neurophysiology, 2007, 118, 1332-1340.	1.5	39
146	Probabilistic diffusion tractography with multiple fibre orientations: What can we gain?. NeuroImage, 2007, 34, 144-155.	4.2	3,129

#	Article	IF	CITATIONS
147	Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. NeuroImage, 2007, 34, 694-701.	4.2	119
148	Cardiorespiratory fitness: A predictor of cortical plasticity in multiple sclerosis. NeuroImage, 2007, 34, 1238-1244.	4.2	107
149	Evidence for cervical cord tissue disorganisation with aging by diffusion tensor MRI. NeuroImage, 2007, 36, 728-735.	4.2	51
150	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. NeuroImage, 2007, 36, 746-754.	4.2	45
151	Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: Cross-validation of BSI, SIENA and SIENAX. NeuroImage, 2007, 36, 1200-1206.	4.2	100
152	Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. NeuroImage, 2007, 38, 529-537.	4.2	35
153	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet, The, 2007, 370, 389-397.	13.7	468
154	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Multiple Sclerosis Journal, 2007, 13, 502-508.	3.0	53
155	Brain Atrophy Is Related to Lacunar Lesions and Tissue Microstructural Changes in CADASIL. Stroke, 2007, 38, 1786-1790.	2.0	100
156	Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 215-223.	1.3	77
157	A diffusion tensor imaging study of white matter in obsessive–compulsive disorder. Depression and Anxiety, 2007, 24, 440-446.	4.1	140
158	Spatial memory and hippocampal volume in humans with unilateral vestibular deafferentation. Hippocampus, 2007, 17, 471-485.	1.9	142
159	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manuallyâ€edited SIENA and SIENAX. Journal of Magnetic Resonance Imaging, 2007, 26, 881-885.	3.4	45
160	Magnetic Resonance Imaging Evidence of Cytotoxic Cerebral Edema in Acute Mountain Sickness. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1064-1071.	4.3	154
161	White matter abnormalities in children with and at risk for bipolar disorder. Bipolar Disorders, 2007, 9, 799-809.	1.9	157
162	Cognitive Performance in Longâ€Term Abstinent Elderly Alcoholics. Alcoholism: Clinical and Experimental Research, 2007, 31, 1788-1799.	2.4	42
163	Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis. Genes, Brain and Behavior, 2007, 6, 177-183.	2.2	42
164	Cerebral Atrophy Measurement in Clinically Isolated Syndromes and Relapsing Remitting Multiple Sclerosis: A Comparison of Registrationâ€Based Methods. Journal of Neuroimaging, 2007, 17, 61-68.	2.0	49

		CITATION RE	PORT	
#	Article		IF	Citations
165	Measuring Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2007, 17, 105	-15S.	2.0	51
166	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. Jou Neuroimmunology, 2007, 187, 159-165.	ırnal of	2.3	43
167	Immune cell BDNF secretion is associated with white matter volume in multiple scleros Neuroimmunology, 2007, 188, 167-174.	sis. Journal of	2.3	57
168	Tracking Alzheimer's Disease. Annals of the New York Academy of Sciences, 2007, 109	97, 183-214.	3.8	209
169	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural N Neuroradiology, 2007, 49, 967-976.	1RI study.	2.2	251
170	A brain magnetization transfer MRI study with a clinical follow up of about four years i with clinically isolated syndromes suggestive of multiple sclerosis. Journal of Neurolog 78-83.	n patients y, 2007, 254,	3.6	16
171	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. Journal of Neurology, 2007, 254, 631-637.	1	3.6	39
172	Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: estimates. Journal of Neurology, 2007, 254, 1588-94.	Sample size	3.6	44
173	The Relationship Between Gray Matter Morphometry and Neuropsychological Perform Sample of Cognitively Healthy Adults. Brain Imaging and Behavior, 2007, 1, 3-10.	ance in a Large	2.1	53
174	Basal ganglia volume and clinical correlates in â€~preclinical' Huntington's dise Neurology, 2008, 255, 1785-1791.	ease. Journal of	3.6	64
175	A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal c 2008, 255, 683-691.	f Neurology,	3.6	65
176	A 3-year diffusion tensor MRI study of grey matter damage progression during the earl stage of MS. Journal of Neurology, 2008, 255, 1209-1214.	iest clinical	3.6	36
177	Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volun permanent tissue injury in MS. Journal of Neurology, 2008, 255, 1473-1478.	ne and	3.6	26
178	Optimizing the design of clinical trials where the outcome is a rate. Can estimating a b runâ€in period increase efficiency?. Statistics in Medicine, 2008, 27, 3717-3731.	aseline rate in a	1.6	28
179	In vivo MR imaging of hippocampal lesions in multiple sclerosis. Journal of Magnetic Re Imaging, 2008, 27, 726-731.	esonance	3.4	85
180	Automated quality control of brain MR images. Journal of Magnetic Resonance Imagin 308-319.	g, 2008, 28,	3.4	54
181	Agreement between different input image types in brain atrophy measurement in multusing SIENAX and SIENA. Journal of Magnetic Resonance Imaging, 2008, 28, 559-565.		3.4	19
182	Relationship among neuroimaging indices of cerebral health during normal aging. Hun Mapping, 2008, 29, 36-45.	nan Brain	3.6	94

#	Article	IF	CITATIONS
183	Decrease in glucose metabolism in frontal cortex associated with deterioration of microstructure of corpus callosum measured by diffusion tensor imaging in healthy elderly. Human Brain Mapping, 2008, 29, 375-384.	3.6	18
184	Gray matter atrophy is related to longâ€ŧerm disability in multiple sclerosis. Annals of Neurology, 2008, 64, 247-254.	5.3	425
185	Performance characterization in computer vision: A guide to best practices. Computer Vision and Image Understanding, 2008, 109, 305-334.	4.7	53
186	Selective Diffusion Changes of The Visual Pathways in Patients with Migraine: A 3-T Tractography Study. Cephalalgia, 2008, 28, 1061-1068.	3.9	69
187	Structural brain imaging in diabetes: A methodological perspective. European Journal of Pharmacology, 2008, 585, 208-218.	3.5	46
188	Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Clatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology, The, 2008, 7, 903-914.	10.2	437
189	Magnetic resonance imaging volumes of the hippocampus in drug-naÃ ⁻ ve patients with post-traumatic stress disorder without comorbidity conditions. Journal of Psychiatric Research, 2008, 42, 752-762.	3.1	69
190	Cross-validation of brain segmentation by SPM5 and SIENAX. Psychiatry Research - Neuroimaging, 2008, 164, 172-177.	1.8	16
191	Cortical recruitment during selective attention in multiple sclerosis: An fMRI investigation of individual differences. Neuropsychologia, 2008, 46, 2888-2895.	1.6	18
192	Preliminary evidences of a NOS2A protective effect from Relapsing–Remitting Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 264, 112-117.	0.6	7
193	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. Journal of the Neurological Sciences, 2008, 268, 12-17.	0.6	147
194	Regional hippocampal atrophy in multiple sclerosis. Brain, 2008, 131, 1134-1141.	7.6	339
195	MR Image Postprocessing for Multiple Sclerosis Research. Neuroimaging Clinics of North America, 2008, 18, 637-649.	1.0	3
196	The Brain in Chronic CRPS Pain: Abnormal Gray-White Matter Interactions in Emotional and Autonomic Regions. Neuron, 2008, 60, 570-581.	8.1	440
197	Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. NeuroImage, 2008, 39, 1752-1762.	4.2	128
198	Enhanced brain extraction improves the accuracy of brain atrophy estimation. NeuroImage, 2008, 40, 583-589.	4.2	58
199	Brain morphometry with multiecho MPRAGE. NeuroImage, 2008, 40, 559-569.	4.2	512
200	A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. NeuroImage, 2008, 42, 315-322.	4.2	189

#	Article	IF	CITATIONS
201	Accuracy assessment of global and local atrophy measurement techniques with realistic simulated longitudinal Alzheimer's disease images. NeuroImage, 2008, 42, 696-709.	4.2	32
202	Detection of structural changes of the human brain in longitudinally acquired MR images by deformation field morphometry: Methodological analysis, validation and application. NeuroImage, 2008, 43, 269-287.	4.2	34
203	Measurement of brain atrophy in subcortical vascular disease: A comparison of different approaches and the impact of ischaemic lesions. NeuroImage, 2008, 43, 312-320.	4.2	27
204	Automated morphological analysis of magnetic resonance brain imaging using spectral analysis. NeuroImage, 2008, 43, 225-235.	4.2	30
205	Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology, 2008, 71, 1521-1526.	1.1	85
206	Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology, 2008, 71, 632-638.	1.1	104
207	The Use of MR Imaging as an Outcome Measure in Multiple Sclerosis Clinical Trials. Neuroimaging Clinics of North America, 2008, 18, 687-701.	1.0	14
208	Brain Atrophy Assessment in Multiple Sclerosis: Importance and Limitations. Neuroimaging Clinics of North America, 2008, 18, 675-686.	1.0	68
209	A new evaluation of the brain parenchymal fraction: Application in multiple sclerosis longitudinal studies. , 2008, , .		2
210	Cerebral Atrophy after Traumatic White Matter Injury: Correlation with Acute Neuroimaging and Outcome. Journal of Neurotrauma, 2008, 25, 1433-1440.	3.4	118
211	Feature Extraction and Strategy of Analyzing Structural Neuroimaging in Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 75-86.	1.8	1
212	Perivascular spacesMRI marker of inflammatory activity in the brain?. Brain, 2008, 131, 2332-2340.	7.6	200
213	Pattern and progression of white-matter changes in a case of posterior cortical atrophy using diffusion tensor imaging. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 80, 432-436.	1.9	22
214	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 455-464.	3.0	58
215	The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain, 2008, 131, 72-89.	7.6	98
216	Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain, 2008, 131, 3277-3285.	7.6	437
217	Vitamin B ₁₂ status and rate of brain volume loss in community-dwelling elderly. Neurology, 2008, 71, 826-832.	1.1	174
218	Whole-brain atrophy rate in Alzheimer disease. Neurology, 2008, 70, 1836-1841.	1.1	94

#	Article	IF	Citations
219	Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1312-1317.	1.9	56
220	Cognitive impairment in relapsing—remitting multiple sclerosis can be predicted by imaging performed several years earlier. Multiple Sclerosis Journal, 2008, 14, 197-204.	3.0	82
221	Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. American Journal of Neuroradiology, 2008, 29, 944-949.	2.4	162
222	A Whole-Brain Analysis in De Novo Parkinson Disease. American Journal of Neuroradiology, 2008, 29, 674-680.	2.4	67
223	Reduction in Cerebral Atrophy Associated with Ethyl-Eicosapentaenoic Acid Treatment in Patients with Huntington's Disease. Journal of International Medical Research, 2008, 36, 896-905.	1.0	30
224	Corticospinal Tract Abnormalities Are Associated with Weakness in Multiple Sclerosis. American Journal of Neuroradiology, 2008, 29, 333-339.	2.4	67
225	Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1068-1075.	3.0	69
226	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 407-414.	1.9	73
227	Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. Radiology, 2008, 248, 590-598.	7.3	133
228	Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain, 2008, 131, 2443-2454.	7.6	393
229	Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 917-923.	1.9	47
230	Pilot Study of Minocycline in Relapsing-Remitting Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2008, 35, 185-191.	0.5	66
231	Multimodal MRI in Cerebral Small Vessel Disease. Stroke, 2008, 39, 1999-2005.	2.0	135
232	Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 201-206.	1.9	174
233	T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 678-686.	3.0	55
234	Magnetic resonance evidence of cortical onset of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 933-941.	3.0	74
235	Quantitative assessment of brain iron by R ₂ * relaxometry in patients with clinically isolated syndrome and relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1048-1054.	3.0	107
236	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 789-794.	3.0	22

#	Article	IF	CITATIONS
237	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. Multiple Sclerosis Journal, 2009, 15, 465-471.	3.0	15
238	Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology, 2009, 73, 498-503.	1.1	90
239	Thalamic Involvement and Its Impact on Clinical Disability in Patients with Multiple Sclerosis: A Diffusion Tensor Imaging Study at 3T. American Journal of Neuroradiology, 2009, 30, 1380-1386.	2.4	77
240	Tissue-Specific Imaging Is a Robust Methodology to Differentiate In Vivo T1 Black Holes with Advanced Multiple Sclerosis–Induced Damage. American Journal of Neuroradiology, 2009, 30, 1394-1401.	2.4	29
241	Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1218-1224.	1.9	21
242	Multiple Sclerosis: Hyperintense Dentate Nucleus on Unenhanced T1-weighted MR Images Is Associated with the Secondary Progressive Subtype. Radiology, 2009, 251, 503-510.	7.3	95
243	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 965-976.	3.0	77
244	Automated Optimization of Subcortical Cerebral MR Imagingâ^'Atlas Coregistration for Improved Postoperative Electrode Localization in Deep Brain Stimulation. American Journal of Neuroradiology, 2009, 30, 1914-1921.	2.4	106
245	Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain, 2009, 132, 3380-3391.	7.6	96
246	Hippocampal atrophy rates in Alzheimer disease. Neurology, 2009, 72, 999-1007.	1.1	315
247	Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology, 2009, 72, 595-601.	1.1	91
248	Structural and metabolic brain abnormalities in preclinical cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 41-47.	1.9	29
249	Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2009, 66, 1144-50.	4.5	458
250	APOE-ε4 is not associated with cognitive impairment in relapsing—remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1489-1494.	3.0	21
251	Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 114-115.	3.0	7
252	Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study. Multiple Sclerosis Journal, 2009, 15, 1481-1488.	3.0	16
253	Early brain swelling in acute hypoxia. Journal of Applied Physiology, 2009, 107, 244-252.	2.5	50
254	PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: A pilot study on relation to clinical findings and brain atrophy. Journal of Neuroimmunology, 2009, 210, 80-86.	2.3	22

#	Article	IF	CITATIONS
255	A longitudinal observation of Brain-Derived Neurotrophic Factor mRNA levels in patients with Relapsing–Remitting Multiple Sclerosis. Brain Research, 2009, 1256, 123-128.	2.2	28
256	Regional fMRI brain activation does correlate with global brain volume. Brain Research, 2009, 1259, 17-25.	2.2	21
257	NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology, The, 2009, 8, 519-529.	10.2	95
258	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, The, 2009, 8, 987-997.	10.2	322
259	Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 780-788.	2.7	64
260	Effects of acute dehydration on brain morphology in healthy humans. Human Brain Mapping, 2009, 30, 291-298.	3.6	91
261	Sensorimotor network rewiring in mild cognitive impairment and Alzheimer's disease. Human Brain Mapping, 2010, 31, 515-525.	3.6	93
262	Visual rating of the hippocampus in nonâ€demented elders: Does it measure hippocampal atrophy or other indices of brain atrophy? The SMARTâ€MR study. Hippocampus, 2009, 19, 1115-1122.	1.9	15
263	Imaging ageâ€related cognitive decline: A comparison of diffusion tensor and magnetization transfer MRI. Journal of Magnetic Resonance Imaging, 2009, 29, 23-30.	3.4	85
264	Brain atrophy and white matter hyperintensities in early Parkinson's disease. Movement Disorders, 2009, 24, 2233-2241.	3.9	50
265	Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. Journal of Neurology, 2009, 256, 427-435.	3.6	27
266	Influence of task complexity during coordinated hand and foot movements in MS patients with and without fatigue. Journal of Neurology, 2009, 256, 470-482.	3.6	30
267	Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. Journal of Neurology, 2009, 256, 1397-1412.	3.6	73
268	Relationship between intelligence and the size and composition of the corpus callosum. Experimental Brain Research, 2009, 192, 455-464.	1.5	49
269	Parallel imaging: is GRAPPA a useful acquisition tool for MR imaging intended for volumetric brain analysis?. BMC Medical Imaging, 2009, 9, 15.	2.7	14
270	Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Molecular Psychiatry, 2009, 14, 976-986.	7.9	117
271	Cognitive impairment and white matter damage in hypertension: a pilot study. Acta Neurologica Scandinavica, 2009, 119, 261-268.	2.1	60
272	Cerebral Atrophy in Cerebrovascular Disorders. Journal of Neuroimaging, 2010, 20, 213-218.	2.0	28

#	Article	IF	CITATIONS
273	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. European Radiology, 2009, 19, 2826-2833.	4.5	88
274	Serum matrix metalloproteinase levels correlate with brain injury in human immunodeficiency virus infection. Journal of NeuroVirology, 2009, 15, 275-281.	2.1	23
275	Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Multiple Sclerosis Journal, 2009, 15, 345-354.	3.0	62
276	Investigation of the neural correlates underlying action observation in multiple sclerosis patients. Experimental Neurology, 2009, 217, 252-257.	4.1	8
277	Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing–remitting multiple sclerosis. Brain and Cognition, 2009, 71, 410-415.	1.8	21
278	Age-related differences in the involvement of the prefrontal cortex in attentional control. Brain and Cognition, 2009, 71, 328-335.	1.8	103
279	Neurofunctional correlates of personality traits in relapsing-remitting multiple sclerosis: An fMRI study. Brain and Cognition, 2009, 71, 320-327.	1.8	19
280	Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiology of Aging, 2009, 30, 890-897.	3.1	63
281	Sex differences in the neuroanatomy of human mirror-neuron system: A voxel-based morphometric investigation. Neuroscience, 2009, 158, 713-720.	2.3	172
282	Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation. Molecular Genetics and Metabolism, 2009, 98, 255-263.	1.1	38
283	Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number. Parkinsonism and Related Disorders, 2009, 15, 213-219.	2.2	50
284	Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 112-119.	0.6	84
285	Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 120-124.	0.6	32
286	Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 55-60.	0.6	66
287	Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. Journal of the Neurological Sciences, 2009, 282, 61-66.	0.6	115
288	A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. Journal of the Neurological Sciences, 2009, 282, 86-95.	0.6	18
289	Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. Journal of the Neurological Sciences, 2009, 282, 96-105.	0.6	110
290	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419

#	Article	IF	CITATIONS
291	Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 47-52.	2.1	80
292	Structural connectivity influences brain activation during PVSAT in Multiple Sclerosis. NeuroImage, 2009, 44, 9-15.	4.2	63
293	Long-term global and regional brain volume changes following severe traumatic brain injury: A longitudinal study with clinical correlates. NeuroImage, 2009, 44, 1-8.	4.2	195
294	Assessing the effects of age on long white matter tracts using diffusion tensor tractography. NeuroImage, 2009, 46, 530-541.	4.2	406
295	MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. NeuroImage, 2009, 46, 177-192.	4.2	482
296	Comparison of phantom and registration scaling corrections using the ADNI cohort. NeuroImage, 2009, 47, 1506-1513.	4.2	54
297	Functional but not structural changes associated with learning: An exploration of longitudinal Voxel-Based Morphometry (VBM). NeuroImage, 2009, 48, 117-125.	4.2	90
298	Improvement of brain segmentation accuracy by optimizing non-uniformity correction using N3. NeuroImage, 2009, 48, 73-83.	4.2	83
299	Brain Imaging of Multiple Sclerosis: the Next 10 Years. Neuroimaging Clinics of North America, 2009, 19, 101-112.	1.0	9
300	Theory of mind associations with other cognitive functions and brain imaging in normal aging Psychology and Aging, 2009, 24, 338-348.	1.6	130
301	Predictive modeling of neuroanatomic structures for brain atrophy detection. , 2010, , .		0
302	Effect of Exercise and Heat-Induced Hypohydration on Brain Volume. Medicine and Science in Sports and Exercise, 2010, 42, 2197-2204.	0.4	29
303	Evidence of Altered Posteromedial Cortical fMRI Activity in Subjects at Risk for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 28-36.	1.3	68
304	Combined Volumetry and DTI in Subcortical Structures of Mild Cognitive Impairment and Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2010, 19, 1273-1282.	2.6	107
305	Frontal networks play a role in fatigue perception in multiple sclerosis Behavioral Neuroscience, 2010, 124, 329-336.	1.2	82
306	Does registration of serial MRI improve diagnosis of dementia?. Neuroradiology, 2010, 52, 987-995.	2.2	2
307	Evaluation of brain atrophy estimation algorithms using simulated ground-truth data. Medical Image Analysis, 2010, 14, 373-389.	11.6	22
308	Magnetization transfer imaging in â€~premanifest' Huntington's disease. Journal of Neurology, 2010, 257, 426-432.	' 3.6 	17

#	Article	IF	CITATIONS
309	A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. Journal of Neurology, 2010, 257, 1508-1516.	3.6	42
310	Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. Journal of Psychiatric Research, 2010, 44, 447-453.	3.1	82
311	The relationship between episodic long-term memory and white matter integrity in normal aging. Neuropsychologia, 2010, 48, 114-122.	1.6	42
312	Atrofia cerebral en pacientes con sÃndrome desmielinizante aislado. NeurologÃa, 2010, 25, 430-434.	0.7	2
313	Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. Brain Research, 2010, 1341, 41-51.	2.2	169
314	Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensorâ€based morphometry. Human Brain Mapping, 2010, 31, 499-514.	3.6	66
315	Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. Journal of Magnetic Resonance Imaging, 2010, 32, 223-228.	3.4	247
316	Effects of gradient nonâ€linearity correction and intensity nonâ€uniformity correction in longitudinal studies using structural image evaluation using normalization of atrophy (SIENA). Journal of Magnetic Resonance Imaging, 2010, 32, 489-492.	3.4	21
317	A novel splice site mutation in the <i>SPG7</i> gene causing widespread fiber damage in homozygous and heterozygous subjects. Movement Disorders, 2010, 25, 413-420.	3.9	25
318	<i>LRRK2</i> variation and Parkinson's disease in African Americans. Movement Disorders, 2010, 25, 1973-1976.	3.9	11
319	Impaired insulin sensitivity and secretion in normoglycemic patients with spinocerebellar ataxia type 1. Movement Disorders, 2010, 25, 1976-1980.	3.9	9
320	The "imprisoned illness:―Motor tic disorder in Rainer Maria Rilke's <i>Notebooks of Malte Laurids Brigge</i> . Movement Disorders, 2010, 25, 1980-1982.	3.9	1
321	Prevalence of <i>THAP1</i> sequence variants in German patients with primary dystonia. Movement Disorders, 2010, 25, 1982-1986.	3.9	31
322	Specific pattern of early whiteâ€matter changes in pure hereditary spastic paraplegia. Movement Disorders, 2010, 25, 1986-1992.	3.9	37
323	Biomarkers of neurological status in HIV infection: A 3â€year study. Proteomics - Clinical Applications, 2010, 4, 295-303.	1.6	23
324	Early Nonischemic Oxidative Metabolic Dysfunction Leads to Chronic Brain Atrophy in Traumatic Brain Injury. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 883-894.	4.3	99
325	The <i>in vivo</i> distribution of brain tissue loss in Richardson's syndrome and PSPâ€parkinsonism: a VBMâ€DARTEL study. European Journal of Neuroscience, 2010, 32, 640-647.	2.6	71
326	Low HDL cholesterol is associated with lower gray matter volume in cognitively healthy adults. Frontiers in Aging Neuroscience, 2010, 2, .	3.4	47

#	Article	IF	CITATIONS
327	Contrasting gray and white matter changes in preclinical Huntington disease. Neurology, 2010, 74, 1208-1216.	1.1	100
328	Medial Temporal Lobe Correlates of Memory Screening Measures in Normal Aging, MCI, and AD. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 100-108.	2.3	24
329	Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology, 2010, 74, 1022-1029.	1.1	196
330	Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1326-1334.	3.0	30
331	Magnetization Transfer MR Imaging Demonstrates Degeneration of the Subcortical and Cortical Gray Matter in Huntington Disease. American Journal of Neuroradiology, 2010, 31, 1807-1812.	2.4	23
332	Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1189-1193.	1.9	18
333	Diffusion tensor imaging detects age related white matter change over a 2 year follow-up which is associated with working memory decline. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 13-19.	1.9	121
334	T ₁ cortical hypointensities and their association with cognitive disability in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1203-1212.	3.0	23
335	High-Grade Internal Carotid Artery Stenosis and Chronic Brain Damage: A Volumetric Magnetic Resonance Imaging Study. Cerebrovascular Diseases, 2010, 30, 540-546.	1.7	25
336	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology, 2010, 74, 1868-1876.	1.1	284
337	Incidence of cerebral microbleeds. Neurology, 2010, 74, 1954-1960.	1.1	115
338	Resistance Training and Executive Functions. Archives of Internal Medicine, 2010, 170, 170.	3.8	599
339	Functional MR Imaging Correlates of Neuropsychological Impairment in Primary-Progressive Multiple Sclerosis. American Journal of Neuroradiology, 2010, 31, 1240-1246.	2.4	34
340	Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Multiple Sclerosis Journal, 2010, 16, 1474-1482.	3.0	157
341	Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1351-1356.	1.9	64
342	Individual white matter fractional anisotropy analysis on patients with MRI negative partial epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 136-139.	1.9	18
343	Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 192-197.	1.9	238
344	Resting state networks change in clinically isolated syndrome. Brain, 2010, 133, 1612-1621.	7.6	215

		CITATION REPORT		
#	Article		IF	Citations
345	Hippocampal mean diffusivity and memory in healthy elderly individuals. Neurology, 2010, 74	, 194-200.	1.1	82
346	Genetic variation influences glutamate concentrations in brains of patients with multiple scle Brain, 2010, 133, 2603-2611.	rosis.	7.6	123
347	Effects of the DASH Diet Alone and in Combination With Exercise and Weight Loss on Blood and Cardiovascular Biomarkers in Men and Women With High Blood Pressure. Archives of Int Medicine, 2010, 170, 126.		3.8	459
348	Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patwith clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 8 204-208.	tients 81,	1.9	79
349	A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pil of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS). Therapeutic Advances in Neurological Dis 2010, 3, 3-13.		3.5	24
350	Functional Connectivity in Late-Life Depression Using Resting-State Functional Magnetic Reso Imaging. American Journal of Geriatric Psychiatry, 2010, 18, 643-651.	onance	1.2	71
351	Global and local morphometric differences in recently abstinent methamphetamine-depender individuals. NeuroImage, 2010, 50, 1392-1401.	ıt	4.2	150
352	Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different in intervals. NeuroImage, 2010, 51, 63-75.	ter-scan	4.2	79
353	White matter structural decline in normal ageing: A prospective longitudinal study using trac spatial statistics. Neurolmage, 2010, 51, 565-577.	t-based	4.2	178
354	Measurement of hippocampal atrophy using 4D graph-cut segmentation: Application to ADN NeuroImage, 2010, 52, 109-118.		4.2	122
355	Evaluation of automated techniques for the quantification of grey matter atrophy in patients multiple sclerosis. NeuroImage, 2010, 52, 1261-1267.	with	4.2	82
356	Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-polymorphism. NeuroImage, 2010, 53, 37-43.	4	4.2	77
357	Head size, age and gender adjustment in MRI studies: a necessary nuisance?. NeuroImage, 20 1244-1255.	10, 53,	4.2	421
358	Atrofia cerebral en pacientes con sÃndrome desmielinizante aislado. Neurologia Argentina, 20 86-89.	010, 2,	0.3	0
359	Brain Atrophy in Clinically Isolated Syndrome. NeurologÃa (English Edition), 2010, 25, 430-43	4.	0.4	5
360	A multimodal MRI investigation of the subventricular zone in mild cognitive impairment and Alzheimer's disease patients. Neuroscience Letters, 2010, 469, 214-218.		2.1	36
361	White matter pathways associated with working memory in normal aging. Cortex, 2010, 46,	474-489.	2.4	142
362	Age-related differences in pain sensitivity and regional brain activity evoked by noxious press Neurobiology of Aging, 2010, 31, 494-503.	ıre.	3.1	141

#	Article	IF	CITATIONS
363	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiology of Aging, 2010, 31, 758-764.	3.1	90
364	Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiology of Aging, 2010, 31, 1463-1480.	3.1	181
365	Smaller Cornu Ammonis 2–3/Dentate Gyrus Volumes and Elevated Cortisol in Multiple Sclerosis Patients with Depressive Symptoms. Biological Psychiatry, 2010, 68, 553-559.	1.3	109
366	MR-elastography reveals degradation of tissue integrity in multiple sclerosis. NeuroImage, 2010, 49, 2520-2525.	4.2	262
367	Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change. NeuroImage, 2010, 49, 1601-1611.	4.2	68
368	Skull stripping using graph cuts. NeuroImage, 2010, 49, 225-239.	4.2	149
369	A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. NeuroImage, 2010, 49, 1524-1535.	4.2	287
370	Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. NeuroImage, 2010, 49, 2216-2224.	4.2	120
371	Structural and cognitive deficits in remitting and non-remitting recurrent depression: A voxel-based morphometric study. NeuroImage, 2010, 50, 347-356.	4.2	200
372	Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: An illustration in ADNI 3 T MRI data. NeuroImage, 2010, 50, 434-445.	4.2	116
373	Reductions of Thalamic Volume and Regional Shape Changes in the Vegetative and the Minimally Conscious States. Journal of Neurotrauma, 2010, 27, 1187-1193.	3.4	64
374	Sensitivity of volumetric brain analysis to systematic and random errors. , 2010, , .		1
375	Neuroimaging to assess safety and efficacy of AD therapies. Expert Opinion on Investigational Drugs, 2010, 19, 23-26.	4.1	25
376	A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 798-805.	1.9	84
377	Complexity of cerebral atrophy evaluation in relapsing-remitting multiple sclerosis context. , 2011, , .		0
378	Evidencia de neuroimagen y de tratamiento respecto a los estadios clÃnicos en los trastornos psicóticos: del estado mental de riesgo a la esquizofrenia crónica. Psiquiatria Biologica, 2011, 18, 117-123.	0.1	0
380	La tasa de atrofia cerebral al año de inicio predice la progresión de la esclerosis múltiple. Neurologia Argentina, 2011, 3, 88-93.	0.3	0
381	Neuroimaging and Treatment Evidence for Clinical Staging in Psychotic Disorders: From the At-Risk Mental State to Chronic Schizophrenia. Biological Psychiatry, 2011, 70, 619-625.	1.3	94

#	Article	IF	CITATIONS
382	Algorithms, atrophy and Alzheimer's disease: Cautionary tales for clinical trials. NeuroImage, 2011, 57, 15-18.	4.2	69
383	The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology, 2011, 18, 43-52.	2.2	23
384	Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case–control diffusion imaging study. Pathophysiology, 2011, 18, 61-68.	2.2	11
385	Pituitary volume increase during emerging psychosis. Schizophrenia Research, 2011, 125, 41-48.	2.0	57
386	Diffusion tensor imaging and cognitive speed in children with multiple sclerosis. Journal of the Neurological Sciences, 2011, 309, 68-74.	0.6	41
387	Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques. NeuroImage, 2011, 56, 788-796.	4.2	83
388	CLADA: Cortical longitudinal atrophy detection algorithm. NeuroImage, 2011, 54, 278-289.	4.2	52
389	A comparison of MR based segmentation methods for measuring brain atrophy progression. NeuroImage, 2011, 54, 760-768.	4.2	50
390	Performance comparison of machine learning algorithms and number of independent components used in fMRI decoding of belief vs. disbelief. NeuroImage, 2011, 56, 544-553.	4.2	92
391	Evaluation of voxel-based group-level analysis of diffusion tensor images using simulated brain lesions. Neuroscience Research, 2011, 71, 377-386.	1.9	1
392	A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1241-1256.	2.6	86
393	Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Multiple Sclerosis Journal, 2011, 17, 838-850.	3.0	46
394	Guidelines for Developing Automated Quality Control Procedures for Brain Magnetic Resonance Images Acquired in Multi-Centre Clinical Trials. , 0, , .		2
396	Measurement of CNS atrophy. , 0, , 128-149.		2
397	Diffusion imaging in multiple sclerosis. , 2011, , 186-197.		1
398	The use of MRI in multiple sclerosis clinical trials. , 2011, , 198-212.		0
400	Quantification of Volumetric Changes of Brain in Neurodegenerative Diseases Using Magnetic Resonance Imaging and Stereology. , 2011, , .		1
401	Fingolimod to treat multiple sclerosis. , 0, , 370-386.		0

#	Article	IF	CITATIONS
402	G-CSF Prevents the Progression of Structural Disintegration of White Matter Tracts in Amyotrophic Lateral Sclerosis: A Pilot Trial. PLoS ONE, 2011, 6, e17770.	2.5	39
403	Metabolic Changes in the Visual Cortex Are Linked to Retinal Nerve Fiber Layer Thinning in Multiple Sclerosis. PLoS ONE, 2011, 6, e18019.	2.5	76
404	Association of Retinal and Macular Damage with Brain Atrophy in Multiple Sclerosis. PLoS ONE, 2011, 6, e18132.	2.5	127
405	The Potential of Relaxation-Weighted Sodium Magnetic Resonance Imaging as Demonstrated on Brain Tumors. Investigative Radiology, 2011, 46, 539-547.	6.2	98
406	Brain Atrophy and Cerebral Small Vessel Disease. Stroke, 2011, 42, 133-138.	2.0	111
407	MRI correlates of cognitive impairment in childhood-onset multiple sclerosis Neuropsychology, 2011, 25, 319-332.	1.3	132
409	Using Diffusion Tensor Imaging and Mixed-Effects Models to Investigate Primary and Secondary White Matter Degeneration in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2011, 26, 667-682.	2.6	33
410	Shape Abnormalities of the Striatum in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 23, 49-59.	2.6	39
411	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. European Journal of Neuroscience, 2011, 33, 1256-1263.	2.6	25
412	Microstructural and volumetric abnormalities of the putamen in juvenile myoclonic epilepsy. Epilepsia, 2011, 52, 1715-1724.	5.1	76
413	Quality and Quantity of Diffuse and Focal White Matter Disease and Cognitive Disability of Patients with Multiple Sclerosis. , 2011, 21, e57-e63.		16
414	Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. Psychiatry Research - Neuroimaging, 2011, 193, 182-190.	1.8	43
415	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurology, The, 2011, 10, 520-529.	10.2	204
416	The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials, 2011, 12, 62.	1.6	104
417	Discriminant analysis of intermediate brain atrophy rates in longitudinal diagnosis of alzheimer's disease. Diagnostic Pathology, 2011, 6, 105.	2.0	6
418	Cerebrospinal Fluid Biomarkers, Education, Brain Volume, and Future Cognition. Archives of Neurology, 2011, 68, 1145.	4.5	42
419	Early atrophy of pallidum and accumbens nucleus in Huntington's disease. Journal of Neurology, 2011, 258, 412-420.	3.6	121
420	Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI. Journal of Neurology, 2011, 258, 2240-2247.	3.6	19

	СПАНОМ	KLFORT	
#	Article	IF	CITATIONS
421	Segmentation ciblée d'images IRM et maladie d'Alzheimer. Irbm, 2011, 32, 19-26.	5.6	3
422	Marked relationship between matrix metalloproteinase 7 and brain atrophy in HIV infection. Journal of NeuroVirology, 2011, 17, 153-158.	2.1	14
423	Cognitively preserved MS patients demonstrate functional differences in processing neutral and emotional faces. Brain Imaging and Behavior, 2011, 5, 241-251.	2.1	64
424	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurology, 2011, 11, 128.	1.8	50
425	Gray matter imaging in multiple sclerosis: what have we learned?. BMC Neurology, 2011, 11, 153.	1.8	82
426	Functional neural correlates of reduced physiological falls risk. Behavioral and Brain Functions, 2011, 7, 37.	3.3	19
427	Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplantation, 2011, 17, 38-46.	2.4	129
428	Effect of scanner in longitudinal studies of brain volume changes. Journal of Magnetic Resonance Imaging, 2011, 34, 438-444.	3.4	94
429	Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year. Movement Disorders, 2011, 26, 1481-1488.	3.9	22
430	Altered functional magnetic resonance imaging restingâ€state connectivity in periaqueductal gray networks in migraine. Annals of Neurology, 2011, 70, 838-845.	5.3	314
431	Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Human Brain Mapping, 2011, 32, 1535-1543.	3.6	92
432	Global <i>N</i> -Acetylaspartate Declines Even in Benign Multiple Sclerosis. American Journal of Neuroradiology, 2011, 32, 204-209.	2.4	18
433	Longitudinal changes in diffusion tensor–based quantitative MRI in multiple sclerosis. Neurology, 2011, 76, 179-186.	1.1	75
434	Volume Changes of Corpus Striatum, Thalamus, Hippocampus and Lateral Ventricles in Posttraumatic Stress Disorder (PTSD) Patients Suffering from Headaches and without Therapy. Central European Neurosurgery, 2011, 72, 133-137.	0.7	32
435	Thalamic Damage Predicts the Evolution of Primary-Progressive Multiple Sclerosis at 5 Years. American Journal of Neuroradiology, 2011, 32, 1016-1020.	2.4	64
436	Strategic role of frontal white matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL. Brain, 2011, 134, 2366-2375.	7.6	163
437	Hippocampi, Thalami, and Accumbens Microstructural Damage in Schizophrenia: A Volumetry, Diffusivity, and Neuropsychological Study. Schizophrenia Bulletin, 2011, 37, 118-130.	4.3	55
438	Enhanced Rapid-Onset Cortical Plasticity in CADASIL as a Possible Mechanism of Preserved Cognition. Cerebral Cortex, 2011, 21, 2774-2787.	2.9	30

#	ARTICLE	IF	CITATIONS
439	Magnetization Transfer Imaging Demonstrates a Distributed Pattern of Microstructural Changes of the Cerebral Cortex in Amyotrophic Lateral Sclerosis. American Journal of Neuroradiology, 2011, 32, 704-708.	2.4	19
440	Voxelwise Analysis of Diffusion Tensor Imaging and Structural MR Imaging in Patients with the m.3243A>G Mutation in Mitochondrial DNA. American Journal of Neuroradiology, 2011, 32, 522-526.	2.4	15
441	Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Multiple Sclerosis Journal, 2011, 17, 1098-1106.	3.0	167
442	Effects of Risk Genes on BOLD Activation in Presymptomatic Carriers of Familial Alzheimer's Disease Mutations during a Novelty Encoding Task. Cerebral Cortex, 2011, 21, 877-883.	2.9	29
443	Lesions by tissue specific imaging characterize multiple sclerosis patients with more advanced disease. Multiple Sclerosis Journal, 2011, 17, 1424-1431.	3.0	12
444	Voxelwise Assessment of the Regional Distribution of Damage in the Brains of Patients with Multiple Sclerosis and Fatigue. American Journal of Neuroradiology, 2011, 32, 874-879.	2.4	76
445	Neither retinal nor brain atrophy can be shown in patients with isolated unilateral optic neuritis at the time of presentation. Multiple Sclerosis Journal, 2011, 17, 89-95.	3.0	18
446	A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology, 2011, 77, 1253-1262.	1.1	222
447	Cerebral Perfusion and Aortic Stiffness Are Independent Predictors of White Matter Brain Atrophy in Type 1 Diabetic Patients Assessed With Magnetic Resonance Imaging. Diabetes Care, 2011, 34, 459-463.	8.6	45
448	Size and Shape of the Corpus Callosum in Adult Niemann-Pick Type C Reflects State and Trait Illness Variables. American Journal of Neuroradiology, 2011, 32, 1340-1346.	2.4	43
449	Retinal Nerve Fiber Layer Thinning in CADASIL: An Optical Coherence Tomography and MRI Study. Cerebrovascular Diseases, 2011, 31, 77-82.	1.7	25
450	Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1432-1440.	3.0	22
451	Age of Onset of Schizophrenia: Perspectives From Structural Neuroimaging Studies. Schizophrenia Bulletin, 2011, 37, 504-513.	4.3	260
452	Role of lean body mass in estimating glomerular filtration rate in Alzheimer disease. Nephrology Dialysis Transplantation, 2011, 26, 2222-2231.	0.7	6
453	Information processing speed, neural efficiency, and working memory performance in multiple sclerosis: Differential relationships with structural magnetic resonance imaging. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 1129-1145.	1.3	38
454	Reorganization in cognitive networks with progression of multiple sclerosis. Neurology, 2011, 76, 526-533.	1.1	72
455	Longitudinal changes of structural connectivity in traumatic axonal injury. Neurology, 2011, 77, 818-826.	1.1	89
456	Magnetic Resonance Imaging Correlates of Dichotic Listening Performance in Multiple Sclerosis. Seminars in Hearing, 2012, 33, 283-294.	1.2	3

#	Article	IF	CITATIONS
457	Brain Volume and Diffusion Markers as Predictors of Disability and Short-Term Disease Evolution in Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1356-1362.	2.4	16
458	Diffuse Tract Damage in the Hemispheric Deep White Matter May Correlate with Global Cognitive Impairment and Callosal Atrophy in Patients with Extensive Leukoaraiosis. American Journal of Neuroradiology, 2012, 33, 726-732.	2.4	28
459	Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS. Neurology, 2012, 78, 194-201.	1.1	80
460	Relating Brain Damage to Brain Plasticity in Patients With Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2012, 26, 581-593.	2.9	61
461	The Architecture of Cross-Hemispheric Communication in the Aging Brain: Linking Behavior to Functional and Structural Connectivity. Cerebral Cortex, 2012, 22, 232-242.	2.9	150
462	Magnetic Resonance Imaging Predictors of Executive Functioning in Patients with Pediatric-Onset Multiple Sclerosis. Archives of Clinical Neuropsychology, 2012, 27, 495-509.	0.5	25
463	Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology, 2012, 78, 309-314.	1.1	169
464	Age-Dependent Structural Connectivity Effects in Fragile X Premutation. Archives of Neurology, 2012, 69, 482-9.	4.5	51
465	Gender-related differences in functional connectivity in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 164-173.	3.0	89
466	Diffusion Tensor Imaging Correlates of Visual Impairment in Multiple Sclerosis and Chronic Optic Neuritis. , 2012, 53, 825.		36
467	Brain Structure and Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 240-245.	5.6	116
468	Deep <i>versus</i> Periventricular White Matter Lesions and Cognitive Function in a Community Sample of Middle-Aged Participants. Journal of the International Neuropsychological Society, 2012, 18, 874-885.	1.8	47
469	Vascular Risk Factors, White Matter Hyperintensities and Hippocampal Volume in Normal Elderly Individuals. Dementia and Geriatric Cognitive Disorders, 2012, 33, 29-34.	1.5	27
470	Human cortical responses to variations of the interocular correlation of binocular signals. , 2012, , .		0
471	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurological Research, 2012, 34, 761-769.	1.3	14
472	Experience-dependent plasticity in white matter microstructure: reasoning training alters structural connectivity. Frontiers in Neuroanatomy, 2012, 6, 32.	1.7	113
473	Memory Performance and Normalized Regional Brain Volumes in Patients with Pediatric-Onset Multiple Sclerosis. Journal of the International Neuropsychological Society, 2012, 18, 471-480.	1.8	24
474	Should we be †nervous' about coeliac disease? Brain abnormalities in patients with coeliac disease referred for neurological opinion. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1216-1221.	1.9	44

#	Article	IF	Citations
475	Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurology, The, 2012, 11, 1082-1092.	10.2	252
476	Brain tissue volumes in familial longevity: the Leiden Longevity Study. Aging Cell, 2012, 11, 933-939.	6.7	11
477	Within-subject template estimation for unbiased longitudinal image analysis. NeuroImage, 2012, 61, 1402-1418.	4.2	1,925
478	Structural brain alterations can be detected early in HIV infection. Neurology, 2012, 79, 2328-2334.	1.1	92
479	Subcortical atrophy and cognition. Neurology, 2012, 79, 1754-1761.	1.1	181
480	MR volumetric changes after diagnostic CSF removal in normal pressure hydrocephalus. Journal of Neurology, 2012, 259, 2440-2446.	3.6	14
481	The Charité Grid Portal: User-friendly and Secure Access to Grid-based Resources and Services. Journal of Grid Computing, 2012, 10, 709-724.	3.9	5
482	A comparative evaluation of quantitative neuroimaging measurements of brain status in HIV infection. Psychiatry Research - Neuroimaging, 2012, 203, 95-99.	1.8	16
483	Thalamic shape and connectivity abnormalities in children with attention- deficit/hyperactivity disorder. Psychiatry Research - Neuroimaging, 2012, 204, 161-167.	1.8	76
484	Brain structural and functional recovery following initiation of combination antiretroviral therapy. Journal of NeuroVirology, 2012, 18, 423-427.	2.1	9
486	Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiology of Aging, 2012, 33, 61-74.	3.1	241
487	Gray matter atrophy rate as a marker of disease progression in AD. Neurobiology of Aging, 2012, 33, 1194-1202.	3.1	65
488	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2012, 33, 2018-2028.	3.1	337
489	Relationships between hippocampal shape and cognitive performances in drug-naÃ⁻ve patients with Alzheimer's disease. Neuroscience Letters, 2012, 516, 124-129.	2.1	20
490	Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 333-339.	3.8	62
491	A functional MRI investigation of the association between childhood aerobic fitness and neurocognitive control. Biological Psychology, 2012, 89, 260-268.	2.2	150
492	Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients. Cardiovascular Diabetology, 2012, 11, 119.	6.8	14
493	Functional Transcranial Doppler: Presymptomatic Changes in Fabry Disease. European Neurology, 2012, 67, 331-337.	1.4	18

#	Article	IF	Citations
π 494	Cognitive Dysfunction in Early Multiple Sclerosis: Altered Centrality Derived from Resting-State	2.5	56
494	Functional Connectivity Using Magneto-Encephalography. PLoS ONE, 2012, 7, e42087.	2.0	30
495	A longitudinal study of brain volume changes in normal aging. European Journal of Radiology, 2012, 81, 2801-2804.	2.6	53
496	The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. European Journal of Radiology, 2012, 81, 3485-3490.	2.6	21
497	Fornix damage limits verbal memory functional compensation in multiple sclerosis. NeuroImage, 2012, 59, 2932-2940.	4.2	43
498	A comprehensive reliability assessment of quantitative diffusion tensor tractography. Neurolmage, 2012, 60, 1127-1138.	4.2	121
499	Measuring longitudinal change in the hippocampal formation from in vivo high-resolution T2-weighted MRI. NeuroImage, 2012, 60, 1266-1279.	4.2	35
500	Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. NeuroImage, 2012, 61, 1484-1494.	4.2	145
501	Regional changes in thalamic shape and volume with increasing age. NeuroImage, 2012, 63, 1134-1142.	4.2	100
502	Acute transverse myelitis in Buenos Aires, Argentina. A retrospective cohort study of 8 years follow-up. NeurologÃa (English Edition), 2012, 27, 348-353.	0.4	1
503	Efficacy and safety of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis: Further outcomes from the IMPROVE study. Journal of the Neurological Sciences, 2012, 312, 97-101.	0.6	31
504	Effect of disease-modifying therapies on brain volume in relapsing–remitting multiple sclerosis: Results of a five-year brain MRI study. Journal of the Neurological Sciences, 2012, 312, 7-12.	0.6	36
505	Left ventricular dysfunction is associated with cerebral grey matter injury: An in-vivo brain MRI segmentation study. Journal of the Neurological Sciences, 2012, 321, 111-113.	0.6	10
506	Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. Expert Review of Neurotherapeutics, 2012, 12, 323-333.	2.8	11
507	Volume Estimation of the Thalamus Using Freesurfer and Stereology: Consistency between Methods. Neuroinformatics, 2012, 10, 341-350.	2.8	77
508	Adaptive image segmentation for robust measurement of longitudinal brain tissue change. , 2012, 2012, 5319-22.		65
510	Brain Imaging and Hepatic Encephalopathy. Clinics in Liver Disease, 2012, 16, 57-72.	2.1	38
511	The Corpus Callosum in Monozygotic Twins Concordant and Discordant for Handedness and Language Dominance. Journal of Cognitive Neuroscience, 2012, 24, 1971-1982.	2.3	8
512	Automated detection of multiple sclerosis lesions in serial brain MRI. Neuroradiology, 2012, 54, 787-807.	2.2	76

#	Article	IF	CITATIONS
513	Lower brain diffusivity in postpartum period compared to late pregnancy: results from a prospective imaging study of multiple sclerosis patients. Neuroradiology, 2012, 54, 823-828.	2.2	9
514	Brain Viscoelasticity Alteration in Chronic-Progressive Multiple Sclerosis. PLoS ONE, 2012, 7, e29888.	2.5	195
515	Revisiting Brain Atrophy and Its Relationship to Disability in Multiple Sclerosis. PLoS ONE, 2012, 7, e37049.	2.5	97
516	Investigating Structural Brain Changes of Dehydration Using Voxel-Based Morphometry. PLoS ONE, 2012, 7, e44195.	2.5	134
517	Reduced Hippocampal Volume in Healthy Young ApoE4 Carriers: An MRI Study. PLoS ONE, 2012, 7, e48895.	2.5	168
518	Myelin-Associated Glycoprotein Gene and Brain Morphometry in Schizophrenia. Frontiers in Psychiatry, 2012, 3, 40.	2.6	32
521	Striatal Volume Increases in Active Methamphetamine-Dependent Individuals and Correlation with Cognitive Performance. Brain Sciences, 2012, 2, 553-572.	2.3	45
522	Brain atrophy at onset and physical disability in multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2012, 70, 765-768.	0.8	9
523	Oligoclonal bands in the cerebrospinal fluid and increased brain atrophy in early stages of relapsing-remitting multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2012, 70, 574-577.	0.8	6
524	Iron deposition in multiple sclerosis lesions measured by susceptibilityâ€weighted imaging filtered phase: A case control study. Journal of Magnetic Resonance Imaging, 2012, 36, 73-83.	3.4	60
525	Automated quantification of white matter disease extent at 3 T: Comparison with volumetric readings. Journal of Magnetic Resonance Imaging, 2012, 36, 305-311.	3.4	20
526	Evaluating and reducing the impact of white matter lesions on brain volume measurements. Human Brain Mapping, 2012, 33, 2062-2071.	3.6	280
527	Cervical cord FMRI abnormalities differ between the progressive forms of multiple sclerosis. Human Brain Mapping, 2012, 33, 2072-2080.	3.6	27
528	Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. Human Brain Mapping, 2012, 33, 2268-2280.	3.6	68
529	Memory training impacts shortâ€ŧerm changes in aging white matter: A Longitudinal Diffusion Tensor Imaging Study. Human Brain Mapping, 2012, 33, 2390-2406.	3.6	228
530	In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS. Neuroradiology, 2012, 54, 771-780.	2.2	32
531	Structural and functional evaluation of cortical motor areas in Amyotrophic Lateral Sclerosis. Experimental Neurology, 2012, 234, 169-180.	4.1	70
532	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. Journal of Neuroimmunology, 2012, 243, 61-68.	2.3	27

#	Article	IF	CITATIONS
533	Nonlinear dimensionality reduction combining MR imaging with non-imaging information. Medical Image Analysis, 2012, 16, 819-830.	11.6	50
535	An efficient incremental strategy for constrained groupwise registration based on symmetric pairwise registration. Pattern Recognition Letters, 2012, 33, 283-290.	4.2	7
536	Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurology, 2012, 12, 10.	1.8	55
537	A Library of Cortical Morphology Analysis Tools to Study Development, Aging and Genetics of Cerebral Cortex. Neuroinformatics, 2012, 10, 81-96.	2.8	43
538	Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology, 2012, 54, 5-12.	2.2	55
539	Evidence of diffuse damage in frontal and occipital cortex in the brain of patients with post-traumatic stress disorder. Neurological Sciences, 2012, 33, 59-68.	1.9	51
540	Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. Journal of Neurology, 2012, 259, 237-245.	3.6	17
541	Functional connectivity changes in multiple sclerosis patients: A graph analytical study of MEG resting state data. Human Brain Mapping, 2013, 34, 52-61.	3.6	106
542	The organization of intrinsic brain activity differs between genders: A restingâ€state fMRI study in a large cohort of young healthy subjects. Human Brain Mapping, 2013, 34, 1330-1343.	3.6	144
543	Cortical plasticity is preserved in nondemented older individuals with severe ischemic small vessel disease. Human Brain Mapping, 2013, 34, 1464-1476.	3.6	27
544	Analysis of "task-positive―and "task-negative―functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis. Experimental Brain Research, 2013, 225, 399-407.	1.5	17
545	Progressive Multiple Sclerosis. , 2013, , .		0
546	Fragile X–Associated Tremor/Ataxia Syndrome. JAMA Neurology, 2013, 70, 1022.	9.0	64
547	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. Journal of Neurology, 2013, 260, 2458-2471.	3.6	96
548	Clinical Course of Two Italian Siblings with Ataxia-Telangiectasia-Like Disorder. Cerebellum, 2013, 12, 596-599.	2.5	20
549	Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 857-865.	10.2	113
550	Cardiovascular risk in cognitively preserved elderlies is associated with glucose hypometabolism in the posterior cingulate cortex and precuneus regardless of brain atrophy and apolipoprotein gene variations. Age, 2013, 35, 777-792.	3.0	14
551	Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. NeuroImage, 2013, 70, 386-401.	4.2	59

#	ARTICLE	IF	CITATIONS
552	White matter microstructure correlates with autism trait severity in a combined clinical–control sample of high-functioning adults. NeuroImage: Clinical, 2013, 3, 106-114.	2.7	40
553	A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Movement Disorders, 2013, 28, 1278-1284.	3.9	31
554	Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 35-41.	1.9	42
555	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 281-288.	3.0	20
556	Tract-specific white matter correlates of fatigue and cognitive impairment in benign multiple sclerosis. Journal of the Neurological Sciences, 2013, 330, 61-66.	0.6	56
557	The association between higher order abilities, processing speed, and age are variably mediated by white matter integrity during typical aging. Neuropsychologia, 2013, 51, 1435-1444.	1.6	100
558	Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1082-1091.	1.9	267
559	Dementia in Down's syndrome: an MRI comparison with Alzheimer's disease in the general population. Journal of Neurodevelopmental Disorders, 2013, 5, 19.	3.1	28
560	Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study. NeuroImage: Clinical, 2013, 2, 727-734.	2.7	33
561	Neurobehavioral comorbidities of pediatric epilepsies are linked to thalamic structural abnormalities. Epilepsia, 2013, 54, 2116-2124.	5.1	15
562	Cognitive Impairment and Its Relation to Imaging Measures in Multiple Sclerosis: A Study Using a Computerized Battery. Journal of Neuroimaging, 2013, 23, 445-452.	2.0	11
563	Six-year follow-up of a case series with non-communicating syringomyelia in multiple sclerosis. European Journal of Neurology, 2013, 20, 578-583.	3.3	4
564	Multi-Modal Magnetic Resonance Imaging in the Acute and Sub-Acute Phase of Mild Traumatic Brain Injury: Can We See the Difference?. Journal of Neurotrauma, 2013, 30, 2-10.	3.4	101
565	De Leiden Lang Leven Studie: weerspiegelt het brein een lang leven?. Neuropraxis, 2013, 17, 167-172.	0.1	0
566	Discriminative analysis of early-stage Alzheimer's disease and normal aging with automatic segmentation technique in subcortical gray matter structures: a multicenter <i>inÂvivo</i> MRI volumetric and DTI study. Acta Radiologica, 2013, 54, 1191-1200.	1.1	19
567	Education modifies the relation of vascular pathology to cognitive function: cognitive reserve in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurobiology of Aging, 2013, 34, 400-407.	3.1	54
568	Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. Neurobiology of Aging, 2013, 34, 238-247.	3.1	31
569	Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling. NeuroImage: Clinical, 2013, 3, 171-179.	2.7	30

		CITATION REPORT		
#	Article		IF	CITATIONS
570	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects wit mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013.	h	3.1	86
571	Development of gray matter atrophy in relapsing–remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. Clinical Neurology and Neurosurgery, 2013, 115, S42-S48.		1.4	12

572 Sex-related differences in atrophy and lesion load in multiple sclerosis patients. NeurologÃa (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

573	Diffusion-weighted lesions after carotid artery stenting are associated with cognitive impairment. Journal of the Neurological Sciences, 2013, 328, 58-63.	0.6	45
574	LCC-Demons: A robust and accurate symmetric diffeomorphic registration algorithm. NeuroImage, 2013, 81, 470-483.	4.2	123
575	The thalamus in cirrhotic patients with and without hepatic encephalopathy: A volumetric MRI study. European Journal of Radiology, 2013, 82, e715-e720.	2.6	20
576	Lithium, Gray Matter, and Magnetic Resonance Imaging Signal. Biological Psychiatry, 2013, 73, 652-657.	1.3	81
577	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	2.3	14
578	Prefrontal vulnerabilities and whole brain connectivity in aging and depression. Neuropsychologia, 2013, 51, 1463-1470.	1.6	12
580	Thalamic atrophy in antero-medial and dorsal nuclei correlates with six-month outcome after severe brain injury. Neurolmage: Clinical, 2013, 3, 396-404.	2.7	59
581	Functional network connectivity in the behavioral variant of frontotemporal dementia. Cortex, 2013, 49, 2389-2401.	2.4	182
582	Thalamic volume and related visual recognition are associated with freezing of gait in non-demented patients with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1106-1109.	2.2	30
583	On the estimation and correction of bias in local atrophy estimations using example atrophy simulations. Computerized Medical Imaging and Graphics, 2013, 37, 538-551.	5.8	7
584	Teaching an adult brain new tricks: A critical review of evidence for training-dependent structural plasticity in humans. NeuroImage, 2013, 73, 225-236.	4.2	187
585	Cerebral Microbleeds and Cognition in Patients With Symptomatic Small Vessel Disease. Stroke, 2013, 44, 356-361.	2.0	96
586	Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease. Movement Disorders, 2013, 28, 302-310.	3.9	27
587	Intensive Reasoning Training Alters Patterns of Brain Connectivity at Rest. Journal of Neuroscience, 2013, 33, 4796-4803.	3.6	110
588	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. Genes and Immunity, 2013, 14, 244-248.	4.1	18

#	Article	IF	CITATIONS
589	The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Molecular Psychiatry, 2013, 18, 443-450.	7.9	110
590	Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. NeuroImage, 2013, 83, 472-484.	4.2	157
591	Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles. NeuroImage, 2013, 65, 288-298.	4.2	31
592	Functional connectivity in obesity during reward processing. NeuroImage, 2013, 66, 232-239.	4.2	50
593	Identification of a strategic brain network underlying processing speed deficits in vascular cognitive impairment. Neurolmage, 2013, 66, 177-183.	4.2	62
594	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. Radiology, 2013, 268, 831-841.	7.3	145
595	Long-term declarative memory deficits in diffuse TBI: Correlations with cortical thickness, white matter integrity and hippocampal volume. Cortex, 2013, 49, 646-657.	2.4	112
596	Sex Differences in Resting-State Functional Connectivity in Multiple Sclerosis. American Journal of Neuroradiology, 2013, 34, 2304-2311.	2.4	24
597	Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. Brain, 2013, 136, 106-115.	7.6	123
598	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. American Journal of Neuroradiology, 2013, 34, 1931-1939.	2.4	90
599	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology, 2013, 80, 2090-2094.	1.1	63
600	The BDNF Val66Met Polymorphism Has Opposite Effects on Memory Circuits of Multiple Sclerosis Patients and Controls. PLoS ONE, 2013, 8, e61063.	2.5	21
601	Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Multiple Sclerosis Journal, 2013, 19, 443-450.	3.0	100
602	Multimodal imaging in systemic lupus erythematosus patients with diffuse neuropsychiatric involvement. Lupus, 2013, 22, 675-683.	1.6	44
603	Sensorimotor Training and Neural Reorganization After Stroke. Journal of Neurologic Physical Therapy, 2013, 37, 27-36.	1.4	40
604	Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis. American Journal of Neuroradiology, 2013, 34, 498-504.	2.4	51
605	Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease: A 2-Year Follow-Up. American Journal of Neuroradiology, 2013, 34, 317-322.	2.4	19
606	Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis. Psychosomatic Medicine, 2013, 75, 253-261.	2.0	24

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
607	Cortical imaging in multiple sclerosis. Current Opinion in Neurology, 2013, 26, 345-352.	3.6	31
608	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis Journal, 2013, 19, 1478-1484.	3.0	85
609	17q25 Locus Is Associated With White Matter Hyperintensity Volume in Ischemic Stroke, But Not With Lacunar Stroke Status. Stroke, 2013, 44, 1609-1615.	2.0	42
610	Sports Concussions and Aging: A Neuroimaging Investigation. Cerebral Cortex, 2013, 23, 1159-1166.	2.9	148
611	Cognitive impairment in MS. Neurology, 2013, 80, 1025-1032.	1.1	155
612	A Modified Fuzzy C-Means Algorithm Brain MR Images Segmentation with Bias Field Compensation. Advanced Materials Research, 2013, 756-759, 1349-1355.	0.3	1
613	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. Radiology, 2013, 269, 542-552.	7.3	126
614	Adenosine A2A Receptors in Secondary Progressive Multiple Sclerosis: A [11C]TMSX Brain PET Study. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1394-1401.	4.3	79
615	Discriminative Analysis of Mild Alzheimer's Disease and Normal Aging Using Volume of Hippocampal Subfields and Hippocampal Mean Diffusivity. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 627-633.	1.9	47
616	Cognitive reserve and cortical atrophy in multiple sclerosis. Neurology, 2013, 80, 1728-1733.	1.1	113
617	Cerebral Blood Flow and Glucose Metabolism Measured With Positron Emission Tomography Are Decreased in Human Type 1 Diabetes. Diabetes, 2013, 62, 2898-2904.	0.6	32
618	Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 23-28.	1.9	78
619	Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology, 2013, 81, 1659-1665.	1.1	118
620	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Multiple Sclerosis International, 2013, 2013, 1-8.	0.8	9
621	Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. Multiple Sclerosis International, 2013, 2013, 1-16.	0.8	27
622	Long-Standing Balancing Selection in the <i>THBS4</i> Gene: Influence on Sex-Specific Brain Expression and Gray Matter Volumes in Alzheimer Disease. Human Mutation, 2013, 34, 743-753.	2.5	7
623	Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 392-397.	1.9	34
624	Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing–remitting multiple sclerosis: a prospective, †nonâ€randomized pilot study. European Journal of Neurology, 2013, 20, 986-990.	3.3	46

#	Article	IF	CITATIONS
625	Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis. Radiology, 2013, 266, 853-861.	7.3	42
626	Active Cognitive Reserve Influences the Regional Atrophy to Cognition Link in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2013, 19, 1128-1133.	1.8	22
627	Longitudinal Neuroimaging Biomarkers in Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 21-39.	1.9	16
628	Uso de volumetrÃa y carga lesional en el seguimiento de pacientes con esclerosis múltiple: Experiencia local y revisión de la literatura. Revista Chilena De Radiologia, 2013, 19, 156-164.	0.2	3
629	Mechanisms of Cognitive Impairment in Cerebral Small Vessel Disease: Multimodal MRI Results from the St George's Cognition and Neuroimaging in Stroke (SCANS) Study. PLoS ONE, 2013, 8, e61014.	2.5	104
630	White matter hyperintensities segmentation: a new semi-automated method. Frontiers in Aging Neuroscience, 2013, 5, 76.	3.4	55
631	The effects of physical activity on functional MRI activation associated with cognitive control in children: a randomized controlled intervention. Frontiers in Human Neuroscience, 2013, 7, 72.	2.0	181
632	Clinical imaging in drug development. , 2013, , 259-274.		0
633	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Frontiers in Bioscience - Elite, 2013, E5, 525-532.	1.8	24
634	Brain Activity Changes in Cognitive Networks in Relapsing-Remitting Multiple Sclerosis – Insights from a Longitudinal fMRI Study. PLoS ONE, 2014, 9, e93715.	2.5	42
635	Secondary Progressive and Relapsing Remitting Multiple Sclerosis Leads to Motor-Related Decreased Anatomical Connectivity. PLoS ONE, 2014, 9, e95540.	2.5	17
636	Effects of Spatial and Feature Attention on Disparity-Rendered Structure-From-Motion Stimuli in the Human Visual Cortex. PLoS ONE, 2014, 9, e100074.	2.5	1
637	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. PLoS ONE, 2014, 9, e102995.	2.5	56
638	Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum. Journal of NeuroVirology, 2014, 20, 514-520.	2.1	15
639	Olfaction evaluation and correlation with brain atrophy in Bardetâ€Biedl syndrome. Clinical Genetics, 2014, 86, 521-529.	2.0	32
640	Diffuse white matter tract abnormalities in clinically normal ageing retired athletes with a history of sports-related concussions. Brain, 2014, 137, 2997-3011.	7.6	108
642	White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study. BMC Neuroscience, 2014, 15, 106.	1.9	39
643	Efficacy of subcutaneous interferon Â-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 647-653.	1.9	23

#	Article	IF	CITATIONS
644	Tract-Specific Fractional Anisotropy Predicts Cognitive Outcome in a Community Sample of Middle-Aged Participants with White Matter Lesions. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 861-869.	4.3	16
645	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology, 2014, 82, 1768-1775.	1.1	51
646	Volumetric Analysis of Amygdala, Hippocampus, and Prefrontal Cortex in Therapy-Naive PTSD Participants. BioMed Research International, 2014, 2014, 1-6.	1.9	20
647	Impact of transcranial direct current stimulation on fatigue in multiple sclerosis. Restorative Neurology and Neuroscience, 2014, 32, 423-436.	0.7	72
648	Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1198-1208.	1.9	130
649	Side of Limb-Onset Predicts Laterality of Gray Matter Loss in Amyotrophic Lateral Sclerosis. BioMed Research International, 2014, 2014, 1-11.	1.9	18
650	Structural network efficiency is associated with cognitive impairment in small-vessel disease. Neurology, 2014, 83, 304-311.	1.1	242
651	Cortical <i>N</i> -acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. Neurological Research, 2014, 36, 701-708.	1.3	9
652	Impact of regional white matter lesions on cognitive function in subcortical vascular cognitive impairment. Neurological Research, 2014, 36, 434-443.	1.3	22
653	Hippocampal atrophy in people with memory deficits: results from the population-based IPREA study. International Psychogeriatrics, 2014, 26, 1067-1081.	1.0	19
654	A randomized controlled phase II trial of riluzole in early multiple sclerosis. Annals of Clinical and Translational Neurology, 2014, 1, 340-347.	3.7	33
655	Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 720-727.	2.0	26
656	What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?. Radiology, 2014, 272, 832-842.	7.3	69
657	Structural correlates of subjective and objective memory performance in multiple sclerosis. Hippocampus, 2014, 24, 436-445.	1.9	23
658	Parahippocampal gray matter alterations in Spinocerebellar Ataxia Type 2 identified by voxel based morphometry. Journal of the Neurological Sciences, 2014, 347, 50-58.	0.6	32
659	MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge. Acta Neurologica Scandinavica, 2014, 129, 32-36.	2.1	14
660	Brain connectivity abnormalities extend beyond the sensorimotor network in peripheral neuropathy. Human Brain Mapping, 2014, 35, 513-526.	3.6	15
661	Gender, ageâ€related, and regional differences of the magnetization transfer ratio of the cortical and subcortical brain gray matter. Journal of Magnetic Resonance Imaging, 2014, 40, 360-366.	3.4	9

#	Article	IF	CITATIONS
662	Longitudinal reliability of tractâ€based spatial statistics in diffusion tensor imaging. Human Brain Mapping, 2014, 35, 4544-4555.	3.6	76
663	Responses to interocular disparity correlation in the human cerebral cortex. Ophthalmic and Physiological Optics, 2014, 34, 186-198.	2.0	17
664	Effect of Leukocyte Telomere Length on Total and Regional Brain Volumes in a Large Population-Based Cohort. JAMA Neurology, 2014, 71, 1247.	9.0	74
665	Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1109-1115.	1.9	155
666	Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study. Human Brain Mapping, 2014, 35, 5799-5814.	3.6	73
667	Cortical and Subcortical Atrophy in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2014, 28, 65-72.	1.3	49
668	Brain atrophy as a non-response predictor to interferon-beta in relapsing–remitting multiple sclerosis. Neurological Research, 2014, 36, 615-618.	1.3	13
669	Simulating Neurodegeneration through Longitudinal Population Analysis of Structural and Diffusion Weighted MRI Data. Lecture Notes in Computer Science, 2014, 17, 57-64.	1.3	7
670	Handgrip-Related Activation in the Primary Motor Cortex Relates to Underlying Neuronal Metabolism After Stroke. Neurorehabilitation and Neural Repair, 2014, 28, 433-442.	2.9	13
671	Microstructural Brain Tissue Damage in Metabolic Syndrome. Diabetes Care, 2014, 37, 493-500.	8.6	49
672	Evidence for structural and functional abnormality in the subgenual anterior cingulate cortex in major depressive disorder. Psychological Medicine, 2014, 44, 3263-3273.	4.5	71
673	Brain Volume and Fatigue in Patients With Postpoliomyelitis Syndrome. PM and R, 2014, 6, 215-220.	1.6	5
674	Automated cerebellar segmentation: Validation and application to detect smaller volumes in children prenatally exposed to alcohol. NeuroImage: Clinical, 2014, 4, 295-301.	2.7	28
675	Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. NeuroImage: Clinical, 2014, 4, 10-17.	2.7	73
676	Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis. Journal of the Neurological Sciences, 2014, 342, 62-68.	0.6	40
677	Cognitive change and neuroimaging following immunoablative therapy and hematopoietic stem cell transplantation in multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders, 2014, 3, 129-135.	2.0	8
678	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	2.3	21
679	Thalamic diffusion differences related to cognitive function in white matter lesions. Neurobiology of Aging, 2014, 35, 1103-1110.	3.1	5

#	Article	IF	CITATIONS
680	Comprehensive morphometry of subcortical grey matter structures in earlyâ€stage Parkinson's disease. Human Brain Mapping, 2014, 35, 1681-1690.	3.6	84
681	Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement. Human Brain Mapping, 2014, 35, 1101-1110.	3.6	32
682	Are there any gender differences in the hippocampus volume after head-size correction? A volumetric and voxel-based morphometric study. Neuroscience Letters, 2014, 570, 119-123.	2.1	77
683	Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease. Human Brain Mapping, 2014, 35, 3132-3142.	3.6	126
684	Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: An MEG source-space study. Neurolmage, 2014, 88, 308-318.	4.2	126
685	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20. 1704-1713.	3.0	41
686	Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology, 2014, 82, 1776-1783.	1.1	156
687	Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. Psychological Medicine, 2014, 44, 1171-1182.	4.5	110
688	The effect of exercise on hippocampal volume and neurotrophines in patients with major depression–A randomized clinical trial. Journal of Affective Disorders, 2014, 165, 24-30.	4.1	91
689	Anticardiolipin antibodies are associated with cognitive dysfunction in strokeâ€free individuals. European Journal of Neurology, 2014, 21, 427.	3.3	8
690	Multiple Sclerosis: Altered Thalamic Resting-State Functional Connectivity and Its Effect on Cognitive Function. Radiology, 2014, 271, 814-821.	7.3	116
691	Structural brain MRI abnormalities in pediatric patients with migraine. Journal of Neurology, 2014, 261, 350-357.	3.6	76
692	Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurology, 2014, 71, 306.	9.0	402
693	Neuroanatomical precursors of dyslexia identified from pre-reading through to age 11. Brain, 2014, 137, 3136-3141.	7.6	127
694	The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemporary Clinical Trials, 2014, 39, 288-293.	1.8	64
695	In vivo evidence of glutamate toxicity in multiple sclerosis. Annals of Neurology, 2014, 76, 269-278.	5.3	88
696	The SIENA/FSL whole brain atrophy algorithm is no more reproducible at 3 T than 1.5 T for Alzheimer׳s disease. Psychiatry Research - Neuroimaging, 2014, 224, 14-21.	1.8	12
697	Sub-millimeter imaging of brain-free water for rapid volume assessment in atrophic brains. NeuroImage, 2014, 100, 370-378.	4.2	10

#	Article	IF	CITATIONS
698	Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington's disease. Movement Disorders, 2014, 29, 1429-1433.	3.9	23
699	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	1.9	35
700	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurology, 2014, 14, 131.	1.8	11
701	Precision medicine in chronic disease management: The multiple sclerosis <scp>B</scp> io <scp>S</scp> creen. Annals of Neurology, 2014, 76, 633-642.	5.3	53
702	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. Journal of Neurology, 2014, 261, 1735-1744.	3.6	45
703	Aortic stiffness is associated with white matter integrity in patients with type 1 diabetes. European Radiology, 2014, 24, 2031-2037.	4.5	9
704	A New Fast Accurate Nonlinear Medical Image Registration Program Including Surface Preserving Regularization. IEEE Transactions on Medical Imaging, 2014, 33, 2118-2127.	8.9	16
705	White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression. Cortex, 2014, 52, 98-112.	2.4	57
706	Hippocampal volume is related to cognitive decline and fornicial diffusion measures in multiple sclerosis. Magnetic Resonance Imaging, 2014, 32, 354-358.	1.8	54
707	Patterns of regional gray matter and white matter atrophy in cortical multiple sclerosis. Journal of Neurology, 2014, 261, 1715-1725.	3.6	11
708	Brain region's relative proximity as marker for Alzheimer's disease based on structural MRI. BMC Medical Imaging, 2014, 14, 21.	2.7	31
709	Neurocognitive enhancement in older adults: Comparison of three cognitive training tasks to test a hypothesis of training transfer in brain connectivity. NeuroImage, 2014, 85, 1027-1039.	4.2	114
710	Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. NeuroImage: Clinical, 2014, 4, 366-373.	2.7	38
711	Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. NeuroImage, 2014, 90, 207-217.	4.2	48
712	Frontal white matter alterations are associated with executive cognitive function in euthymic bipolar patients. Journal of Affective Disorders, 2014, 155, 223-233.	4.1	73
713	Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. Multiple Sclerosis and Related Disorders, 2014, 3, 533-541.	2.0	16
714	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. Journal of Diabetes and Its Complications, 2014, 28, 85-90.	2.3	17
715	Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis. NeuroImage: Clinical, 2014, 4, 641-648.	2.7	22

			_
#	ARTICLE	IF	CITATIONS
716	Deficits in episodic memory retrieval reveal impaired default mode network connectivity in amnestic mild cognitive impairment. NeuroImage: Clinical, 2014, 4, 473-480.	2.7	61
717	Automated algorithm to measure changes in medial temporal lobe volume in Alzheimer disease. Journal of Neuroscience Methods, 2014, 227, 35-46.	2.5	14
718	Cardiovascular risks and brain function: a functional magnetic resonance imaging study of executive function in older adults. Neurobiology of Aging, 2014, 35, 1396-1403.	3.1	51
719	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurology, The, 2014, 13, 472-481.	10.2	83
720	Strategic lacunes and their relationship to cognitive impairment in cerebral small vessel disease. NeuroImage: Clinical, 2014, 4, 828-837.	2.7	65
721	Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage: Clinical, 2014, 4, 454-460.	2.7	107
722	Remote thalamic microstructural abnormalities related to cognitive function in ischemic stroke patients Neuropsychology, 2014, 28, 984-996.	1.3	26
723	Automatic MRI image threshold using fuzzy support vector machines. , 2015, , .		2
724	Determinants of HIV-induced brain changes in three different periods of the early clinical course: A data mining analysis. NeuroImage: Clinical, 2015, 9, 75-82.	2.7	16
725	Changes in cerebral vascular reactivity and structure following prolonged exposure to high altitude in humans. Physiological Reports, 2015, 3, e12647.	1.7	14
726	In Vivo MRI Evidence that Neuropathology is Attenuated by Cognitive Enrichment in the Yac128 Huntington's Disease Mouse Model. Journal of Huntington's Disease, 2015, 4, 149-160.	1.9	6
727	Hippocampal volume and auditory attention on a verbal memory task with adult survivors of pediatric brain tumor Neuropsychology, 2015, 29, 303-319.	1.3	36
728	Decreased bilateral thalamic gray matter volume in first-episode schizophrenia with prominent hallucinatory symptoms: A volumetric MRI study. Scientific Reports, 2015, 5, 14505.	3.3	42
729	More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 635-647.	2.6	46
730	Effects of diazoxide in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e147.	6.0	8
731	Set-Shifting Ability Is Associated with Gray Matter Volume in Older People with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 395-403.	1.3	6
732	Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker. NeuroImage: Clinical, 2015, 9, 574-580.	2.7	44
733	Multiâ€modal robust inverseâ€consistent linear registration. Human Brain Mapping, 2015, 36, 1365-1380.	3.6	5

#	Article	IF	CITATIONS
734	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurology, 2015, 15, 232.	1.8	12
735	Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. Journal of Computer Assisted Tomography, 2015, 39, 559-564.	0.9	4
736	Periventricular lesions correlate with cortical thinning in multiple sclerosis. Annals of Neurology, 2015, 78, 530-539.	5.3	29
737	Heterogeneity of Multiple Sclerosis White Matter Lesions Detected With T2*â€Weighted Imaging at 7.0 Tesla. Journal of Neuroimaging, 2015, 25, 799-806.	2.0	26
738	Brainstem morphological changes in Alzheimer's disease. NeuroReport, 2015, 26, 411-415.	1.2	55
739	Dissociating Statistically-Determined Alzheimer's Disease/Vascular Dementia Neuropsychological Syndromes Using White and Gray Neuroradiological Parameters. Journal of Alzheimer's Disease, 2015, 48, 833-847.	2.6	13
740	ICA-based artifact removal diminishes scan site differences in multi-center resting-state fMRI. Frontiers in Neuroscience, 2015, 9, 395.	2.8	61
741	Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing. Frontiers in Neuroscience, 2015, 9, 456.	2.8	19
742	The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0116511.	2.5	37
743	Temporal Lobe and Frontal-Subcortical Dissociations in Non-Demented Parkinson's Disease with Verbal Memory Impairment. PLoS ONE, 2015, 10, e0133792.	2.5	20
744	Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis. Mediators of Inflammation, 2015, 2015, 1-5.	3.0	15
745	Objectively Measured Physical Activity Is Associated with Brain Volumetric Measurements in Multiple Sclerosis. Behavioural Neurology, 2015, 2015, 1-5.	2.1	55
746	Cross-Hemispheric Collaboration and Segregation Associated with Task Difficulty as Revealed by Structural and Functional Connectivity. Journal of Neuroscience, 2015, 35, 8191-8200.	3.6	53
747	Beating the brain about abuse: Empirical and meta-analytic studies of the association between maltreatment and hippocampal volume across childhood and adolescence. Development and Psychopathology, 2015, 27, 507-520.	2.3	94
748	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309903.	1.9	162
749	Neuroimaging evidence of gray and white matter damage and clinical correlates in progressive supranuclear palsy. Journal of Neurology, 2015, 262, 1850-1858.	3.6	28
750	Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy. Journal of Neurology, 2015, 262, 2617-2626.	3.6	34
751	Improved Correction of Residual Intensity Nonuniformity in 2D FLAIR MR Images of Brain at 3-T MRI scanner. Applied Magnetic Resonance, 2015, 46, 941-951.	1.2	0

#	Article	IF	CITATIONS
752	Interhemispheric microstructural connectivity in bitemporal lobe epilepsy with hippocampal sclerosis. Cortex, 2015, 67, 106-121.	2.4	33
753	Cardiorespiratory fitness and its association with thalamic, hippocampal, and basal ganglia volumes in multiple sclerosis. NeuroImage: Clinical, 2015, 7, 661-666.	2.7	62
754	Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations. NeuroImage, 2015, 118, 126-132.	4.2	96
755	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310051.	1.9	95
756	Subcortical structure alterations impact language processing in individuals with schizophrenia and those at high genetic risk. Schizophrenia Research, 2015, 169, 76-82.	2.0	19
757	Longitudinal brain MR retrieval with diffeomorphic demons registration: What happened to those patients with similar changes?. , 2015, , .		11
758	Predictive value of early brain atrophy on response in patients treated with interferon β. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e132.	6.0	28
759	Do small differences in hydration status affect mood and mental performance?. Nutrition Reviews, 2015, 73, 83-96.	5.8	96
760	Very Early Brain Damage Leads to Remodeling of the Working Memory System in Adulthood: A Combined fMRI/Tractography Study. Journal of Neuroscience, 2015, 35, 15787-15799.	3.6	34
761	Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. NeuroImage: Clinical, 2015, 9, 640-647.	2.7	31
762	Impaired Functional Connectivity Unmasked by Simple Repetitive Motor Task in Early Relapsing-Remitting Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 557-565.	2.9	9
763	Characterising the grey matter correlates of leukoaraiosis in cerebral small vessel disease. NeuroImage: Clinical, 2015, 9, 194-205.	2.7	66
764	Comparison of automated brain segmentation using a brain phantom and patients with early Alzheimer's dementia or mild cognitive impairment. Psychiatry Research - Neuroimaging, 2015, 233, 299-305.	1.8	39
765	3†magnetic resonance imaging simultaneous automated multimodal approach improves detection of ambiguous visual hippocampal sclerosis. European Journal of Neurology, 2015, 22, 725.	3.3	13
766	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. NeuroImage: Clinical, 2015, 9, 418-429.	2.7	38
767	Smaller Amygdala Volumes in Patients With Chronic Low Back Pain Compared With Healthy Control Individuals. Journal of Pain, 2015, 16, 1366-1376.	1.4	22
768	Functional brain networks: Linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG Study. Human Brain Mapping, 2015, 36, 603-618.	3.6	96
769	The role of cerebellar abnormalities in neuromyelitis optica – a comparison with multiple sclerosis and healthy controls. Multiple Sclerosis Journal, 2015, 21, 757-766.	3.0	9

#	Article	IF	CITATIONS
770	Neurophysiological correlates of dysregulated emotional arousal in severe traumatic brain injury. Clinical Neurophysiology, 2015, 126, 314-324.	1.5	18
771	Brain alterations within the first 100Âdays of <scp>HIV</scp> infection. Annals of Clinical and Translational Neurology, 2015, 2, 12-21.	3.7	85
772	Morphological derivation overflow as a result of disruption of the left frontal aslant white matter tract. Brain and Language, 2015, 142, 54-64.	1.6	56
773	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology, 2015, 84, 1145-1152.	1.1	63
774	Linked alterations in gray and white matter morphology in adults with high-functioning autism spectrum disorder: A multimodal brain imaging study. NeuroImage: Clinical, 2015, 7, 155-169.	2.7	71
775	The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and <scp>A</scp> lzheimer's disease. Human Brain Mapping, 2015, 36, 2093-2117.	3.6	54
776	Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies. NeuroImage: Clinical, 2015, 7, 456-462.	2.7	44
777	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology, 2015, 84, 784-793.	1.1	119
778	Empowering imaging biomarkers of Alzheimer's disease. Neurobiology of Aging, 2015, 36, S69-S80.	3.1	22
779	Brain Atrophy in Radiologically Isolated Syndromes. Journal of Neuroimaging, 2015, 25, 68-71.	2.0	53
780	Morphometric and functional MRI changes in essential tremor with and without resting tremor. Journal of Neurology, 2015, 262, 719-728.	3.6	39
781	What drives MRI-measured cortical atrophy in multiple sclerosis?. Multiple Sclerosis Journal, 2015, 21, 1280-1290.	3.0	94
782	Computer-aided cognitive rehabilitation improves cognitive performances and induces brain functional connectivity changes in relapsing remitting multiple sclerosis patients: an exploratory study. Journal of Neurology, 2015, 262, 91-100.	3.6	93
783	Disrupted Resting-State Functional Connectivity in Progressive Supranuclear Palsy. American Journal of Neuroradiology, 2015, 36, 915-921.	2.4	27
784	Identifying craniofacial features associated with prenatal exposure to androgens and testing their relationship with brain development. Brain Structure and Function, 2015, 220, 3233-3244.	2.3	14
785	Microstructure of the superior longitudinal fasciculus predicts stimulation-induced interference with on-line motor control. NeuroImage, 2015, 120, 254-265.	4.2	25
786	Longitudinal regional brain volume loss in schizophrenia: Relationship to antipsychotic medication and change in social function. Schizophrenia Research, 2015, 168, 297-304.	2.0	56
787	Pallidal and caudate volumes correlate with walking function in multiple sclerosis. Journal of the Neurological Sciences, 2015, 354, 33-36.	0.6	34

	CHANON		
#	Article	IF	CITATIONS
788	Gray matter damage in multiple sclerosis: Impact on clinical symptoms. Neuroscience, 2015, 303, 446-461.	2.3	65
789	Exploring the 3D geometry of the diffusion kurtosis tensor—Impact on the development of robust tractography procedures and novel biomarkers. NeuroImage, 2015, 111, 85-99.	4.2	45
790	Cortical morphology and early adverse birth events in men with first-episode psychosis. Psychological Medicine, 2015, 45, 1825-1837.	4.5	17
791	Qualitative and Quantitative Analysis of MR Imaging Findings in Patients with Middle Cerebral Artery Stroke Implanted with Mesenchymal Stem Cells. American Journal of Neuroradiology, 2015, 36, 1063-1068.	2.4	4
792	Computing Brain Change over Time. , 2015, , 417-428.		2
793	Volume of hippocampal substructures in borderline personality disorder. Psychiatry Research - Neuroimaging, 2015, 231, 218-226.	1.8	16
794	Thalamic and extrathalamic mechanisms of consciousness after severe brain injury. Annals of Neurology, 2015, 78, 68-76.	5.3	137
795	The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis. Journal of the Neurological Sciences, 2015, 351, 18-23.	0.6	19
796	Cluster analysis reveals abnormal hippocampal neurometabolic profiles in young people with mood disorders. European Neuropsychopharmacology, 2015, 25, 836-845.	0.7	23
797	Connectivityâ€based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. Human Brain Mapping, 2015, 36, 2809-2825.	3.6	69
798	Lower Blood Pressure and Gray Matter Integrity Loss in Older Persons. Journal of Clinical Hypertension, 2015, 17, 630-637.	2.0	10
799	Boosting diagnosis accuracy of Alzheimer's disease using high dimensional recognition of longitudinal brain atrophy patterns. Behavioural Brain Research, 2015, 290, 124-130.	2.2	40
800	11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1081-1092.	6.4	77
801	Automated CT-based segmentation and quantification of total intracranial volume. European Radiology, 2015, 25, 3151-3160.	4.5	17
802	Relationship between iron accumulation and white matter injury in multiple sclerosis: a case–control study. Journal of Neurology, 2015, 262, 402-409.	3.6	22
803	Distributed abnormalities of brain white matter architecture in patients with dominant optic atrophy and OPA1 mutations. Journal of Neurology, 2015, 262, 1216-1227.	3.6	5
804	Freezing of gait and white matter changes: a tract-based spatial statistics study. Journal of Clinical Movement Disorders, 2015, 2, 1.	2.2	32
805	Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. American Journal of Clinical Nutrition, 2015, 102, 215-221.	4.7	150

#	Article	IF	CITATIONS
806	Altered functional connectivity within the central reward network in overweight and obese women. Nutrition and Diabetes, 2015, 5, e148-e148.	3.2	61
807	Cognitive impairment and memory disorders in relapsing–remitting multiple sclerosis: the role of white matter, gray matter and hippocampus. Journal of Neurology, 2015, 262, 1691-1697.	3.6	53
808	Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease. NeuroImage: Clinical, 2015, 8, 126-132.	2.7	45
809	Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiology of Aging, 2015, 36, 2429-2442.	3.1	76
810	Know your tools—concordance of different methods for measuring brain volume change after ischemic stroke. Neuroradiology, 2015, 57, 685-695.	2.2	7
811	Extensive Gray Matter Volume Reduction in Treatment-Resistant Schizophrenia. International Journal of Neuropsychopharmacology, 2015, 18, pyv016-pyv016.	2.1	67
812	Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients. NeuroImage: Clinical, 2015, 9, 110-116.	2.7	16
813	Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. JAMA Neurology, 2015, 72, 1466.	9.0	32
814	Genetic Architecture of White Matter Hyperintensities Differs in Hypertensive and Nonhypertensive Ischemic Stroke. Stroke, 2015, 46, 348-353.	2.0	25
815	White matter microstructural changes in pure Alzheimer's disease and subcortical vascular dementia. European Journal of Neurology, 2015, 22, 709-716.	3.3	34
816	Changes of Migraineâ€Related White Matter Hyperintensities After 3 Years: A Longitudinal <scp>MRI</scp> Study. Headache, 2015, 55, 55-70.	3.9	46
817	Subcortical Structure Volumes and Correlation to Clinical Variables in Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 275-280.	2.0	18
818	Diffuse and Focal Corticospinal Tract Disease and Its Impact on Patient Disability in Multiple Sclerosis. Journal of Neuroimaging, 2015, 25, 200-206.	2.0	26
819	Parameters of glucose metabolism and the aging brain: a magnetization transfer imaging study of brain macro- and micro-structure in older adults without diabetes. Age, 2015, 37, 9802.	3.0	8
820	Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology, 2015, 85, 1722-1723.	1.1	26
821	Structural MRI substrates of cognitive impairment in neuromyelitis optica. Neurology, 2015, 85, 1491-1499.	1.1	63
822	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurology, 2015, 72, 1458.	9.0	130
823	The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders, 2015, 8, 193-202.	3.5	24

#	Article	IF	CITATIONS
824	Effect of Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning—the DANTE Study Leiden. JAMA Internal Medicine, 2015, 175, 1622.	5.1	107
825	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. American Journal of Neuroradiology, 2015, 36, 1457-1464.	2.4	13
826	Lower Blood Pressure Is Associated With Smaller Subcortical Brain Volumes in Older Persons. American Journal of Hypertension, 2015, 28, 1127-1133.	2.0	23
827	Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies. Journal of the Neurological Sciences, 2015, 358, 46-52.	0.6	52
828	A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. Journal of Neurology, 2015, 262, 149-153.	3.6	32
829	Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS. Brain Structure and Function, 2015, 220, 435-444.	2.3	74
830	Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST). NeuroImage: Clinical, 2015, 7, 43-52.	2.7	23
831	Non-Gaussian diffusion MRI of gray matter is associated with cognitive impairment in multiple sclerosis Journal, 2015, 21, 935-944.	3.0	64
832	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 410-418.	1.9	111
833	The Prognostic Utility of MRI in Clinically Isolated Syndrome: A Literature Review. American Journal of Neuroradiology, 2015, 36, 425-431.	2.4	15
834	Measuring brain atrophy with a generalized formulation of the boundary shift integral. Neurobiology of Aging, 2015, 36, S81-S90.	3.1	24
835	Mindfulness Training for Older Adults with Subjective Cognitive Decline: Results from a Pilot Randomized Controlled Trial. Journal of Alzheimer's Disease, 2016, 52, 757-774.	2.6	83
836	Vertex-wise shape analysis of subcortical structures in Alzheimer's disease. Healthy Aging Research, 2016, 5, 1-8.	0.3	0
837	Aberrant brain-stem morphometry associated with sleep disturbance in drug-naïve subjects with Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2089-2093.	2.2	3
838	Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. Parkinson's Disease, 2016, 2016, 1-7.	1.1	9
839	Motor Skill Acquisition Promotes Human Brain Myelin Plasticity. Neural Plasticity, 2016, 2016, 1-7.	2.2	74
840	Abnormal Subcortical Brain Morphology in Patients with Knee Osteoarthritis: A Cross-sectional Study. Frontiers in Aging Neuroscience, 2016, 8, 3.	3.4	39
841	Whole-Brain Atrophy Differences between Progressive Supranuclear Palsy and Idiopathic Parkinson's Disease. Frontiers in Aging Neuroscience, 2016, 8, 218.	3.4	7

#	Article	IF	CITATIONS
842	Global Efficiency of Structural Networks Mediates Cognitive Control in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2016, 08, 292.	3.4	51
843	Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment. Frontiers in Neurology, 2016, 7, 131.	2.4	59
844	Inter-Method Discrepancies in Brain Volume Estimation May Drive Inconsistent Findings in Autism. Frontiers in Neuroscience, 2016, 10, 439.	2.8	35
845	Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. International Journal of Molecular Sciences, 2016, 17, 1894.	4.1	28
846	Robustness of Automated Methods for Brain Volume Measurements across Different MRI Field Strengths. PLoS ONE, 2016, 11, e0165719.	2.5	83
847	Neuroanatomical Abnormalities in Violent Individuals with and without a Diagnosis of Schizophrenia. PLoS ONE, 2016, 11, e0168100.	2.5	25
848	A Neural Basis for the Acquired Capability for Suicide. Frontiers in Psychiatry, 2016, 7, 125.	2.6	42
849	Subgenual Cingulate Cortex Functional Connectivity in Relation to Depressive Symptoms and Cognitive Functioning in Type 1 Diabetes Mellitus Patients. Psychosomatic Medicine, 2016, 78, 740-749.	2.0	16
850	Whole-brain atrophy. Current Opinion in Neurology, 2016, 29, 237-242.	3.6	30
851	Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. European Journal of Neurology, 2016, 23, 1101-1109.	3.3	18
852	Automated alignment of perioperative MRI scans: A technical note and application in pediatric epilepsy surgery. Human Brain Mapping, 2016, 37, 3530-3543.	3.6	4
853	Improved spatial regression analysis of diffusion tensor imaging for lesion detection during longitudinal progression of multiple sclerosis in individual subjects. Physics in Medicine and Biology, 2016, 61, 2497-2513.	3.0	4
854	Postmortem validation of MRI cortical volume measurements in MS. Human Brain Mapping, 2016, 37, 2223-2233.	3.6	31
855	Alterations of putaminal shape in de novo Parkinson's disease. Movement Disorders, 2016, 31, 676-683.	3.9	15
856	White Matter Volume Mediates the Relationship Between Self-Efficacy and Mobility in Older Women. Experimental Aging Research, 2016, 42, 460-470.	1.2	1
857	Automated brain volumetrics in multiple sclerosis: a step closer to clinical application. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 754-757.	1.9	47
858	Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 580-588.	1.9	82
859	Ageing and brain white matter structure in 3,513 UK Biobank participants. Nature Communications, 2016, 7, 13629.	12.8	373

#	Article	IF	CITATIONS
860	Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis. Scientific Reports, 2016, 6, 38481.	3.3	54
861	Striatal morphology correlates with frontostriatal electrophysiological motor processing in Huntington's disease: an IMAGEâ€HD study. Brain and Behavior, 2016, 6, e00511.	2.2	7
862	Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731665536.	1.0	7
863	Segmentation of longitudinal brain MR images using bias correction embedded fuzzy c-means with non-locally spatio-temporal regularization. Journal of Visual Communication and Image Representation, 2016, 38, 517-529.	2.8	20
864	White Matter Lesions, Carotid and Coronary Atherosclerosis in Late-Onset Depression and Healthy Controls. Psychosomatics, 2016, 57, 369-377.	2.5	13
865	Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). Journal of Neurology, 2016, 263, 1364-1374.	3.6	13
866	Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1319-1337.	4.3	80
867	Head circumference as a useful surrogate for intracranial volume in older adults. International Psychogeriatrics, 2016, 28, 157-162.	1.0	18
868	Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2016, 7, 98-101.	2.0	23
869	Gray Matter Involvement in Radiologically Isolated Syndrome. Medicine (United States), 2016, 95, e3208.	1.0	22
869 870	Gray Matter Involvement in Radiologically Isolated Syndrome. Medicine (United States), 2016, 95, e3208. Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 981-991.	1.0 4.3	22 10
	Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Journal of Cerebral Blood Flow and		
870	Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 981-991. Variations in multiple sclerosis practice within Europe $\hat{a} \in$ Is it time for a new treatment guideline?	4.3	10
870 871	Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 981-991. Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline?. Multiple Sclerosis and Related Disorders, 2016, 8, 35-44. Cerebral Microbleeds and Lacunar Infarcts Are Associated with Walking Speed Independent of	4.3 2.0	10 23
870 871 872	Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 981-991. Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline?. Multiple Sclerosis and Related Disorders, 2016, 8, 35-44. Cerebral Microbleeds and Lacunar Infarcts Are Associated with Walking Speed Independent of Cognitive Performance in Middle-Aged to Older Adults. Gerontology, 2016, 62, 500-507. Liver Fat Assessed With CT Relates to MRI Markers of Incipient Brain Injury in Middle-Aged to Elderly	4.3 2.0 2.8	10 23 20
870 871 872 873	Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 981-991. Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline?. Multiple Sclerosis and Related Disorders, 2016, 8, 35-44. Cerebral Microbleeds and Lacunar Infarcts Are Associated with Walking Speed Independent of Cognitive Performance in Middle-Aged to Older Adults. Gerontology, 2016, 62, 500-507. Liver Fat Assessed With CT Relates to MRI Markers of Incipient Brain Injury in Middle-Aged to Elderly Overweight Persons. American Journal of Roentgenology, 2016, 206, 1087-1092. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a	4.3 2.0 2.8 2.2	10 23 20 7
870 871 872 873 874	Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 981-991. Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline?. Multiple Sclerosis and Related Disorders, 2016, 8, 35-44. Cerebral Microbleeds and Lacunar Infarcts Are Associated with Walking Speed Independent of Cognitive Performance in Middle-Aged to Older Adults. Gerontology, 2016, 62, 500-507. Liver Fat Assessed With CT Relates to MRI Markers of Incipient Brain Injury in Middle-Aged to Elderly Overweight Persons. American Journal of Roentgenology, 2016, 206, 1087-1092. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793. Episodic memory in depression: the unique contribution of the anterior caudate and hippocampus.	4.3 2.0 2.8 2.2 2.8	10 23 20 7 126

#	Article	IF	CITATIONS
878	Severe Progressive Brain Atrophy in Pediatric Multiple Sclerosis. Journal of Pediatric Neuroradiology, 2016, 04, 032-035.	0.1	0
879	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2016, 252, 26-35.	1.8	20
880	Machine Learning and Interpretation in Neuroimaging. Lecture Notes in Computer Science, 2016, , .	1.3	0
881	The association between retinal nerve fibre layer thickness and <i>N</i> â€acetyl aspartate levels in multiple sclerosis brain normalâ€appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography. European Journal of Neurology, 2016, 23, 1769-1774.	3.3	9
882	Multisite, multimodal neuroimaging of chronic urological pelvic pain: Methodology of the MAPP Research Network. NeuroImage: Clinical, 2016, 12, 65-77.	2.7	29
883	Total intracranial and lateral ventricle volumes measurement in Alzheimer's disease: A methodological study. Journal of Clinical Neuroscience, 2016, 34, 133-139.	1.5	17
884	In vivo delineation of subdivisions of the human amygdaloid complex in a highâ€resolution group template. Human Brain Mapping, 2016, 37, 3979-3998.	3.6	132
885	Brain Activity and Functional Connectivity Associated with Hypnosis. Cerebral Cortex, 2017, 27, 4083-4093.	2.9	98
886	Quantifying brain volumes for Multiple Sclerosis patients followâ€up in clinical practice – comparison of 1.5 and 3 Tesla magnetic resonance imaging. Brain and Behavior, 2016, 6, e00422.	2.2	27
887	Fully automated openâ€source lesion mapping of T2â€ <scp>FLAIR</scp> images with <scp>FSL</scp> correlates with clinical disability in <scp>MS</scp> . Brain and Behavior, 2016, 6, e00440.	2.2	11
888	Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. Journal of Neuroimaging, 2016, 26, 62-67.	2.0	48
889	Abnormal functional connectivity and cortical integrity influence dominant hand motor disability in multiple sclerosis: a multimodal analysis. Human Brain Mapping, 2016, 37, 4262-4275.	3.6	21
890	Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. NeuroImage, 2016, 142, 188-197.	4.2	81
891	Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy. Psychiatry Research - Neuroimaging, 2016, 255, 87-93.	1.8	42
892	Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome. Brain and Behavior, 2016, 6, e00539.	2.2	9
893	Structural sex differences at disease onset in multiple sclerosis patients. Neuroradiology Journal, 2016, 29, 368-371.	1.2	11
894	Brain volume loss contributes to arousal and empathy dysregulation following severe traumatic brain injury. Neurolmage: Clinical, 2016, 12, 607-614.	2.7	18
895	A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurology, 2016, 16, 240.	1.8	14

ARTICLE IF CITATIONS # Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. Journal of the 896 1.8 18 International Neuropsychological Society, 2016, 22, 920-927. Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain and 2.2 58 Behavior, 2016, 6, e00518. Striatal functional connectivity changes following specific balance training in elderly people: MRI 898 1.4 25 results of a randomized controlled pilot study. Gait and Posture, 2016, 49, 334-339. Bayesian longitudinal segmentation of hippocampal substructures in brain MRI using subject-specific 899 130 atlases. NeuroImage, 2016, 141, 542-555. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease. 900 2.7 46 Neurolmage: Clinical, 2016, 11, 736-742. Reversible Brain Abnormalities in People Without Signs of Mountain Sickness During High-Altitude 3.3 Exposure. Scientific Reports, 2016, 6, 33596. Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following 902 immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis. Multiple 1.1 2 Sclerosis and Demyelinating Disorders, 2016, 1, . Normal-appearing brain tissue analysis in radiologically isolated syndrome using 3 T MRI. Medicine (United States), 2016, 95, e4101. 903 1.0 Brain white matter changes associated with urological chronic pelvic pain syndrome: multisite 904 4.2 43 neuroimaging from a MAPP case–control study. Pain, 2016, 157, 2782-2791. Does hydration status affect MRI measures of brain volume or water content?. Journal of Magnetic 3.4 Resonance Imaging, 2016, 44, 296-304. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple 906 13.7 296 sclerosis: a multicentre single-group phase 2 trial. Lancet, The, 2016, 388, 576-585. A semi-automated measuring system of brain diffusion and perfusion magnetic resonance imaging abnormalities in patients with multiple sclerosis based on the integration of coregistration and tissue segmentation procedures. BMC Medical Imaging, 2016, 16, 4. Abnormalities of white matter integrity in the corpus callosum of adolescents with PTSD after 908 4.7 44 childhood sexual abuse: a DTI study. European Child and Adolescent Psychiatry, 2016, 25, 869-878. Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and 909 Quantitative Susceptibility Maps: A Case-Control Study. Radiology, 2016, 281, 884-895. 63 Brain activation profiles during kinesthetic and visual imagery: An fMRI study. Brain Research, 2016, 910 2.2 44 1646, 249-261. Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological 53 status in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 36-42. Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. 912 6.0 39 Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e190. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, 379 double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084.

	CHATION		
#	Article	IF	CITATIONS
914	Brain structural changes in women and men during midlife. Neuroscience Letters, 2016, 615, 107-112.	2.1	15
915	Frontoparietal white matter integrity predicts haptic performance in chronic stroke. Neurolmage: Clinical, 2016, 10, 129-139.	2.7	12
916	Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 1010-1016.	2.4	27
917	White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 1030-1037.	2.4	10
918	Diffusion tensor imaging of the corticospinal tract and walking performance in multiple sclerosis. Journal of the Neurological Sciences, 2016, 363, 225-231.	0.6	28
919	Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study. Radiology, 2016, 280, 869-879.	7.3	29
920	Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegenerative Diseases, 2016, 16, 77-86.	1.4	29
921	Fatigue in multiple sclerosis: The contribution of occult white matter damage. Multiple Sclerosis Journal, 2016, 22, 1676-1684.	3.0	48
922	The relationship between the rate of brain volume loss during first 24Âmonths and disability progression over 24 and 48Âmonths in relapsing MS. Journal of Neurology, 2016, 263, 299-305.	3.6	10
923	Impairments in precision, rather than spatial strategy, characterize performance on the virtual Morris Water Maze: A case study. Neuropsychologia, 2016, 80, 90-101.	1.6	62
924	Structural and functional brain changes in delusional disorder. British Journal of Psychiatry, 2016, 208, 153-159.	2.8	25
925	What you cannot get from routine MRI of MS patient and why – The growing need for atrophy assessment and seeing beyond the plaque. Neurologia I Neurochirurgia Polska, 2016, 50, 123-130.	1.2	5
926	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Multiple Sclerosis Journal, 2016, 22, 1709-1718.	3.0	69
927	Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program. Radiology, 2016, 280, 202-211.	7.3	48
928	Segmentation of human brain using structural MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 111-124.	2.0	27
929	Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions. European Radiology, 2016, 26, 2982-2991.	4.5	17
930	Predictors of Clinical Worsening in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke, 2016, 47, 4-11.	2.0	81
931	Genome-wide meta-analysis of cerebral white matter hyperintensities in patients with stroke. Neurology, 2016, 86, 146-153.	1.1	91

#	Article	IF	CITATIONS
932	The role of MRI in the evaluation of secondary progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 157-171.	2.8	8
933	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Multiple Sclerosis Journal, 2016, 22, 1327-1336.	3.0	88
934	Longitudinal associations between brain structural changes and fatigue in early MS. Multiple Sclerosis and Related Disorders, 2016, 5, 29-33.	2.0	36
935	Aortic Arch Stiffness Is Associated With Incipient Brain Injury in Patients With Hypertension. American Journal of Hypertension, 2016, 29, 705-712.	2.0	8
936	Male brain ages faster: the age and gender dependence of subcortical volumes. Brain Imaging and Behavior, 2016, 10, 901-910.	2.1	54
937	The neural correlates of motor intentional disorders in patients with subcortical vascular cognitive impairment. Journal of Neurology, 2016, 263, 89-99.	3.6	6
938	Longitudinal associations between MRI and cognitive changes in very early MS. Multiple Sclerosis and Related Disorders, 2016, 5, 47-52.	2.0	28
939	Association between baseline peri-infarct magnetic resonance spectroscopy and regional white matter atrophy after stroke. Neuroradiology, 2016, 58, 3-10.	2.2	8
940	Decreasing ADHD phenotypic heterogeneity: searching for neurobiological underpinnings of the restrictive inattentive phenotype. European Child and Adolescent Psychiatry, 2016, 25, 273-282.	4.7	17
941	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 425-432.	1.9	88
942	Test-retest reliability of high angular resolution diffusion imaging acquisition within medial temporal lobe connections assessed via tract based spatial statistics, probabilistic tractography and a novel graph theory metric. Brain Imaging and Behavior, 2016, 10, 533-547.	2.1	13
943	Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice. Multiple Sclerosis Journal, 2016, 22, 340-346.	3.0	13
944	Combined structural and functional patterns discriminating upper limb motor disability in multiple sclerosis using multivariate approaches. Brain Imaging and Behavior, 2017, 11, 754-768.	2.1	26
945	Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 420-431.	3.0	33
946	Traumatic hemorrhagic brain injury: impact of location and resorption on cognitive outcome. Journal of Neurosurgery, 2017, 126, 796-804.	1.6	21
947	White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 107-113.	2.0	25
948	Objectively measured sedentary behavior and brain volumetric measurements in multiple sclerosis. Neurodegenerative Disease Management, 2017, 7, 31-37.	2.2	11
949	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	2.4	57

#	Article	IF	CITATIONS
950	The Potential for Advanced Magnetic Resonance Neuroimaging Techniques in Pediatric Stroke Research. Pediatric Neurology, 2017, 69, 24-36.	2.1	8
951	Brain Atrophy in Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 289-300.	1.0	64
952	Long-term cerebral white and gray matter changes after preeclampsia. Neurology, 2017, 88, 1256-1264.	1.1	77
953	rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 386-394.	1.9	55
954	Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. Multiple Sclerosis and Related Disorders, 2017, 13, 58-66.	2.0	14
955	Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS Drugs, 2017, 31, 217-236.	5.9	143
956	Altered neural mechanisms of cognitive control in patients with primary progressive multiple sclerosis: An effective connectivity study. Human Brain Mapping, 2017, 38, 2580-2588.	3.6	14
957	Increased hippocampal, thalamus and amygdala volume in longâ€ŧerm lithiumâ€ŧreated bipolar I disorder patients compared with unmedicated patients and healthy subjects. Bipolar Disorders, 2017, 19, 41-49.	1.9	63
958	Brain structural changes in patients in the early stages of multiple sclerosis with depression. Neurological Research, 2017, 39, 596-600.	1.3	11
959	Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. CNS Drugs, 2017, 31, 289-305.	5.9	55
960	Utility of the cumulative stress and mismatch hypotheses in understanding the neurobiological impacts of childhood abuse and recent stress in youth with emerging mental disorder. Human Brain Mapping, 2017, 38, 2709-2721.	3.6	16
961	An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM). Magnetic Resonance Imaging, 2017, 39, 110-122.	1.8	36
962	Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 146-151.	1.9	52
963	Altered eigenvector centrality is related to local restingâ€state network functional connectivity in patients with longstanding type 1 diabetes mellitus. Human Brain Mapping, 2017, 38, 3623-3636.	3.6	33
964	Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. NeuroImage, 2017, 155, 159-168.	4.2	287
965	Using DTI to assess white matter microstructure in cerebral small vessel disease (SVD) in multicentre studies. Clinical Science, 2017, 131, 1361-1373.	4.3	76
966	Leveraging Clinical Imaging Archives for Radiomics: Reliability of Automated Methods for Brain Volume Measurement. Radiology, 2017, 284, 862-869.	7.3	15
967	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Longâ€Term Comparative Study. Journal of Neuroimaging, 2017, 27, 620-629.	2.0	20

ARTICLE IF CITATIONS Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess 968 2.7 25 atrophy in subcortical regions. NeuroImage: Clinical, 2017, 13, 9-15. Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1469-1478. 23 Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images. 970 7 1.5 Journal of Medical Imaging, 2017, 4, 025504. Defining a multimodal signature of remote sports concussions. European Journal of Neuroscience, 971 2017, 46, 1956-1967. Serum iron concentration is associated with subcortical deep gray matter iron levels in multiple 972 1.2 13 sclerosis patients. NeuroReport, 2017, 28, 645-648. Sodium intake and multiple sclerosis activity and progression in <scp>BENEFIT</scp>. Annals of 5.3 Neurology, 2017, 82, 20-29. Hippocampal development in youth with a history of childhood maltreatment. Journal of Psychiatric 974 3.1 15 Research, 2017, 91, 149-155. White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Brain, 2017, 140, 1300-1315. Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. 976 3.1 48 Neurobiology of Aging, 2017, 55, 78-90. Monophasic demyelination reduces brain growth in children. Neurology, 2017, 88, 1744-1750. 1.1 Fractional anisotropy derived from the diffusion tensor distribution function boosts power to 978 31 3.0detect Alzheimer's disease deficits. Magnetic Resonance in Medicine, 2017, 78, 2322-2333. Altered microstructure rather than morphology in the corpus callosum after lower limb amputation. 979 3.3 Scientific Reports, 2017, 7, 44780. tDCS-Induced Modulation of GABA Levels and Resting-State Functional Connectivity in Older Adults. 980 3.6 109 Journal of Neuroscience, 2017, 37, 4065-4073. FTLD-TDP and progressive supranuclear palsy in comorbidity—a report of two cases with different clinical presentations. Neurocase, 2017, 23, 5-11. An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis 982 2.0 14 Clinical Practiceâ€"The MSâ€MRIUS Study. Journal of Neuroimaging, 2017, 27, 339-347. Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. European Journal of Neurology, 2017, 24, 437-445. A Fully Automated, Atlas-Based Approach for Superior Cerebellar Peduncle Evaluation in Progressive 984 2.4 20 Supranuclear Palsy Phenotypes. American Journal of Neuroradiology, 2017, 38, 523-530. Brain volume change in firstâ€episode psychosis: an effect of antipsychotic medication independent of 4.5 scp>BMI</scp> change. Acta Psychiatrica Scandinavica, 2017, 135, 117-126.

#	Article	IF	Citations
986	Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis. Journal of Neurology, 2017, 264, 482-493.	3.6	38
987	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
988	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
989	Brain MRI atrophy quantification in MS. Neurology, 2017, 88, 403-413.	1.1	188
990	White Matter Disruption and Connected Speech in Non-Fluent and Semantic Variants of Primary Progressive Aphasia. Dementia and Geriatric Cognitive Disorders Extra, 2017, 7, 52-73.	1.3	37
991	Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year. Journal of the Neurological Sciences, 2017, 382, 73-78.	0.6	4
992	Short-term mechanisms influencing volumetric brain dynamics. NeuroImage: Clinical, 2017, 16, 507-513.	2.7	32
993	Information processing deficits as a driving force for memory impairment in MS: A crossÂ-sectional study of memory functions and MRI in early and late stage MS. Multiple Sclerosis and Related Disorders, 2017, 18, 119-127.	2.0	8
994	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481.	9.0	77
995	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain, 2017, 140, 2814-2819.	7.6	51
996	Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain, 2017, 140, 2927-2938.	7.6	75
997	An Objective Short Sleep Insomnia Disorder Subtype Is Associated With Reduced Brain Metabolite Concentrations In Vivo: A Preliminary Magnetic Resonance Spectroscopy Assessment. Sleep, 2017, 40, .	1.1	19
998	Teriflunomide slows BVL in relapsing MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e390.	6.0	65
999	â€~Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis. Journal of Neurology, 2017, 264, 2201-2204.	3.6	13
1000	Structural connectivityâ€defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations. Human Brain Mapping, 2017, 38, 6005-6018.	3.6	40
1001	Serum retinol levels are associated with brain volume loss in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772968.	1.0	6
1002	REST, a master regulator of neurogenesis, evolved under strong positive selection in humans and in non human primates. Scientific Reports, 2017, 7, 9530.	3.3	27
1003	Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. Scientific Reports, 2017, 7, 9180.	3.3	21

Article	IF	CITATIONS
Structural differences in impaired verbal fluency in essential tremor patients compared to healthy controls. Brain and Behavior, 2017, 7, e00722.	2.2	11
Longitudinal MR spectroscopy of neurodegeneration in multiple sclerosis with diffusion of the intra-axonal constituent N-acetylaspartate. NeuroImage: Clinical, 2017, 15, 780-788.	2.7	12
Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. NeuroImage: Clinical, 2017, 15, 843-853.	2.7	32
The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS. NeuroImage: Clinical, 2017, 16, 111-115.	2.7	12
Relationship between postural instability and subcortical volume loss in Alzheimer's disease. Medicine (United States), 2017, 96, e7286.	1.0	17
Comparison of image intensity, local, and multiâ€atlas priors in brain tissue classification. Medical Physics, 2017, 44, 5782-5794.	3.0	3
Atypical activation of action-semantic network in adolescents with autism spectrum disorder. Brain and Cognition, 2017, 117, 57-64.	1.8	6
Duration of untreated psychosis/illness and brain volume changes in early psychosis. Psychiatry Research, 2017, 255, 332-337.	3.3	25
Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clinical, 2017, 15, 769-779.	2.7	48
Association between total-Tau and brain atrophy one year after first-ever stroke. BMC Neurology, 2017, 17, 107.	1.8	10
Use Case I: Imaging Biomarkers in Neurological Disease. Focus on Multiple Sclerosis. , 2017, , 169-180.		2
Bayesian vector autoregressive model for multiâ€subject effective connectivity inference using multiâ€modal neuroimaging data. Human Brain Mapping, 2017, 38, 1311-1332.	3.6	22
Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2017, 14, 11-23.	4.4	72
Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis. Multiple Sclerosis Journal, 2017, 23, 1194-1203.	3.0	53
The role of sleep on cognition and functional connectivity in patients with multiple sclerosis. Journal of Neurology, 2017, 264, 72-80.	3.6	35
Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Multiple Sclerosis Journal, 2017, 23, 1336-1345.	3.0	93
Imaging Biomarkers. , 2017, , .		7
The anterior hypothalamus in cluster headache. Cephalalgia, 2017, 37, 1039-1050.	3.9	50
	Structural differences in impaired webal fluency in essential tremor patients compared to healthy Langthudinal MR spectroscopy of neurodegeneration in multiple sclerosis with diffusion of the Intra-axonal constituent N-axetylaspartate. NeuroImage: Clinical, 2017, 15, 780-788. Agreement of MSmetrix with established methods for measuring cross-sectional and longtudinal Final atrophy. NeuroImage: Clinical, 2017, 15, 843-853. The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared Relationship between postural instability and subcortical volume loss in Alzheimer's disease. Medicine Comparison of Image Intensity, local, and multiBeatias priors in brain tissue classification. Medical Physics, 2017, 44, 5782-5794. Augolical activation of action semantic network in adolescents with autism spectrum disorder. Brain and Cognition, 2017, 117, 57-64. Duration of untreated psychosis/Illness and brain volume changes in early psychosis. Psychiatry Research, 2017, 2017, 2017, 210, 2017, 211, 2017, 15, 2017, 211, 2017, 2017, 211, 2017, 211, 2017, 211, 2017, 211, 2017, 211	Structural differences in impaired verbal fluency in essential tremor patients compared to healthy2.2Lengitudinal MR spectroscopy of neurodegeneration in multiple sclerosis with diffusion of the Intra-axonal constituent Nacetylaspartate. NeuroImage: Clinical, 2017, 15, 780-788.2.7Aggenennt of MSmertin with established methods for measuring cross-sectional and longitudinal brain atrophy. NeuroImage: Clinical, 2017, 15, 843-853.2.7The relationship between potural leatobility and subcortical volume loss in Alzheimer's disease. Medicine1.0Comparison of image intensity. local, and multia&entas priors in brain tissue classification. Medical0.0Physics, 2017, 14, 5782-5794.0.3Ourparison of action-semantic network in adolescents with autism spectrum disorder. Brain and Cognition, 2017, 117, 57-64.0.3Duration of untracted psychossilliness and brain volume changes in early psychosis. Psychiatry essearch, 2017, 25, 532-5794.0.3Neurological software tool for reliable atrophy messurement (NeuroSTREAM) of the lateral vertroises on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clinical, 2017, 15, 263-702.1.4Sessciatri, D217, 107.1.41.4Case is lingging Biomarkers in Neurological Disease. Focus on Multiple Sclerosis., 2017, 1, 169-180.1.4Supsishin vector autorgeresiste model for multiASculpet offictive connectivity inforence using multiAScensis journal, 2017, 28, 1311332.4.4Genetoling ging Endpoints in Amyotrophic Lateral Sclerosis. NeuroImage: Clinical, 2017, 14, 11-23.4.4Supsishin vector autorgeresiste model for multiASculpet offictive connectivity inforence using multiAScensis journal, 2017, 28, 1311332.<

	CHARC		
#	Article	IF	CITATIONS
1022	Brain atrophy in paediatric sickle cell anaemia: findings from the silent infarct transfusion (<scp>SIT</scp>) trial. British Journal of Haematology, 2017, 177, 151-153.	2.5	17
1023	A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 221-226.	2.0	43
1024	Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Multiple Sclerosis Journal, 2017, 23, 818-829.	3.0	31
1025	Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Multiple Sclerosis Journal, 2017, 23, 665-674.	3.0	111
1026	Automated tissue segmentation of MR brain images in the presence of white matter lesions. Medical Image Analysis, 2017, 35, 446-457.	11.6	55
1027	Simultaneous total intracranial volume and posterior fossa volume estimation using multiâ€atlas label fusion. Human Brain Mapping, 2017, 38, 599-616.	3.6	32
1028	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Multiple Sclerosis Journal, 2017, 23, 656-664.	3.0	34
1029	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. American Journal of Neuroradiology, 2017, 38, 250-256.	2.4	9
1030	Computer-based segmentation, change detection and quantification for lesions in multiple sclerosis. , 2017, , .		4
1031	Recent advances in longitudinal structural neuroimaging of younger-onset dementias. Neurodegenerative Disease Management, 2017, 7, 349-352.	2.2	1
1032	Critical analysis on the present methods for brain volume measurements in multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2017, 75, 464-469.	0.8	5
1033	Hippocampal and Amygdala Gray Matter Loss in Elderly Controls with Subtle Cognitive Decline. Frontiers in Aging Neuroscience, 2017, 9, 50.	3.4	56
1034	Retrospective Diagnosis of Parkinsonian Syndromes Using Whole-Brain Atrophy Rates. Frontiers in Aging Neuroscience, 2017, 9, 99.	3.4	8
1035	The Mirror Neurons Network in Aging, Mild Cognitive Impairment, and Alzheimer Disease: A functional MRI Study. Frontiers in Aging Neuroscience, 2017, 9, 371.	3.4	28
1036	Gray Matter Atrophy Is Primarily Related to Demyelination of Lesions in Multiple Sclerosis: A Diffusion Tensor Imaging MRI Study. Frontiers in Neuroanatomy, 2017, 11, 23.	1.7	19
1037	Subregional Structural Alterations in Hippocampus and Nucleus Accumbens Correlate with the Clinical Impairment in Patients with Alzheimer's Disease Clinical Spectrum: Parallel Combining Volume and Vertex-Based Approach. Frontiers in Neurology, 2017, 8, 399.	2.4	57
1038	The Combined Quantification and Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis Patients. Frontiers in Neurology, 2017, 8, 506.	2.4	27
1039	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Frontiers in Neurology, 2017, 8, 608.	2.4	19

#	Article	IF	CITATIONS
1040	Simulating Longitudinal Brain MRIs with Known Volume Changes and Realistic Variations in Image Intensity. Frontiers in Neuroscience, 2017, 11, 132.	2.8	10
1041	Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis. Neurology Research International, 2017, 2017, 1-7.	1.3	35
1042	Multitemporal Volume Registration for the Analysis of Rheumatoid Arthritis Evolution in the Wrist. International Journal of Biomedical Imaging, 2017, 2017, 1-12.	3.9	1
1043	Brain Parenchymal Fraction in Healthy Adults—A Systematic Review of the Literature. PLoS ONE, 2017, 12, e0170018.	2.5	29
1044	Altered Microstructural Caudate Integrity in Posttraumatic Stress Disorder but Not Traumatic Brain Injury. PLoS ONE, 2017, 12, e0170564.	2.5	18
1045	Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS ONE, 2017, 12, e0173299.	2.5	13
1046	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. Veins and Lymphatics, 2017, 6, .	0.1	2
1047	Quantitative, functional MRI and neurophysiological markers in a case of Gerstmann-Str�ussler-Scheinker syndrome. Functional Neurology, 2017, 37, 153.	1.3	3
1048	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case–control MRI study. Journal of Neurology, 2018, 265, 1096-1101.	3.6	14
1049	Establishing pathological cut-offs for lateral ventricular volume expansion rates. NeuroImage: Clinical, 2018, 18, 494-501.	2.7	26
1050	Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS. Current Treatment Options in Neurology, 2018, 20, 17.	1.8	15
1051	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. Radiology, 2018, 288, 234-244.	7.3	40
1052	Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients. Psychoneuroendocrinology, 2018, 92, 72-80.	2.7	26
1053	Relationship between Social Cognition and traditional cognitive impairment in Progressive Multiple Sclerosis and possible implicated neuroanatomical regions. Multiple Sclerosis and Related Disorders, 2018, 20, 122-128.	2.0	33
1054	Effect of switching from glatiramer acetate 20†mg/daily to glatiramer acetate 40†mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. Journal of the Neurological Sciences, 2018, 387, 152-156.	0.6	7
1055	Orthostatic hypotension in older persons is not associated with cognitive functioning, features of cerebral damage or cerebral blood flow. Journal of Hypertension, 2018, 36, 1201-1206.	0.5	21
1056	Lacunar Infarcts, but Not Perivascular Spaces, Are Predictors of Cognitive Decline in Cerebral Small-Vessel Disease. Stroke, 2018, 49, 586-593.	2.0	80
1057	MR Imaging–based Estimation of Upper Motor Neuron Density in Patients with Amyotrophic Lateral Sclerosis: A Feasibility Study. Radiology, 2018, 287, 955-964.	7.3	7

#	Article	IF	CITATIONS
1058	Structural connectivity of the amygdala in young adults with autism spectrum disorder. Human Brain Mapping, 2018, 39, 1270-1282.	3.6	49
1059	Retrospective assessment of MRI-based volumetric changes of normal tissues in glioma patients following radio(chemo)therapy. Clinical and Translational Radiation Oncology, 2018, 8, 17-21.	1.7	14
1060	The evolution of "No Evidence of Disease Activity―in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 20, 231-238.	2.0	48
1061	Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL—a longitudinal brain volumetry study in healthy adults. Neurobiology of Aging, 2018, 65, 1-6.	3.1	25
1062	Mitochondrial dysfunction in myotonic dystrophy type 1. Neuromuscular Disorders, 2018, 28, 144-149.	0.6	29
1063	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2018, 39, 289-295.	2.4	24
1064	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nature Reviews Neurology, 2018, 14, 75-93.	10.1	115
1065	Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Annals of Neurology, 2018, 83, 223-234.	5.3	169
1066	Deep gray matter volume loss drives disability worsening in multiple sclerosis. Annals of Neurology, 2018, 83, 210-222.	5.3	295
1067	Cognition in multiple sclerosis: Between cognitive reserve and brain volume. Journal of the Neurological Sciences, 2018, 386, 19-22.	0.6	24
1068	Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. European Journal of Neurology, 2018, 25, 584-e36.	3.3	11
1069	Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Radiology, 2018, 288, 554-564.	7.3	47
1070	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. NeuroImage: Clinical, 2018, 19, 466-475.	2.7	47
1071	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the <scp>INFORMS</scp> study. Annals of Clinical and Translational Neurology, 2018, 5, 346-356.	3.7	17
1072	Children's academic attainment is linked to the global organization of the white matter connectome. Developmental Science, 2018, 21, e12662.	2.4	23
1073	Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study. NeuroImage: Clinical, 2018, 19, 66-70.	2.7	14
1074	The importance of hippocampal dynamic connectivity in explaining memory function in multiple sclerosis. Brain and Behavior, 2018, 8, e00954.	2.2	33
1075	Brain gray matter alterations in Chinese patients with chronic knee osteoarthritis pain based on voxel-based morphometry. Medicine (United States), 2018, 97, e0145.	1.0	39

#	Article	IF	CITATIONS
1076	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. Journal of the Neurological Sciences, 2018, 388, 175-181.	0.6	15
1077	Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL. Journal of Neurology, 2018, 265, 1158-1165.	3.6	18
1078	Amygdala structure and aggressiveness in borderline personality disorder. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 417-427.	3.2	16
1079	Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. Multiple Sclerosis Journal, 2018, 24, 623-631.	3.0	8
1080	Macro- and microstructural alterations of the subcortical structures in episodic cluster headache. Cephalalgia, 2018, 38, 662-673.	3.9	18
1081	Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis Journal, 2018, 24, 222-226.	3.0	47
1082	Attention and processing speed performance in multiple sclerosis is mostly related to thalamic volume. Brain Imaging and Behavior, 2018, 12, 20-28.	2.1	53
1083	Lesion symptom map of cognitive–postural interference in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 653-662.	3.0	21
1084	Fronto-striatal network activation leads to less fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1174-1182.	3.0	38
1085	Abnormal Gray Matter Shape, Thickness, and Volume in the Motor Cortico-Subcortical Loop in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Association with Clinical and Motor Features. Cerebral Cortex, 2018, 28, 658-671.	2.9	51
1086	Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1039-1045.	3.0	19
1087	Vasoreactivity in CADASIL: Comparison to structural MRI and neuropsychology. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1085-1095.	4.3	27
1088	Brain endothelial cell expression of SPARCLâ€1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators <i>in vitro</i> . Neuropathology and Applied Neurobiology, 2018, 44, 404-416.	3.2	9
1089	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. European Radiology, 2018, 28, 96-103.	4.5	24
1090	Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?. Multiple Sclerosis Journal, 2018, 24, 1356-1365.	3.0	85
1091	The role of abnormalities in the corpus callosum in social cognition deficits after Traumatic Brain Injury. Social Neuroscience, 2018, 13, 471-479.	1.3	22
1092	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. NeuroImage, 2018, 167, 438-452.	4.2	60
1093	Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. NeuroImage, 2018, 166, 400-424.	4.2	1,026

#	Article	IF	CITATIONS
1094	Neuronal and behavioral effects of multi-day brain stimulation and memory training. Neurobiology of Aging, 2018, 61, 245-254.	3.1	65
1095	Volumetric reconstruction from printed films: Enabling 30 year longitudinal analysis in MR neuroimaging. NeuroImage, 2018, 165, 238-250.	4.2	11
1096	Processing of structural neuroimaging data in young children: Bridging the gap between current practice and state-of-the-art methods. Developmental Cognitive Neuroscience, 2018, 33, 206-223.	4.0	50
1097	Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease. Parkinsonism and Related Disorders, 2018, 46, 56-61.	2.2	46
1098	Microstructural cerebral lesions are associated with the severity of central sleep apnea with Cheyne-Stokes-respiration in heart failure and are modified by PAP-therapy. Respiratory Physiology and Neurobiology, 2018, 247, 181-187.	1.6	3
1099	Progressive Multiple Sclerosis. , 2018, , .		1
1100	A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 330-338.	1.9	23
1101	Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. Clinical EEG and Neuroscience, 2018, 49, 55-65.	1.7	31
1102	Preliminary evidence of the cerebellar role on cognitive performances in clinically isolated syndrome. Journal of the Neurological Sciences, 2018, 385, 1-6.	0.6	7
1103	SIENAâ€XL for improving the assessment of gray and white matter volume changes on brain MRI. Human Brain Mapping, 2018, 39, 1063-1077.	3.6	20
1104	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. NeuroImage: Clinical, 2018, 17, 530-540.	2.7	32
1105	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage: Clinical, 2018, 17, 444-451.	2.7	58
1106	Neural basis of exertional fatigue in the heat: A review of magnetic resonance imaging methods. Scandinavian Journal of Medicine and Science in Sports, 2018, 28, 807-818.	2.9	5
1107	A Multimodal Magnetic Resonance Imaging Study of Recovery of Consciousness in Severe Traumatic Brain Injury: Preliminary Results. Journal of Neurotrauma, 2018, 35, 308-313.	3.4	5
1108	Thalamic volume reduction in drugâ€naive patients with newâ€onset genetic generalized epilepsy. Epilepsia, 2018, 59, 226-234.	5.1	38
1109	Brain volume in early MS patients with and without IgG oligoclonal bands in CSF. Multiple Sclerosis and Related Disorders, 2018, 19, 55-58.	2.0	2
1110	Classification of Patients with Alzheimer's Disease and Healthy Subjects from MRI Brain Images Using the Existence Probability of Tissue Types. , 2018, , .		1
1111	Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. Journal of Head Trauma Rehabilitation, 2018, 33, E24-E32.	1.7	25

#	Article	IF	CITATIONS
1112	Body mass index, but not vitamin D status, is associated with brain volume change in MS. Neurology, 2018, 91, e2256-e2264.	1.1	65
1113	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. American Journal of Neuroradiology, 2018, 39, 2237-2242.	2.4	25
1114	MRI Lesion Load of Cerebral Small Vessel Disease and Cognitive Impairment in Patients With CADASIL. Frontiers in Neurology, 2018, 9, 862.	2.4	13
1115	Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731881953.	1.0	19
1116	Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS ONE, 2018, 13, e0209326.	2.5	13
1117	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. European Neurology, 2018, 80, 207-214.	1.4	5
1118	Structural Magnetic Resonance Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 335-380.	2.0	14
1119	Progressive loss of brain volume in children with sickle cell anemia and silent cerebral infarct: A report from the silent cerebral infarct transfusion trial. American Journal of Hematology, 2018, 93, E406-E408.	4.1	12
1120	Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimer's Research and Therapy, 2018, 10, 96.	6.2	109
1121	Improving the SIENA performance using BEaST brain extraction. PLoS ONE, 2018, 13, e0196945.	2.5	6
1122	The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 26, 96-102.	2.0	1
1123	Relation between functional connectivity and disability in multiple sclerosis: a non-linear model. Journal of Neurology, 2018, 265, 2881-2892.	3.6	21
1124	Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature, 2018, 562, 210-216.	27.8	551
1125	FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 108.	6.2	87
1126	A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression. Journal of Neuroinflammation, 2018, 15, 255.	7.2	20
1127	Temporal lobe epilepsy affects spatial organization of entorhinal cortex connectivity. Epilepsy and Behavior, 2018, 88, 87-95.	1.7	6
1128	Fast CSF MRI for brain segmentation; Cross-validation by comparison with 3D T1-based brain segmentation methods. PLoS ONE, 2018, 13, e0196119.	2.5	8
1129	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 2018, 8, e021944.	1.9	43

#	Article	IF	CITATIONS
1130	Information processing speed in multiple sclerosis: Relevance of default mode network dynamics. NeuroImage: Clinical, 2018, 19, 507-515.	2.7	51
1131	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 490-495.	2.0	50
1132	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. American Journal of Neuroradiology, 2018, 39, 1480-1486.	2.4	13
1133	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	9.0	32
1134	Involvement of the Amygdala in Memory and Psychosocial Functioning in Pediatric-Onset Multiple Sclerosis. Developmental Neuropsychology, 2018, 43, 524-534.	1.4	12
1135	Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1250-1258.	1.9	39
1136	An MRI evaluation of grey matter damage in African Americans with MS. Multiple Sclerosis and Related Disorders, 2018, 25, 29-36.	2.0	18
1137	Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain, 2018, 141, 2605-2618.	7.6	113
1138	Wholeâ€brain atrophy assessed by proportional―versus registrationâ€based pipelines from 3T <scp>MRI</scp> in multiple sclerosis. Brain and Behavior, 2018, 8, e01068.	2.2	7
1139	Altered hippocampal GABA and glutamate levels and uncoupling from functional connectivity in multiple sclerosis. Hippocampus, 2018, 28, 813-823.	1.9	33
1140	A Fully Automated Pipeline for Normative Atrophy in Patients with Neurodegenerative Disease. Frontiers in Neurology, 2017, 8, 727.	2.4	13
1141	Health-related quality of life, neuropsychiatric symptoms and structural brain changes in clinically isolated syndrome. PLoS ONE, 2018, 13, e0200254.	2.5	12
1142	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology, 2018, 289, 487-496.	7.3	75
1143	Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 14-20.	2.0	13
1144	Longitudinal evaluation of ventricular volume changes associated with mild traumatic brain injury in military service members. Brain Injury, 2018, 32, 1244-1254.	1.2	5
1145	A longitudinal magnetic resonance imaging study of neurodegenerative and small vessel disease, and clinical cognitive trajectories in non demented patients with transient ischemic attack: the PREVENT study. BMC Geriatrics, 2018, 18, 163.	2.7	13
1146	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurology, 2018, 18, 67.	1.8	27
1147	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis and Related Disorders, 2018, 25, 37-42.	2.0	11

#	Article	IF	CITATIONS
1148	Atrophy of the putamen at time of clinical motor onset in Huntington's disease: a 6-year follow-up study. Journal of Clinical Movement Disorders, 2018, 5, 2.	2.2	10
1149	Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis and Demyelinating Disorders, 2018, 3, .	1.1	21
1150	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Human Brain Mapping, 2018, 39, 3682-3690.	3.6	23
1151	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MSâ€MRIUS. Journal of Neuroimaging, 2018, 28, 399-405.	2.0	12
1152	Association between brain atrophy and cognitive motor interference in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 208-211.	2.0	10
1153	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. Journal of the Neurological Sciences, 2018, 393, 128-134.	0.6	26
1154	Vitamin D levels, brain volume, and genetic architecture in patients with psychosis. PLoS ONE, 2018, 13, e0200250.	2.5	11
1155	Neural Correlates of Outcome Anticipation in Multiple Sclerosis. Frontiers in Neurology, 2018, 9, 572.	2.4	3
1156	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	6.2	87
1157	Gadolinium effect on thalamus and whole brain tissue segmentation. Neuroradiology, 2018, 60, 1167-1173.	2.2	5
1158	Thalamus volume change and cognitive impairment in early relapsing–remitting multiple sclerosis patients. Neuroradiology Journal, 2018, 31, 350-355.	1.2	19
1159	White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques. PLoS ONE, 2018, 13, e0191131.	2.5	9
1160	Thalamic and hippocampal volume associated with memory functions in multiple sclerosis. Brain and Cognition, 2018, 125, 61-68.	1.8	4
1161	Postmortem magnetic resonance imaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 150, 335-354.	1.8	3
1162	White matter alterations in Parkinson's disease with normal cognition precede grey matter atrophy. PLoS ONE, 2018, 13, e0187939.	2.5	57
1163	Thalamic white matter in multiple sclerosis: A combined diffusionâ€ŧensor imaging and quantitative susceptibility mapping study. Human Brain Mapping, 2018, 39, 4007-4017.	3.6	19
1164	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. Multiple Sclerosis Journal, 2019, 25, 980-986.	3.0	11
1165	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5â€year longitudinal study. European Journal of Neurology, 2019, 26, 87.	3.3	72

#	Article	IF	CITATIONS
1166	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. Clinical Autonomic Research, 2019, 29, 329-338.	2.5	6
1167	A decade of changes in brain volume and cognition. Brain Imaging and Behavior, 2019, 13, 554-563.	2.1	32
1168	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology, 2019, 93, e611-e623.	1.1	30
1169	Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice. Frontiers in Neurology, 2019, 10, 788.	2.4	16
1170	Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 529-537.	2.4	8
1171	Editorial: Multimodal and Longitudinal Bioimaging Methods for Characterizing the Progressive Course of Dementia. Frontiers in Aging Neuroscience, 2019, 11, 45.	3.4	4
1172	Longitudinal Mapping of Cortical Thickness Measurements: An Alzheimer's Disease Neuroimaging Initiative-Based Evaluation Study. Journal of Alzheimer's Disease, 2019, 71, 165-183.	2.6	31
1173	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. Annals of Neurology, 2019, 86, 704-713.	5.3	32
1174	Is 1H-MR spectroscopy useful as a diagnostic aid in MSA-C?. Cerebellum and Ataxias, 2019, 6, 7.	1.9	3
1175	Quantifying deep grey matter atrophy using automated segmentation approaches: A systematic review of structural MRI studies. NeuroImage, 2019, 201, 116018.	4.2	20
1176	A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. Brain, 2019, 142, 2756-2774.	7.6	35
1177	Brain volume dynamics in multiple sclerosis. A case-control study. Neurological Research, 2019, 41, 936-942.	1.3	5
1178	Characterising neural plasticity at the single patient level using connectivity fingerprints. NeuroImage: Clinical, 2019, 24, 101952.	2.7	9
1179	Plasma proteome in multiple sclerosis disease progression. Annals of Clinical and Translational Neurology, 2019, 6, 1582-1594.	3.7	21
1180	Imaging in mice and men: Pathophysiological insights into multiple sclerosis from conventional and advanced MRI techniques. Progress in Neurobiology, 2019, 182, 101663.	5.7	21
1181	Hippocampal volume across age: Nomograms derived from over 19,700 people in UK Biobank. NeuroImage: Clinical, 2019, 23, 101904.	2.7	130
1182	Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex. Brain, 2019, 142, 1921-1937.	7.6	38
1183	Poster Viewing Sessions PB01-B01 to PB03-V09. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 167-523.	4.3	7

#	Article	IF	CITATIONS
1184	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. Brain Communications, 2019, 1, fcz026.	3.3	15
1185	Low-dose ladostigil for mild cognitive impairment. Neurology, 2019, 93, e1474-e1484.	1.1	40
1186	Octave-Spanning High-Repetition-Rate Mid-IR Supercontinuum for Frequency Comb Synthesis. , 2019, , .		0
1187	Optic Chiasm Morphometric Changes in Multiple Sclerosis: Feasibility of a Simplified Brain Magnetic Resonance Imaging Measure of White Matter Atrophy. Clinical Anatomy, 2019, 32, 1072-1081.	2.7	5
1188	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. Human Brain Mapping, 2019, 40, 5231-5241.	3.6	37
1189	Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. Journal of Alzheimer's Disease, 2019, 71, 1037-1048.	2.6	22
1190	Regional Structural Hippocampal Differences Between Dementia with Lewy Bodies and Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 775-783.	2.8	8
1191	Longitudinal analysis of brain atrophy in Alzheimer's disease and frontotemporal dementia. Journal of International Medical Research, 2019, 47, 5019-5027.	1.0	10
1192	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology, 2019, 293, 424-433.	7.3	36
1193	Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101388.	2.0	22
1194	Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641882346.	3.5	26
1195	Genetic variation in <i>PLEKHG1</i> is associated with white matter hyperintensities (n = 11,226). Neurology, 2019, 92, e749-e757.	1.1	47
1196	Lifespan normative data on rates of brain volume changes. Neurobiology of Aging, 2019, 81, 30-37.	3.1	40
1197	Anatomical context improves deep learning on the brain age estimation task. Magnetic Resonance Imaging, 2019, 62, 70-77.	1.8	32
1198	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. Multiple Sclerosis and Related Disorders, 2019, 34, 103-111.	2.0	24
1199	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1156-1164.	1.9	20
1200	Structural and functional MRI correlates of T2 hyperintensities of brain white matter in young neurologically asymptomatic adults. European Radiology, 2019, 29, 7027-7036.	4.5	8
1201	Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 459.	2.4	23

#	Article	IF	CITATIONS
1202	Differential medial temporal lobe and default-mode network functional connectivity and morphometric changes in Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101860.	2.7	21
1203	Combined Assessment of Diffusion Parameters and Cerebral Blood Flow Within Basal Ganglia in Early Parkinson's Disease. Frontiers in Aging Neuroscience, 2019, 11, 134.	3.4	21
1204	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Annals of Clinical and Translational Neurology, 2019, 6, 1081-1089.	3.7	43
1205	Microstructural integrity of corticospinal and medial lemniscus tracts: insights from diffusion tensor tractography of right-hand amputees. Journal of Neurophysiology, 2019, 122, 316-324.	1.8	4
1206	Vision and Vision-Related Measures in Progressive Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 455.	2.4	17
1207	Damage of the lateral geniculate nucleus in MS. Neurology, 2019, 92, e2240-e2249.	1.1	29
1208	Mild cognitive impairment in Parkinson's disease is associated with decreased P300 amplitude and reduced putamen volume. Clinical Neurophysiology, 2019, 130, 1208-1217.	1.5	42
1209	Aging and Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 527-535.	2.0	33
1210	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 334.	2.4	31
1211	White matter microstructural properties in bipolar disorder in relationship to the spatial distribution of lithium in the brain. Journal of Affective Disorders, 2019, 253, 224-231.	4.1	11
1212	Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview. Biomedicines, 2019, 7, 22.	3.2	75
1213	Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping, 2019, 40, 2917-2932.	3.6	36
1214	Whole-brain white matter organization, intelligence, and educational attainment. Trends in Neuroscience and Education, 2019, 15, 38-47.	3.1	33
1215	Enhanced Recruitment During Executive Control Processing in Cognitively Preserved Patients With Pediatric-Onset MS. Journal of the International Neuropsychological Society, 2019, 25, 432-442.	1.8	2
1216	Links Between Metabolic and Structural Changes in the Brain of Cognitively Normal Older Adults: A 4-Year Longitudinal Follow-Up. Frontiers in Aging Neuroscience, 2019, 11, 15.	3.4	27
1217	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. Neuroradiology, 2019, 61, 667-674.	2.2	15
1218	Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles. Frontiers in Neurology, 2019, 10, 18.	2.4	15
1219	MRS and DTI evidence of progressive posterior cingulate cortex and corpus callosum injury in the hyper-acute phase after Traumatic Brain Injury. Brain Injury, 2019, 33, 854-868.	1.2	10

		CITATION REPORT		
#	Article		IF	CITATIONS
1220	Robust, atlas-free, automatic segmentation of brain MRI in health and disease. Heliyon,	2019, 5, e01226.	3.2	16
1221	Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep b Sleep, 2019, 42, .	ehavior disorder.	1.1	41
1222	Normalization enhances brain network features that predict individual intelligence in chepilepsy. PLoS ONE, 2019, 14, e0212901.	nildren with	2.5	12
1223	Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of pos high-field imaging, neuropathological and morphometric datasets of non-neurological c NeuroImage: Clinical, 2019, 22, 101698.		2.7	25
1224	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningea in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. Journal o Medicine, 2019, 8, 344.	al Inflammation of Clinical	2.4	17
1225	Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation ar course. EBioMedicine, 2019, 43, 392-410.	nd disease	6.1	36
1226	Cerebral blood flow and cerebrovascular reactivity correlate with severity of motor sym Parkinson's disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175	ptoms in 5628641983835.	3.5	29
1227	Relevance of brain lesion location for cognition in vascular mild cognitive impairment. N Clinical, 2019, 22, 101789.	Neurolmage:	2.7	12
1228	Childhood multiple sclerosis is associated with reduced brain volumes at first clinical prand brain growth failure. Multiple Sclerosis Journal, 2019, 25, 927-936.	esentation	3.0	32
1229	The Contribution of Various MRI Parameters to Clinical and Cognitive Disability in Multi Frontiers in Neurology, 2018, 9, 1172.	ple Sclerosis.	2.4	23
1230	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with rela MS in the retrospective real-world Teri-RADAR study. Journal of Comparative Effectivene 2019, 8, 305-316.	psing forms of ess Research,	1.4	14
1231	Volume alterations of brainstem subregions in migraine with aura. NeuroImage: Clinical 101714.	, 2019, 22,	2.7	13
1232	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longi study. Journal of Neurology, 2019, 266, 866-875.	itudinal MRI	3.6	36
1233	Monitoring the health of transitioning professional footballers: protocol of an observati prospective cohort study. BMJ Open Sport and Exercise Medicine, 2019, 5, e000680.	ional	2.9	5
1234	High serum neurofilament light chain normalizes after hematopoietic stem cell transpla MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e598.	intation for	6.0	50
1235	Contribution of normal aging to brain atrophy in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	d	6.0	57
1236	Regional brain atrophy in gray and white matter is associated with cognitive impairmen Dystrophy type 1. NeuroImage: Clinical, 2019, 24, 102078.	t in Myotonic	2.7	24
1237	2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multip Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987708.	ble sclerosis.	3.5	8

#	Article	IF	CITATIONS
1238	Amygdala Changes in Chronic Insomnia and Their Association with Sleep and Anxiety Symptoms: Insight from Shape Analysis. Neural Plasticity, 2019, 2019, 1-8.	2.2	26
1239	A Polygenic Score for Higher Educational Attainment is Associated with Larger Brains. Cerebral Cortex, 2019, 29, 3496-3504.	2.9	36
1240	One-shot domain adaptation in multiple sclerosis lesion segmentation using convolutional neural networks. NeuroImage: Clinical, 2019, 21, 101638.	2.7	91
1241	Brain volume loss and no evidence of disease activity over 3†years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment. Journal of Clinical Neuroscience, 2019, 59, 175-178.	1.5	3
1242	Spinal cord lesions and atrophy in NMOSD with AQP4-lgG and MOG-lgG associated autoimmunity. Multiple Sclerosis Journal, 2019, 25, 1926-1936.	3.0	47
1243	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. Multiple Sclerosis and Related Disorders, 2019, 27, 298-304.	2.0	16
1244	Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS. Multiple Sclerosis Journal, 2019, 25, 1896-1906.	3.0	19
1245	Predicting clinical progression in multiple sclerosis after 6 and 12Âyears. European Journal of Neurology, 2019, 26, 893-902.	3.3	40
1246	MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis. Neuroradiology, 2019, 61, 155-162.	2.2	38
1247	Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study Multiple Sclerosis and Related Disorders, 2019, 27, 74-78.	2.0	20
1248	Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires. Journal of Neurology, 2019, 266, 112-118.	3.6	12
1249	Plasma levels of soluble NCAM in multiple sclerosis. Journal of the Neurological Sciences, 2019, 396, 36-41.	0.6	13
1250	Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 28, 44-49.	2.0	7
1251	Structural and cognitive correlates of fatigue in progressive multiple sclerosis. Neurological Research, 2019, 41, 168-176.	1.3	14
1252	Brain Atrophy in Natalizumabâ€treated Patients with Multiple Sclerosis: A 5â€year Retrospective Study. Journal of Neuroimaging, 2019, 29, 190-192.	2.0	7
1253	Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy?. Journal of Magnetic Resonance Imaging, 2019, 50, 201-208.	3.4	29
1254	Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis. European Radiology, 2019, 29, 1355-1364.	4.5	93
1255	Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements. NeuroImage, 2019, 184, 555-565.	4.2	45

#	Article	IF	CITATIONS
1256	Decreased cingulo-opercular network functional connectivity mediates the impact of aging on visual processing speed. Neurobiology of Aging, 2019, 73, 50-60.	3.1	40
1257	Structural covariance across the lifespan: Brain development and aging through the lens of interâ€network relationships. Human Brain Mapping, 2019, 40, 125-136.	3.6	24
1258	Calcium channel blockade with nimodipine reverses MRI evidence of cerebral oedema following acute hypoxia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 285-301.	4.3	13
1259	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 541-553.	3.0	32
1260	Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. Multiple Sclerosis Journal, 2019, 25, 217-223.	3.0	5
1261	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. Multiple Sclerosis Journal, 2019, 25, 23-30.	3.0	11
1262	Fronto-limbic disconnection in patients with multiple sclerosis and depression. Multiple Sclerosis Journal, 2019, 25, 715-726.	3.0	30
1263	Increased hippocampal-prefrontal functional connectivity in insomnia. Neurobiology of Learning and Memory, 2019, 160, 144-150.	1.9	44
1264	Clinical correlates of longitudinal MRI changes in CADASIL. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1299-1305.	4.3	22
1265	Neurovascular Coupling During Visual Stimulation in Multiple Sclerosis: A MEG-fMRI Study. Neuroscience, 2019, 403, 54-69.	2.3	26
1266	Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study. Multiple Sclerosis Journal, 2019, 25, 372-381.	3.0	40
1267	The effect of midlife cardiovascular risk factors on white matter hyperintensity volume and cognition two decades later in normal ageing women. Brain Imaging and Behavior, 2020, 14, 51-61.	2.1	28
1268	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. Multiple Sclerosis Journal, 2020, 26, 201-209.	3.0	24
1269	Brain activity pattern changes after adaptive working memory training in multiple sclerosis. Brain Imaging and Behavior, 2020, 14, 142-154.	2.1	17
1270	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Multiple Sclerosis Journal, 2020, 26, 322-332.	3.0	28
1271	Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2020, 26, 795-805.	3.0	14
1272	Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide. Multiple Sclerosis Journal, 2020, 26, 1207-1216.	3.0	23
1273	Cerebrovascular reactivity and its correlation with age in patients with multiple sclerosis. Brain Imaging and Behavior, 2020, 14, 1889-1898.	2.1	9

~			~		
C1	TATI	ON	12 E	DC	DT
\sim			INL	. F C	

#	Article	IF	CITATIONS
1274	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. Journal of Neurology, 2020, 267, 192-202.	3.6	12
1275	STrategically Acquired Gradient Echo (STAGE) imaging, part III: Technical advances and clinical applications of a rapid multi-contrast multi-parametric brain imaging method. Magnetic Resonance Imaging, 2020, 65, 15-26.	1.8	46
1276	[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 366-378.	6.4	19
1277	Interaction between ventricular expansion and structural changes in the corpus callosum and putamen in males with FMR1 normal and premutation alleles. Neurobiology of Aging, 2020, 86, 27-38.	3.1	10
1278	Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross ectional and Gray Matter Areas. Journal of Neuroimaging, 2020, 30, 110-118.	2.0	31
1279	Tractography in the presence of multiple sclerosis lesions. NeuroImage, 2020, 209, 116471.	4.2	36
1280	Hippocampal and trigeminal nerve volume predict outcome of surgical treatment for trigeminal neuralgia. Cephalalgia, 2020, 40, 586-596.	3.9	18
1281	Assessment and correction of macroscopic field variations in 2D spoiled gradientâ€echo sequences. Magnetic Resonance in Medicine, 2020, 84, 620-633.	3.0	2
1282	Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months. Multiple Sclerosis and Related Disorders, 2020, 39, 101926.	2.0	16
1283	Cognitive dysfunction and brain atrophy in Susac syndrome. Journal of Neurology, 2020, 267, 994-1003.	3.6	13
1284	Association between midlife dementia risk factors and longitudinal brain atrophy: the PREVENT-Dementia study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 158-161.	1.9	26
1285	Brain atrophy in cerebral small vessel diseases: Extent, consequences, technical limitations and perspectives: The HARNESS initiative. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 231-245.	4.3	49
1286	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. Journal of Neurology, 2020, 267, 802-811.	3.6	11
1287	Structural MRI Analysis of Chronic Pain Patients Following Interdisciplinary Treatment Shows Changes in Brain Volume and Opiate-Dependent Reorganization of the Amygdala and Hippocampus. Pain Medicine, 2020, 21, 2765-2776.	1.9	7
1288	Late onset multiple sclerosis is associated with more severe ventricle expansion. Multiple Sclerosis and Related Disorders, 2020, 46, 102588.	2.0	13
1289	Paramagnetic Metal Accumulation in the Deep Gray Matter Nuclei Is Associated With Neurodegeneration in Wilson's Disease. Frontiers in Neuroscience, 2020, 14, 573633.	2.8	7
1290	Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732095735.	1.0	6
1291	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation. Journal of Biological Chemistry, 2020, 295, 17413-17424.	3.4	29

#	Article	IF	CITATIONS
1292	Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Frontiers in Neurology, 2020, 11, 1045.	2.4	4
1293	Stimulating aged brains with transcranial direct current stimulation: Opportunities and challenges. Psychiatry Research - Neuroimaging, 2020, 306, 111179.	1.8	21
1294	Five years of ocrelizumab in relapsing multiple sclerosis. Neurology, 2020, 95, e1854-e1867.	1.1	81
1295	Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2021, 27, 1533-1542.	3.0	29
1296	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. BMJ Open, 2020, 10, e040100.	1.9	11
1297	Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097075.	3.5	7
1298	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 553616.	2.4	4
1299	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. American Journal of Neuroradiology, 2020, 41, 2209-2218.	2.4	10
1300	Deficits in ascending and descending pain modulation pathways in patients with postherpetic neuralgia. Neurolmage, 2020, 221, 117186.	4.2	38
1301	Randomized feasibility trial to assess tolerance and clinical effects of lithium in progressive multiple sclerosis. Heliyon, 2020, 6, e04528.	3.2	8
1302	Subcortical atrophy correlates with the perturbational complexity index in patients with disorders of consciousness. Brain Stimulation, 2020, 13, 1426-1435.	1.6	20
1303	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. Frontiers in Neurology, 2020, 11, 700.	2.4	12
1304	MRI Measurement of Upper Cervical Spinal Cord Crossâ€Sectional Area in Children. Journal of Neuroimaging, 2020, 30, 598-602.	2.0	7
1305	A pilot study of magnetic resonance fingerprinting in Parkinson's disease. NMR in Biomedicine, 2020, 33, e4389.	2.8	10
1306	Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. European Journal of Neurology, 2020, 27, 2549-2560.	3.3	30
1307	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1577-1583.	2.4	4
1308	Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands. Scientific Reports, 2020, 10, 13703.	3.3	6
1309	Vanishing White Matter Hyperintensities in CADASIL: A Case Report with Insight into Disease Mechanisms. Journal of Alzheimer's Disease, 2020, 78, 907-910.	2.6	4

#	Article	IF	CITATIONS
1310	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 46, 102579.	2.0	14
1311	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. Diagnostics, 2020, 10, 685.	2.6	4
1312	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. Frontiers in Neurology, 2020, 11, 499910.	2.4	14
1313	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 998-1009.	10.2	98
1314	Multimodal Evaluation of Neurovascular Functionality in Early Parkinson's Disease. Frontiers in Neurology, 2020, 11, 831.	2.4	13
1315	Inter-scanner reproducibility of brain volumetry: influence of automated brain segmentation software. BMC Neuroscience, 2020, 21, 35.	1.9	18
1316	EEG Power spectra and subcortical pathology in chronic disorders of consciousness. Psychological Medicine, 2022, 52, 1491-1500.	4.5	19
1317	Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration. Scientific Reports, 2020, 10, 15644.	3.3	7
1318	The subcortical basis of outcome and cognitive impairment in TBI. Neurology, 2020, 95, e2398-e2408.	1.1	31
1319	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. Journal of the Neurological Sciences, 2020, 418, 117120.	0.6	5
1320	Early brain biomarkers of post-traumatic seizures: initial report of the multicentre epilepsy bioinformatics study for antiepileptogenic therapy (EpiBioS4Rx) prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1154-1157.	1.9	18
1321	Neurodegeneration trajectory in pediatric and adult/late DM1: A followâ€up MRI study across a decade. Annals of Clinical and Translational Neurology, 2020, 7, 1802-1815.	3.7	15
1322	Brain gray matter abnormalities in osteoarthritis pain: a cross-sectional evaluation. Pain, 2020, 161, 2167-2178.	4.2	32
1323	T ₂ relaxation time of the normal-appearing white matter is related to the cognitive status in cerebral small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1767-1777.	4.3	9
1324	Physical activity monitoring to assess disability progression in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732097518.	1.0	10
1325	Bipolar disorders and deep grey matter in multiple sclerosis: A preliminary quantitative MRI study. Multiple Sclerosis and Related Disorders, 2020, 46, 102564.	2.0	5
1326	The default network of the human brain is associated with perceived social isolation. Nature Communications, 2020, 11, 6393.	12.8	108
1327	Levels of brainâ€derived neurotrophic factor in patients with multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 2251-2261.	3.7	23

#	Article	IF	CITATIONS
1328	Longitudinal analysis of brain structure using existence probability. Brain and Behavior, 2020, 10, e01869.	2.2	2
1329	Efficacy of High-Intensity Aerobic Exercise on Brain MRI Measures in Multiple Sclerosis. Neurology, 2021, 96, e203-e213.	1.1	35
1330	White matter integrity correlates with cognition and disease severity in Fabry disease. Brain, 2020, 143, 3331-3342.	7.6	12
1331	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. American Journal of Neuroradiology, 2020, 41, 2219-2226.	2.4	14
1332	Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndrome—A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies. Brain Sciences, 2020, 10, 798.	2.3	7
1333	Inclusion of the Symbol Digit Modalities Test in a revised assessment of â€~no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102076.	2.0	6
1334	Clinically reliable cognitive decline in relapsing remitting multiple sclerosis: Is it the tip of the iceberg?. Neurological Research, 2020, 42, 575-586.	1.3	7
1335	Network Efficiency Mediates the Relationship Between Vascular Burden and Cognitive Impairment. Stroke, 2020, 51, 1682-1689.	2.0	31
1336	Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial. BMC Neurology, 2020, 20, 173.	1.8	22
1337	Functional Connectivity and Structural Disruption in the Defaultâ€Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 523-530.	2.0	21
1338	Assessment of brain volumes obtained from MP-RAGE and MP2RAGE images, quantified using different segmentation methods. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 757-767.	2.0	3
1339	Parietal Perfusion Alterations in Parkinson's Disease Patients Without Dementia. Frontiers in Neurology, 2020, 11, 562.	2.4	16
1340	The effects of an aerobic training intervention on cognition, grey matter volumes and white matter microstructure. Physiology and Behavior, 2020, 223, 112923.	2.1	18
1341	Diffusion tensor imaging findings in children with sluggish cognitive tempo comorbid Attention Deficit Hyperactivity Disorder. Nordic Journal of Psychiatry, 2020, 74, 620-626.	1.3	7
1342	Trajectories of brain volume change over 13Âyears in chronic schizophrenia. Schizophrenia Research, 2020, 222, 525-527.	2.0	5
1343	Population variability in social brain morphology for social support, household size and friendship satisfaction. Social Cognitive and Affective Neuroscience, 2020, 15, 635-647.	3.0	13
1344	Brain volume loss in individuals over time: Source of variance and limits of detectability. NeuroImage, 2020, 214, 116737.	4.2	11
1345	Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. Multiple Sclerosis and Related Disorders, 2020, 42, 102049.	2.0	4

#	Article	IF	CITATIONS
1346	Detection of subtle gait disturbance and future fall risk in early multiple sclerosis. Neurology, 2020, 94, e1395-e1406.	1.1	25
1347	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. Journal of Neurology, 2020, 267, 3541-3554.	3.6	14
1348	The impact of deep grey matter volume on cognition in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102351.	2.0	11
1349	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	10.1	150
1350	2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis. European Radiology, 2020, 30, 3813-3822.	4.5	18
1351	Brain atrophy and employment in multiple sclerosis patients: a 10-year follow-up study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090248.	1.0	2
1352	Anatomical substrates of symptom remission and persistence in young adults with childhood attention deficit/hyperactivity disorder. European Neuropsychopharmacology, 2020, 33, 117-125.	0.7	9
1353	Serum vitamin D level is associated with speed of processing in multiple sclerosis patients. Journal of Steroid Biochemistry and Molecular Biology, 2020, 200, 105628.	2.5	5
1354	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	10.2	81
1355	New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients. Neurological Research, 2020, 42, 148-152.	1.3	5
1356	Striatum Shape Hypertrophy in Early Stage Parkinson's Disease With Excessive Daytime Sleepiness. Frontiers in Neuroscience, 2019, 13, 1353.	2.8	8
1357	Differential white and gray matter damage in highly active multiple sclerosis: A prospective cohort study. Journal of Clinical Neuroscience, 2020, 74, 65-68.	1.5	0
1358	Subcortical Brain Abnormalities and Clinical Relevance in Patients With Hemifacial Spasm. Frontiers in Neurology, 2019, 10, 1383.	2.4	10
1359	A validation study of manual atrophy measures in patients with MultipleÂSclerosis. Neuroradiology, 2020, 62, 955-964.	2.2	10
1360	Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. Journal of Neurology, 2020, 267, 2042-2053.	3.6	20
1361	Early putamen hypertrophy and ongoing hippocampus atrophy predict cognitive performance in the first ten years of relapsing-remitting multiple sclerosis. Neurological Sciences, 2020, 41, 2893-2904.	1.9	8
1362	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. European Radiology, 2020, 30, 5048-5058.	4.5	9
1363	Late drugâ€resistance in mild MTLE: Can it be influenced by preexisting white matter alterations?. Epilepsia, 2020, 61, 924-934.	5.1	7

#	Article	IF	CITATIONS
1364	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 767-775.	3.7	20
1365	Clinical and Magnetic Resonance Imaging Outcome Predictors in Pediatric <scp>Anti–Nâ€Methylâ€Dâ€Aspartate</scp> Receptor Encephalitis. Annals of Neurology, 2020, 88, 148-159.	5.3	26
1366	Loss of nucleus accumbens low-frequency fluctuations is a signature of chronic pain. Proceedings of the United States of America, 2020, 117, 10015-10023.	7.1	42
1367	Evaluation of the â€ [~] ring sign' and the â€ [~] core sign' as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732091548.	1.0	25
1368	Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?. Multiple Sclerosis Journal, 2021, 27, 401-409.	3.0	6
1369	Confound modelling in UK Biobank brain imaging. NeuroImage, 2021, 224, 117002.	4.2	135
1370	State-of-the-Art Segmentation Techniques and Future Directions for Multiple Sclerosis Brain Lesions. Archives of Computational Methods in Engineering, 2021, 28, 951-977.	10.2	22
1371	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 28-38.	3.0	11
1372	Lithium prevents grey matter atrophy in patients with bipolar disorder: an international multicenter study. Psychological Medicine, 2021, 51, 1201-1210.	4.5	15
1373	Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 61-70.	3.0	16
1374	Diagnosis of depression in multiple sclerosis is predicted by frontal–parietal white matter tract disruption. Journal of Neurology, 2021, 268, 169-177.	3.6	10
1375	Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?. Journal of Neurology, 2021, 268, 77-89.	3.6	5
1376	Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach. Multiple Sclerosis Journal, 2021, 27, 841-854.	3.0	20
1377	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Crossâ€5ectional Structural <scp>MRI</scp> Study. Journal of Magnetic Resonance Imaging, 2021, 53, 731-739.	3.4	19
1378	Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls. Journal of Neurology, 2021, 268, 1316-1322.	3.6	5
1379	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102653.	2.0	13
1380	Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study. Neurology, 2021, 96, e491-e500.	1.1	27
1381	Pneumocephalus in subthalamic deep brain stimulation for Parkinson's disease: a comparison of two different surgical techniques considering factors conditioning brain shift and target precision. Acta	1.7	12

	Сітаті	on Report	
#	Article	IF	CITATIONS
1382	Biomarkers of treatment response in patients with progressive multiple sclerosis treated with highâ€dose pharmaceuticalâ€grade biotin (MD1003). Brain and Behavior, 2021, 11, e01998.	2.2	3
1383	Do increases in deep grey matter volumes after electroconvulsive therapy persist in patients with major depression? A longitudinal MRI-study. Journal of Affective Disorders, 2021, 281, 908-917.	4.1	6
1384	ls it time to switch your T1W sequence? Assessing the impact of prospective motion correction on the reliability and quality of structural imaging. NeuroImage, 2021, 226, 117585.	4.2	16
1385	Adaptive sliceâ€specific zâ€shimming for 2D spoiled gradientâ€echo sequences. Magnetic Resonance in Medicine, 2021, 85, 818-830.	3.0	1
1386	A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis. NeuroImage, 2021, 225, 117471.	4.2	54
1387	Brainstem networkÂconnectivity with mid-anterior insula predicts lower systolic blood pressure at rest in older adults with hypertension. Journal of Human Hypertension, 2021, 35, 1098-1108.	2.2	3
1388	Generating Longitudinal Atrophy Evaluation Datasets on Brain Magnetic Resonance Images Using Convolutional Neural Networks and Segmentation Priors. Neuroinformatics, 2021, 19, 477-492.	2.8	5
1389	Quantitative MRI using STrategically Acquired Gradient Echo (STAGE): optimization for 1.5 T scanners and T1 relaxation map validation. European Radiology, 2021, 31, 4504-4513.	4.5	4
1390	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. NeuroImage: Clinical, 2021, 29, 102549.	2.7	20
1391	Deep learning identifies partially overlapping subnetworks in the human social brain. Communications Biology, 2021, 4, 65.	4.4	11
1392	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	2.7	5
1393	Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199239.	1.0	5
1395	Relationships between retinal layer thickness and brain volumes in the UK Biobank cohort. European Journal of Neurology, 2021, 28, 1490-1498.	3.3	25
1396	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. Neurolmage: Clinical, 2021, 29, 102554.	2.7	3
1397	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. NeuroImage: Clinical, 2021, 31, 102705.	2.7	3
1398	Predicting MEG resting-state functional connectivity from microstructural information. Network Neuroscience, 2021, 5, 477-504.	2.6	20
1399	Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis. Journal of the Neurological Sciences, 2021, 421, 117324.	0.6	5
1400	Altered Processing of Complex Visual Stimuli in Patients with Postconcussive Visual Motion Sensitivity. American Journal of Neuroradiology, 2021, 42, 930-937.	2.4	11

#	Article	IF	CITATIONS
1401	Evaluating the Effect of Intensity Standardisation on Longitudinal Whole Brain Atrophy Quantification in Brain Magnetic Resonance Imaging. Applied Sciences (Switzerland), 2021, 11, 1773.	2.5	2
1402	Epigallocatechin Gallate in Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	12
1403	Cervical Dystonia Is Associated With Aberrant Inhibitory Signaling Within the Thalamus. Frontiers in Neurology, 2020, 11, 575879.	2.4	12
1404	Odorant-induced brain activation as a function of normal aging and Alzheimer's disease: A preliminary study. Behavioural Brain Research, 2021, 402, 113078.	2.2	8
1405	Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance. Frontiers in Neurology, 2021, 12, 619135.	2.4	4
1407	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
1408	A Comparative Analysis of MRI Automated Segmentation of Subcortical Brain Volumes in a Large Dataset of Elderly Subjects. Neuroinformatics, 2022, 20, 63-72.	2.8	6
1409	Study Protocol: The Heart and Brain Study. Frontiers in Physiology, 2021, 12, 643725.	2.8	2
1410	Longitudinal Reproducibility of Neurite Orientation Dispersion and Density Imaging (NODDI) Derived Metrics in the White Matter. Neuroscience, 2021, 457, 165-185.	2.3	17
1411	<i>NOTCH3</i> variants are more common than expected in the general population and associated with stroke and vascular dementia: an analysis of 200 000 participants. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 694-701.	1.9	39
1412	Cognitive behavioral therapy for patients with mild to moderate depression: Treatment effects and neural mechanisms. Journal of Psychiatric Research, 2021, 136, 288-295.	3.1	11
1413	Event-related potentials and deep grey matter atrophy in multiple sclerosis: Exploring the possible associations with cognition. Multiple Sclerosis and Related Disorders, 2021, 49, 102785.	2.0	6
1414	Psychosocial, Functional, and Emotional Correlates of Long-Term Opioid Use in Patients with Chronic Back Pain: A Cross-Sectional Case–Control Study. Pain and Therapy, 2021, 10, 691-709.	3.2	11
1415	Dynamic Functional Connectivity in the Main Clinical Phenotypes of Multiple Sclerosis. Brain Connectivity, 2021, 11, 678-690.	1.7	14
1416	Cognitive Function and Whole-Brain MRI Metrics Are Not Associated with Mobility in Older Adults with Multiple Sclerosis. International Journal of Environmental Research and Public Health, 2021, 18, 4232.	2.6	7
1417	Diffusely appearing white matter in multiple sclerosis: Insights from sodium (23Na) MRI. Multiple Sclerosis and Related Disorders, 2021, 49, 102752.	2.0	10
1418	Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue. European Journal of Radiology, 2021, 137, 109610.	2.6	20
1420	Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102840.	2.0	5

ARTICLE IF CITATIONS # Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and 1421 3.6 3 multiple sclerosis. Journal of Neurology, 2022, 269, 269-279. Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular 1422 4.2 38 alternatives. NeuroImage, 2021, 231, 117845. Sleep disturbance and memory dysfunction in early multiple sclerosis. Annals of Clinical and 1423 3.7 7 Translational Neurology, 2021, 8, 1172-1182. Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their 1424 2.4 Caregivers. Frontiers in Neurology, 2021, 12, 636463. Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive 1425 3.9 26 Decline. Movement Disorders, 2021, 36, 2066-2076. Sex is a defining feature of neuroimaging phenotypes in major brain disorders. Human Brain Mapping, 2022, 43, 500-542. 3.6 Variability in Brain Structure and Function Reflects Lack of Peer Support. Cerebral Cortex, 2021, 31, 1428 2.9 22 4612-4627. Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab 1429 1.9 therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1319-1324. Brainstem Involvement in Amyotrophic Lateral Sclerosis: A Combined Structural and Diffusion Tensor 1430 9 2.8 MRI Analysis. Frontiers in Neuroscience, 2021, 15, 675444. Altered anterior default mode network dynamics in progressive multiple sclerosis. Multiple Sclerosis 1431 Journal, 2022, 28, 206-216. Verbal Episodic Memory Alterations and Hippocampal Atrophy in Acute Mild Traumatic Brain Injury. 1432 2 3.4 Journal of Neurotrauma, 2021, 38, 1506-1514. Cognitive trajectories in multiple sclerosis: a long-term follow-up study. Neurological Sciences, 2022, 43, 1215-1222. Dissecting the midlife crisis: disentangling social, personality and demographic determinants in social 1434 4.4 18 brain anatomy. Communications Biology, 2021, 4, 728. Association of Epilepsy Surgery With Changes in Imaging-Defined Brain Age. Neurology, 2021, 97, 1435 1.1 e554-e563. The thalamus in trigeminal neuralgia: structural and metabolic abnormalities, and influence on 1436 10 1.8 surgical response. BMC Neurology, 2021, 21, 290. MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple 1437 sclerosis. Multiple Sclerosis Journal, 2022, 28, 561-572. Engagement in cognitively stimulating activities in individuals with Mild Cognitive Impairment: 1438 relationships with neuropsychological domains and hippocampal volume. Aging, Neuropsychology, 1.33 and Cognition, 2021, , 1-22. Structural brain dynamics across reading development: A longitudinal <scp>MRI</scp> study from 1439 kindergarten to grade 5. Human Brain Mapping, 2021, 42, 4497-4509.

#	Article	IF	CITATIONS
1440	Value of magnetic resonance imaging in multiple sclerosis patients. Al-Azhar International Medical Journal, 2021, .	0.1	0
1441	Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review. Frontiers in Neurology, 2021, 12, 666868.	2.4	13
1442	Regional brain atrophy is related to social cognition impairment in multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2021, 79, 666-675.	0.8	0
1443	Abnormality of subcortical volume and resting functional connectivity in adolescents with early-onset and prodromal schizophrenia. Journal of Psychiatric Research, 2021, 140, 282-288.	3.1	11
1444	Leveraging Neuroimaging Tools to Assess Precision and Accuracy in an Alzheimer's Disease Neuropathologic Sampling Protocol. Frontiers in Neuroscience, 2021, 15, 693242.	2.8	1
1445	Brain Atrophy and White Matter Damage Linked to Peripheral Bioenergetic Deficits in the Neurodegenerative Disease FXTAS. International Journal of Molecular Sciences, 2021, 22, 9171.	4.1	8
1446	Central nervous system atrophy predicts future dynamics of disability progression in a realâ€world multiple sclerosis cohort. European Journal of Neurology, 2021, 28, 4153-4166.	3.3	10
1449	Improved Assessment of Longitudinal Spinal Cord Atrophy in Multiple Sclerosis Using a <scp>Registrationâ€Based</scp> Approach: Relevance for Clinical Studies. Journal of Magnetic Resonance Imaging, 2022, 55, 1559-1568.	3.4	3
1451	Higher Framingham Risk Scores are associated with greater loss of brain volume over time in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103088.	2.0	10
1452	Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis—a systematic review. Neuroradiology, 2021, 63, 1773-1789.	2.2	29
1453	Altered sensorimotor integration in multiple sclerosis: A combined neurophysiological and functional MRI study. Clinical Neurophysiology, 2021, 132, 2191-2198.	1.5	7
1454	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	3.3	14
1456	Predictors of thermal response and lesion size in patients undergoing magnetic resonance-guided focused ultrasound thalamotomy. Journal of Clinical Neuroscience, 2021, 91, 75-79.	1.5	4
1457	Optimization of epilepsy surgery through virtual resections on individual structural brain networks. Scientific Reports, 2021, 11, 19025.	3.3	13
1458	Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. European Radiology, 2022, 32, 2012-2022.	4.5	19
1459	Visual Function and Brief Cognitive Assessment for Multiple Sclerosis in Optic Neuritis Clinically Isolated Syndrome Patients. Journal of Neuro-Ophthalmology, 2022, 42, e22-e31.	0.8	4
1460	Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Multiple Sclerosis and Related Disorders, 2021, 55, 103170.	2.0	8
1461	Does local cerebellar volume predict treatment success in anorexia nervosa?. Psychiatry Research - Neuroimaging, 2021, 317, 111355.	1.8	8

			0
#	Article	IF	CITATIONS
1462	Brain Structure and Function of Chronic Low Back Pain Patients on Long-Term Opioid Analgesic Treatment: A Preliminary Study. Molecular Pain, 2021, 17, 174480692199093.	2.1	5
1463	Memory, processing of emotional stimuli, and volume of limbic structures in pediatric-onset multiple sclerosis. NeuroImage: Clinical, 2021, 31, 102753.	2.7	4
1464	Dynamic functional connectivity as a neural correlate of fatigue in multiple sclerosis. NeuroImage: Clinical, 2021, 29, 102556.	2.7	21
1465	Study protocol: randomised controlled trial evaluating exercise therapy as a supplemental treatment strategy in early multiple sclerosis: the Early Multiple Sclerosis Exercise Study (EMSES). BMJ Open, 2021, 11, e043699.	1.9	11
1466	Cerebral amyloid angiopathy is associated with decreased functional brain connectivity. NeuroImage: Clinical, 2021, 29, 102546.	2.7	4
1467	Effects of the dopamine transporter gene on neuroimaging findings in different attention deficit hyperactivity disorder presentations. Brain Imaging and Behavior, 2021, 15, 1103-1114.	2.1	3
1468	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. NeuroImage: Clinical, 2021, 30, 102608.	2.7	9
1469	Multiple Sclerosis Lesion Filling Using a Non-lesion Attention Based Convolutional Network. Lecture Notes in Computer Science, 2020, , 448-460.	1.3	4
1470	Modeling the Variability in Brain Morphology and Lesion Distribution in Multiple Sclerosis by Deep Learning. Lecture Notes in Computer Science, 2014, 17, 462-469.	1.3	29
1471	Mapping Lifetime Brain Volumetry with Covariate-Adjusted Restricted Cubic Spline Regression from Cross-Sectional Multi-site MRI. Lecture Notes in Computer Science, 2016, 9900, 81-88.	1.3	14
1472	Longitudinal Brain MRI Analysis with Uncertain Registration. Lecture Notes in Computer Science, 2011, 14, 647-654.	1.3	23
1473	Transdiagnostic hippocampal damage patterns in neuroimmunological disorders. NeuroImage: Clinical, 2020, 28, 102515.	2.7	11
1474	Translating research findings into clinical practice: a systematic and critical review of neuroimaging-based clinical tools for brain disorders. Translational Psychiatry, 2020, 10, 107.	4.8	29
1475	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications, 2020, 11, 812.	12.8	316
1476	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Communications, 2020, 2, fcaa166.	3.3	24
1477	Hippocampus shape deformation: a potential diagnostic biomarker for chronic back pain in women. Pain, 2021, 162, 1457-1467.	4.2	12
1478	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 294-300.	0.9	3
1492	A Multi-Modal Deep Learning Approach to the Early Prediction of Mild Cognitive Impairment Conversion to Alzheimer's Disease. , 2020, , .		5

#	Article	IF	CITATIONS
1493	Multimodal MRI Response to Fingolimod in Multiple Sclerosis: A Nonrandomized, Single Arm, Observational Study. Journal of Neuroimaging, 2021, 31, 379-387.	2.0	5
1494	Brain atrophy in Multiple Sclerosis. American Journal of Psychiatry and Neuroscience, 2015, 3, 40.	0.1	2
1495	Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple Sclerosis. , 2005, 15, 27-36.		12
1496	High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090347.	1.0	27
1497	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. Fluids and Barriers of the CNS, 2020, 17, 9.	5.0	7
1498	Early childhood bilingualism: effects on brain structure and function. F1000Research, 2020, 9, 370.	1.6	3
1499	Colocalized Structural and Functional Changes in the Cortex of Patients with Trigeminal Neuropathic Pain. PLoS ONE, 2008, 3, e3396.	2.5	109
1500	Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. PLoS ONE, 2010, 5, e12244.	2.5	612
1501	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. PLoS ONE, 2011, 6, e19452.	2.5	74
1502	Neurexin-1 and Frontal Lobe White Matter: An Overlapping Intermediate Phenotype for Schizophrenia and Autism Spectrum Disorders. PLoS ONE, 2011, 6, e20982.	2.5	58
1503	White Matter Atrophy and Cognitive Dysfunctions in Neuromyelitis Optica. PLoS ONE, 2012, 7, e33878.	2.5	85
1504	White Matter Differences between Healthy Young ApoE4 Carriers and Non-Carriers Identified with Tractography and Support Vector Machines. PLoS ONE, 2012, 7, e36024.	2.5	19
1505	Sexual Dimorphism in Healthy Aging and Mild Cognitive Impairment: A DTI Study. PLoS ONE, 2012, 7, e37021.	2.5	26
1506	Different Patterns of White Matter Degeneration Using Multiple Diffusion Indices and Volumetric Data in Mild Cognitive Impairment and Alzheimer Patients. PLoS ONE, 2012, 7, e52859.	2.5	68
1507	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	2.5	68
1508	It's All in the Eyes: Subcortical and Cortical Activation during Grotesqueness Perception in Autism. PLoS ONE, 2013, 8, e54313.	2.5	42
1509	Brainstem Involvement as a Cause of Central Sleep Apnea: Pattern of Microstructural Cerebral Damage in Patients with Cerebral Microangiopathy. PLoS ONE, 2013, 8, e60304.	2.5	33
1510	Cognitive and Clinical Dysfunction, Altered MEG Resting-State Networks and Thalamic Atrophy in Multiple Sclerosis. PLoS ONE, 2013, 8, e69318.	2.5	68

#	Article	IF	CITATIONS
1511	Alcohol Induces Sensitization to Gluten in Genetically Susceptible Individuals: A Case Control Study. PLoS ONE, 2013, 8, e77638.	2.5	12
1512	Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis. PLoS ONE, 2014, 9, e86916.	2.5	73
1513	Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation to Symptom Severity, Cognition and Antipsychotic Medication. PLoS ONE, 2014, 9, e101689.	2.5	92
1514	Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0119356.	2.5	35
1515	Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis. PLoS ONE, 2015, 10, e0137715.	2.5	47
1516	Tracking Parkinson's Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. PLoS ONE, 2015, 10, e0143923.	2.5	21
1517	Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method. PLoS ONE, 2016, 11, e0143942.	2.5	45
1518	Verbal Memory Decline following DBS for Parkinson's Disease: Structural Volumetric MRI Relationships. PLoS ONE, 2016, 11, e0160583.	2.5	7
1519	From Cortical and Subcortical Grey Matter Abnormalities to Neurobehavioral Phenotype of Angelman Syndrome: A Voxel-Based Morphometry Study. PLoS ONE, 2016, 11, e0162817.	2.5	18
1520	Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies. PLoS ONE, 2016, 11, e0164617.	2.5	6
1521	Cerebellar volume as imaging outcome in progressive multiple sclerosis. PLoS ONE, 2017, 12, e0176519.	2.5	19
1522	Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression. Journal of Psychiatry and Neuroscience, 2020, 45, 45-54.	2.4	22
1523	Novel Automated Method for the Detection of White Matter Hyperintensities in Brain Multispectral MR Images. Current Medical Imaging, 2020, 16, 469-478.	0.8	2
1524	Cerebrospinal Fluid Markers of Synaptic Injury and Functional Connectivity in Alzheimer Disease: Protocol for a Cross-Sectional Study. JMIR Research Protocols, 2019, 8, e14302.	1.0	2
1525	Connectivity of the human pedunculopontine nucleus region and diffusion tensor imaging in surgical targeting. Journal of Neurosurgery, 2007, 107, 814-820.	1.6	1
1526	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.7	11
1527	The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technology Assessment, 2015, 19, 1-188.	2.8	53
1528	Volumetric and Shape Analysis of the Subcortical Regions in Schizophrenia Patients: A Pilot Study. Journal of Clinical Imaging Science, 2019, 9, 1.	1.1	6

#	Article	IF	CITATIONS
1529	Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. Swiss Medical Weekly, 2013, 143, w13887.	1.6	19
1530	BRAIN AND LESION VOLUMES CORRELATE WITH EDSS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS. Journal of IMAB, 2015, 21, 1015-1018.	0.1	3
1531	Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting. PeerJ, 2016, 4, e2442.	2.0	14
1532	A comparison of automated atrophy measures across the frontotemporal dementia spectrum: Implications for trials. NeuroImage: Clinical, 2021, 32, 102842.	2.7	2
1533	Sensitivity of Arterial Spin Labeling for Characterization of Longitudinal Perfusion Changes in Frontotemporal Dementia and Related Disorders. NeuroImage: Clinical, 2022, 35, 102853.	2.7	9
1534	Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis. Neurology, 2021, 97, e1886-e1897.	1.1	18
1535	Enhanced Temporal Coupling between Thalamus and Dorsolateral Prefrontal Cortex Mediates Chronic Low Back Pain and Depression. Neural Plasticity, 2021, 2021, 1-10.	2.2	20
1536	Long-term dynamics of multiple sclerosis iron rim lesions. Multiple Sclerosis and Related Disorders, 2022, 57, 103340.	2.0	24
1538	The Association of Age at Diagnosis of Hypertension With Brain Structure and Incident Dementia in the UK Biobank. Hypertension, 2021, 78, 1463-1474.	2.7	35
1539	How Accurate Is Brain Volumetry?. Lecture Notes in Computer Science, 2004, , 335-342.	1.3	0
1540	Measuring and Interpreting White Matter Volume Changes in Multiple Sclerosis. , 2004, , 23-35.		0
1541	Imaging Cerebral Grey Matter Volume in Multiple Sclerosis. , 2004, , 111-120.		0
1542	Use of Simulated Atrophy for Performance Analysis of Brain Atrophy Estimation Approaches. Lecture Notes in Computer Science, 2009, 12, 566-574.	1.3	2
1543	Anatomical Imaging: Volumetric Analysis. , 2010, , 31-45.		0
1544	Automated Detection of Dementia Symptoms in MR Brain Images. Lecture Notes in Computer Science, 2010, , 627-634.	1.3	0
1545	Brain Imaging in Hepatic Encephalopathy. , 2012, , 123-137.		2
1546	Imaging Disease Progression. , 2013, , 93-114.		0
1547	A CASE STUDY OF BRAIN VOLUME REDUCTION IN MULTIPLE SCLEROSIS. Journal of IMAB, 2013, 19, 438-441.	0.1	1

#	Article	IF	CITATIONS
1548	Quantitative MR Markers and Psychiatric Symptoms in a Patient with Fahr Disease. American Journal of Case Reports, 2015, 16, 382-385.	0.8	1
1549	Manual adjustment of brain extraction parameters in a volumetric study. Scripta Scientifica Medica, 2015, 47, 54.	0.1	1
1550	Vertex-wise shape analysis of subcortical structures in Alzheimer's disease. Healthy Aging Research, 2016, 5, 1-8.	0.3	1
1552	Template-Free Estimation of Intracranial Volume: A Preterm Birth Animal Model Study. Lecture Notes in Computer Science, 2017, , 3-13.	1.3	0
1554	Imaging Disease Progression. , 2018, , 93-121.		0
1558	The Role of Mindfulness in Neurorehabilitation: From the Monastery to the Clinic. , 2019, , 749-788.		3
1565	Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103353.	2.0	9
1566	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. Neurology and Therapy, 2022, 11, 39-49.	3.2	12
1567	Adapting the UK Biobank Brain Imaging Protocol and Analysis Pipeline for the C-MORE Multi-Organ Study of COVID-19 Survivors. Frontiers in Neurology, 2021, 12, 753284.	2.4	16
1568	Relationship Between Interpersonal Depressive Symptoms and Reduced Amygdala Volume in People with Multiple Sclerosis. International Journal of MS Care, 2021, 23, 178-185.	1.0	1
1572	A Longitudinal Method for Simultaneous Whole-Brain and Lesion Segmentation in Multiple Sclerosis. Lecture Notes in Computer Science, 2020, , 119-128.	1.3	3
1573	The dihydrofolate reductase 19-bp deletion modifies the beneficial effect of B-vitamin therapy in mild cognitive impairment: pooled study of two randomized placebo-controlled trials. Human Molecular Genetics, 2022, 31, 1151-1158.	2.9	4
1575	Efficacy and safety of ocrelizumab in patients with relapsingâ€remitting multiple sclerosis with suboptimal response to prior diseaseâ€modifying therapies: A primary analysis from the phase 3b CASTING singleâ€arm, openâ€label trial. European Journal of Neurology, 2022, 29, 790-801.	3.3	15
1576	Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: A multimodal magnetic resonance imaging study. Brain, Behavior, & Immunity - Health, 2021, 18, 100387.	2.5	57
1577	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. Radiology, 2013, 269, 542-552.	7.3	52
1578	Population Based Analysis of Directional Information in Serial Deformation Tensor Morphometry. , 2007, 10, 311-318.		10
1581	Brain imaging factors associated with progression of subcortical hyperintensities in CADASIL over 2â€year followâ€up. European Journal of Neurology, 2021, 28, 220-228.	3.3	5
1583	Interactions Between Age, Sex, Menopause, and Brain Structure at Midlife: A UK Biobank Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 410-420.	3.6	21

		CITATION RE	PORT	
#	Article		IF	Citations
1584	Early childhood bilingualism: effects on brain structure and function. F1000Research, 0,	9, 370.	1.6	0
1587	In vivo Age-related Changes in Cortical, Subcortical Nuclei, and Subventricular Zone: A D Tensor Imaging Study. , 2013, 4, 65-75.	iffusion		2
1588	Gray Matter Changes in Demyelinating Disease: Correlations with Clinical Scores. $M\tilde{A}_{1}^{\dagger}di$ 319-324.	ca, 2015, 10,	0.1	2
1589	Regional brain atrophy evolves differently in patients with multiple sclerosis according to phenotype. American Journal of Neuroradiology, 2005, 26, 341-6.	clinical	2.4	113
1590	Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. American Journa Neuroradiology, 2007, 28, 255-9.	l of	2.4	112
1591	Whole-brain histogram and voxel-based analyses of apparent diffusion coefficient and m transfer ratio in celiac disease, epilepsy, and cerebral calcifications syndrome. American J Neuroradiology, 2007, 28, 479-85.	agnetization ournal of	2.4	10
1592	Normal-appearing white matter changes vary with distance to lesions in multiple scleros Journal of Neuroradiology, 2006, 27, 2005-11.	is. American	2.4	52
1593	Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts t the normal-appearing white matter. American Journal of Neuroradiology, 2006, 27, 868-		2.4	27
1594	MR imaging assessment of brain and cervical cord damage in patients with neuroborrelic Journal of Neuroradiology, 2006, 27, 892-4.	osis. American	2.4	39
1595	Effectiveness of B Vitamins and Their Interactions with Aspirin in Improving Cognitive Fu Older People with Mild Cognitive Impairment: Pooled Post-Hoc Analyses of Two Random Journal of Nutrition, Health and Aging, 2021, 25, 1154-1160.		3.3	9
1596	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis. Dia 11, 2230.	gnostics, 2021,	2.6	2
1597	Loneliness is linked to specific subregional alterations in hippocampus-default network o Journal of Neurophysiology, 2021, 126, 2138-2157.	ovariation.	1.8	8
1598	Early brain injury and cognitive impairment after aneurysmal subarachnoid haemorrhage Reports, 2021, 11, 23245.	. Scientific	3.3	11
1599	T1 Relaxation Times in the Cortex and Thalamus Are Associated With Working Memory Processing Speed in Patients With Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 2		2.4	7
1600	CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multi sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110603.	ole	1.0	8
1601	Can we identify the category of imagined phoneme from EEG?. , 2021, 2021, 459-462.			7
1602	Ipsilesional volume loss of basal ganglia and thalamus is associated with poor hand func ischemic perinatal stroke. BMC Neurology, 2022, 22, 23.	tion after	1.8	9
1603	A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Resonance Imaging. Investigative Radiology, 2022, 57, 423-432.	Magnetic	6.2	18

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1604	Restoration of Aberrant Shape of Caudate Subregions Associated with Cognitive Function Improvement in Mild Traumatic Brain Injury. Journal of Neurotrauma, 2022, 39, 348-357.		3.4	12
1605	Cortical morphology predicts placebo response in multiple sclerosis. Scientific Reports, 2	022, 12, 732.	3.3	0
1606	Pregnancyâ€induced brain magnetic resonance imaging changes in women with multiple European Journal of Neurology, 2022, 29, 1446-1456.	2 sclerosis.	3.3	7
1607	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. Annals Neurology, 2022, 91, 268-281.	of	5.3	39
1608	The effect of gadolinium-based contrast-agents on automated brain atrophy measureme FreeSurfer in patients with multiple sclerosis. European Radiology, 2022, 32, 3576-3587		4.5	4
1609	Priming cardiovascular exercise improves complex motor skill learning by affecting the tr learning-related brain plasticity. Scientific Reports, 2022, 12, 1107.	ajectory of	3.3	6
1610	Cerebral blood flow is lower in youth with type 2 diabetes compared to obese controls: A Pediatric Diabetes, 2022, 23, 291-300.	vpilot study.	2.9	4
1611	Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomize Controlled Trial. Annals of Neurology, 2022, 91, 203-216.	ed	5.3	83
1612	Reflections of the sensory findings in the central nervous system in patients with neurop Experimental Brain Research, 2022, 240, 1081-1091.	athic pain.	1.5	2
1613	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Pro People With Subjective Cognitive Decline. Neurology, 2022, 98, .	bgression in	1.1	41
1614	Preliminary Outcomes of Combined Treadmill and Overground High-Intensity Interval Tra Ambulatory Chronic Stroke. Frontiers in Neurology, 2022, 13, 812875.	ining in	2.4	11
1615	Different saccadic profile in bulbar versus spinal-onset amyotrophic lateral sclerosis. Brai 266-277.	n, 2023, 146,	7.6	6
1616	Intrinsic Structural Connectivity of the Default Mode Network and Behavioral Correlates Executive Function and Social Skills in Youth with Autism Spectrum Disorders. Journal of Developmental Disorders, 2023, 53, 1930-1941.	of Autism and	2.7	3
1618	Chronic pain precedes disrupted eating behavior in low-back pain patients. PLoS ONE, 20)22, 17, e0263527.	2.5	8
1619	Lateral entorhinal cortex dysfunction in amnestic mild cognitive impairment. Neurobiolog 2022, 112, 151-160.	zy of Aging,	3.1	13
1620	A Tractometry Investigation of White Matter Tract Network Structure and Relationships Cognitive Function in Relapsing-Remitting Multiple Sclerosis. SSRN Electronic Journal, 0,	with ,.	0.4	0
1621	The Influence of White Matter Lesions on the Electric Field in Transcranial Electric Stimul Electronic Journal, 0, , .	ation. SSRN	0.4	1
1622	A tractometry principal component analysis of white matter tract network structure and relationships with cognitive function in relapsing-remitting multiple sclerosis. NeuroImag 2022, 34, 102995.	e: Clinical,	2.7	1

#	Article	IF	CITATIONS
1623	Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients. NeuroImage: Clinical, 2022, 34, 102985.	2.7	5
1624	Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 820256.	2.4	6
1625	Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. Journal of Neurology, 2022, 269, 3400-3412.	3.6	68
1627	The association between cognition and motor performance is beyond structural damage in relapsing–remitting multiple sclerosis. Journal of Neurology, 2022, 269, 4213-4221.	3.6	6
1628	Neuroanatomical Correlates of Mild-to-Moderate Depression: Memory Ability Mediates the Association Between Gray Matter Volume and Antidepressant Treatment Outcome. Frontiers in Neuroscience, 2022, 16, 872228.	2.8	0
1629	MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions. Journal of Neurology, 2022, , 1.	3.6	6
1630	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis. Neurology, 2022, 98, .	1.1	31
1631	Right fronto-parietal networks mediate the neurocognitive benefits of enriched environments. Brain Communications, 2022, 4, fcac080.	3.3	3
1633	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis. European Radiology, 2022, , 1.	4.5	1
1634	Retinal nerve fiber and ganglion cell complex layer thicknesses mirror brain atrophy in patients with relapsing-remitting multiple sclerosis. Restorative Neurology and Neuroscience, 2022, 40, 35-42.	0.7	7
1635	Time course of lesion-induced atrophy in multiple sclerosis. Journal of Neurology, 2022, 269, 4478-4487.	3.6	3
1637	A new approach to symmetric registration of longitudinal structural MRI of the human brain. Journal of Neuroscience Methods, 2022, 373, 109563.	2.5	2
1638	Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. Multiple Sclerosis Journal, 2021, , 135245852110636.	3.0	1
1639	Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer's disease: an open-label extension study. BMJ Neurology Open, 2021, 3, e000223.	1.6	7
1640	Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study. Journal of Clinical Medicine, 2022, 11, 61.	2.4	10
1642	Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis. Journal of Neurology, 2022, 269, 4729-4741.	3.6	4
1643	Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation. Frontiers in Neuroscience, 2022, 16, 819010.	2.8	15
1659	Shape deformations of the basal ganglia in patients with classical trigeminal neuralgia: a cross-sectional evaluation. Neurological Sciences, 2022, 43, 5007-5015.	1.9	3

#	Article	IF	CITATIONS
1660	Brain magnetic resonance imaging findings and brain volumetric differences in a large series of benign rolandic epilepsy. Neuroradiology Journal, 2022, 35, 692-700.	1.2	1
1661	A phase 1b openâ€label study of sodium selenate as a diseaseâ€modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12299.	3.7	7
1662	The Epidermal Growth Factor Domain of the Mutation Does Not Appear to Influence Disease Progression in CADASIL When Brain Volume and Sex Are Taken into Account. American Journal of Neuroradiology, 2022, , .	2.4	1
1663	Free water diffusion MRI and executive function with a speed component in healthy aging. NeuroImage, 2022, 257, 119303.	4.2	7
1664	Association of a wide range of individual chronic diseases and their multimorbidity with brain volumes in the UK Biobank: A cross-sectional study. EClinicalMedicine, 2022, 47, 101413.	7.1	10
1665	Evolution of Neuroimaging Findings in Severe COVID-19 Patients with Initial Neurological Impairment: An Observational Study. Viruses, 2022, 14, 949.	3.3	13
1666	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology, 2022, 79, 682.	9.0	41
1667	MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD. Journal of Neurology, Neurosurgery and Psychiatry, 2022, , jnnp-2022-328956.	1.9	1
1668	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. NeuroImage: Clinical, 2022, 35, 103048.	2.7	17
1669	Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure. Frontiers in Neurology, 2022, 13, .	2.4	11
1670	The influence of white matter lesions on the electric field in transcranial electric stimulation. NeuroImage: Clinical, 2022, 35, 103071.	2.7	4
1672	Prevalence and Predictors of Vascular Cognitive Impairment in Patients With CADASIL. Neurology, 2022, 99, .	1.1	13
1673	Association of <i>NOTCH3</i> Variant Position With Stroke Onset and Other Clinical Features Among Patients With CADASIL. Neurology, 2022, 99, .	1.1	11
1674	Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica. Annals of Neurology, 2022, 92, 173-183.	5.3	18
1675	Increased Magnetic Susceptibility in the Deep Gray Matter Nuclei of Wilson's Disease: Have We Been Ignoring Atrophy?. Frontiers in Neuroscience, 2022, 16, .	2.8	3
1677	Image Segmentation for MR Brain Tumor Detection Using Machine Learning: A Review. IEEE Reviews in Biomedical Engineering, 2023, 16, 70-90.	18.0	53
1678	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. European Radiology, 2022, 32, 7789-7799.	4.5	3
1679	A comparison of intracranial volume estimation methods and their crossâ€sectional and longitudinal associations with age. Human Brain Mapping, 2022, 43, 4620-4639.	3.6	9

щ	Article	IF	Citations
#	Incipient chronic traumatic encephalopathy in active American football players: neuropsychological	IF	CHATIONS
1681	assessment and brain perfusion measures. Neurological Sciences, 2022, 43, 5383-5390.	1.9	2
1682	Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study. NeuroImage: Clinical, 2022, 35, 103099.	2.7	8
1683	Cholesterol efflux capacity of <scp>highâ€density lipoprotein</scp> was not associated with cognitive decline and brain structures in older people with diabetes mellitus. Journal of Diabetes Investigation, 2022, 13, 1873-1880.	2.4	1
1685	Spatial distribution of multiple sclerosis iron rim lesions and their impact on disability. Multiple Sclerosis and Related Disorders, 2022, 64, 103967.	2.0	6
1686	Painâ€related reorganization in the primary somatosensory cortex of patients with postherpetic neuralgia. Human Brain Mapping, 2022, 43, 5167-5179.	3.6	12
1687	Prediction of high and low disease activity in early MS patients using multiple kernel learning identifies importance of lateral ventricle intensity. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211097.	1.0	3
1688	Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study. Multiple Sclerosis Journal, 2022, 28, 2057-2069.	3.0	5
1689	The Role of Supply Chain Resilience on SMEs' Performance: The Case of an Emerging Economy. Logistics, 2022, 6, 47.	4.3	4
1690	Aberrant hippocampal shape development in young adults with heavy cannabis use: Evidence from a longitudinal study. Journal of Psychiatric Research, 2022, 152, 343-351.	3.1	6
1691	A Spatially Sensitive Kernel to Predict Cognitive Performance from Short-Term Changes in Neural Structure. Proceedings of the AAAI Conference on Artificial Intelligence, 2014, 28, .	4.9	0
1692	Brain atrophy measurement over a MRI scanner change in multiple sclerosis. NeuroImage: Clinical, 2022, 36, 103148.	2.7	3
1693	Mechanisms of central brain atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2038-2045.	3.0	3
1694	The hypertrophic amygdala shape associated with anxiety in patients with primary dysmenorrhea during pain-free phase: insight from surface-based shape analysis. Brain Imaging and Behavior, 2022, 16, 1954-1963.	2.1	1
1695	Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-world study is associated with disability progression. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1128-1136.	1.9	6
1696	Combined fractional anisotropy and subcortical volumetric deficits in patients with mild-to-moderate depression: Evidence from the treatment of antidepressant traditional Chinese medicine. Frontiers in Neuroscience, 0, 16, .	2.8	0
1697	The comorbidity and cognition in multiple sclerosis (CCOMS) neuroimaging protocol: Study rationale, MRI acquisition, and minimal image processing pipelines. , 0, 1, .		4
1698	Associations of Sex, Age, and Cardiometabolic Risk Profiles With Brain Structure and Cognition. Neurology, 2022, 99, .	1.1	4
1699	The prognostic significance of early blood neurofilament light chain concentration and magnetic resonance imaging variables in relapseâ€onset multiple sclerosis. Brain and Behavior, 2022, 12, .	2.2	2

#	Article	IF	Citations
1700	Association of Blood Pressure Lowering Intensity With White Matter Network Integrity in Patients With Cerebral Small Vessel Disease. Neurology, 2022, 99, .	1.1	4
1701	Safety of low-intensity repetitive transcranial magneTic brAin stimUlation foR people living with mUltiple Sclerosis (TAURUS): study protocol for a randomised controlled trial. Trials, 2022, 23, .	1.6	3
1702	Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study. Multiple Sclerosis and Related Disorders, 2022, 67, 104094.	2.0	14
1703	Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2022, 442, 120415.	0.6	2
1704	Hippocampal Growth is Altered from Term Equivalence to One Year of Age in Preterm Born Infants. SSRN Electronic Journal, 0, , .	0.4	0
1705	Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina. Arquivos De Neuro-Psiquiatria, 2022, 80, 699-705.	0.8	0
1706	Harmonized Z-Scores Calculated from a Large-Scale Normal MRI Database to Evaluate Brain Atrophy in Neurodegenerative Disorders. Journal of Personalized Medicine, 2022, 12, 1555.	2.5	0
1707	Cortical change after a 2-week novel robotic rehabilitation program in children with prior hemispherectomy: pilot imaging study. Child's Nervous System, 2023, 39, 443-449.	1.1	1
1708	Sex differences of vascular brain lesions in patients with atrial fibrillation. Open Heart, 2022, 9, e002033.	2.3	0
1710	B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy. Journal of Alzheimer's Disease, 2022, 89, 1453-1461.	2.6	3
1711	Social belonging: brain structure and function is linked to membership in sports teams, religious groups, and social clubs. Cerebral Cortex, 2023, 33, 4405-4420.	2.9	2
1712	Association of type 1 diabetes and age at diagnosis of type 2 diabetes with brain volume and risk of dementia in the <scp>UK</scp> Biobank: A prospective cohort study of communityâ€dwelling participants. Diabetic Medicine, 2023, 40, .	2.3	5
1713	Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 1528-1537.	3.7	24
1714	NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis. Journal of Neurology, 2023, 270, 810-823.	3.6	7
1715	The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis. NeuroImage: Clinical, 2022, 36, 103220.	2.7	3
1716	Reduced power and phase-locking values were accompanied by thalamus, putamen, and hippocampus atrophy in Parkinson's disease with mild cognitive impairment: an event-related oscillation study. Neurobiology of Aging, 2023, 121, 88-106.	3.1	5
1717	Shedding light on motor premanifest myotonic dystrophy type 1: A molecular, muscular and central nervous system followâ€up study. European Journal of Neurology, 2023, 30, 215-223.	3.3	1
1718	Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke. JAMA Neurology, 2022, 79, 1303.	9.0	14

#	Article	IF	CITATIONS
1719	Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis and Related Disorders, 2023, 69, 104374.	2.0	2
1720	Early spinal cord pseudoatrophy in interferonâ€beta treated multiple sclerosis. European Journal of Neurology, 0, , .	3.3	0
1721	Exploring (peri-) lesional and structural connectivity tissue damage through T1/T2-weighted ratio in iron rim multiple sclerosis lesions. Magnetic Resonance Imaging, 2023, 95, 12-18.	1.8	4
1722	Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives. Journal of Neurology, 0, , .	3.6	1
1723	Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence. Neuroradiology, 2023, 65, 5-24.	2.2	9
1724	Segmentation and differentiation of periventricular and deep white matter hyperintensities in 2D T2-FLAIR MRI based on a cascade U-net. Frontiers in Neurology, 0, 13, .	2.4	1
1725	Cerebral and cognitive modifications in retired professional soccer players: TC-FOOT protocol, a transverse analytical study. BMJ Open, 2022, 12, e060459.	1.9	2
1726	Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease. Revista Brasileira De Psiquiatria, 2022, , .	1.7	0
1727	Minimizing the effect of white matter lesions on deep learning based tissue segmentation for brain volumetry. Computerized Medical Imaging and Graphics, 2023, 103, 102157.	5.8	2
1728	Adapting UK Biobank imaging for use in a routine memory clinic setting: The Oxford Brain Health Clinic. NeuroImage: Clinical, 2022, 36, 103273.	2.7	4
1729	Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume. Annals of Clinical and Translational Neurology, 0, , .	3.7	1
1730	Heritability of Subcortical Grey Matter Structures. Medicina (Lithuania), 2022, 58, 1687.	2.0	1
1732	Interpretable brain disease classification and relevance-guided deep learning. Scientific Reports, 2022, 12, .	3.3	5
1733	Effect of spinal anesthesia-induced deafferentation on pain processing in healthy male volunteers: A task-related fMRI study. Frontiers in Pain Research, 0, 3, .	2.0	2
1734	Physical activity and brain health in patients with atrial fibrillation. European Journal of Neurology, 2023, 30, 567-577.	3.3	1
1735	Multiple sclerosis iron rim lesions are linked to impaired cervical spinal cord integrity using the T1/T2â€weighted ratio. Journal of Neuroimaging, 2023, 33, 240-246.	2.0	4
1736	Artificial neural network applied to fragile X-associated tremor/ataxia syndrome stage diagnosis based on peripheral mitochondrial bioenergetics and brain imaging outcomes. Scientific Reports, 2022, 12, .	3.3	2
1737	Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis. Neurology, 2023, 100, .	1.1	17

#	Article	IF	CITATIONS
1738	Cerebellar alterations in Parkinson's disease with postural instability and gait disorders. Journal of Neurology, 2023, 270, 1735-1744.	3.6	5
1739	Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants. Nature Communications, 2022, 13, .	12.8	14
1740	APOE alleles are associated with sex-specific structural differences in brain regions affected in Alzheimer's disease and related dementia. PLoS Biology, 2022, 20, e3001863.	5.6	1
1741	Proof of principle for the clinical use of a CE-certified automatic imaging analysis tool in rare diseases studying hereditary spastic paraplegia type 4 (SPG4). Scientific Reports, 2022, 12, .	3.3	0
1742	Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. Nature Medicine, 2023, 29, 75-85.	30.7	29
1743	Regional shape alteration of left thalamus associated with late chronotype in young adults. Chronobiology International, 2023, 40, 234-245.	2.0	1
1744	Cervical spinal cord atrophy in amyotrophic lateral sclerosis across disease stages. Annals of Clinical and Translational Neurology, 2023, 10, 213-224.	3.7	4
1745	Neurodegenerative disease of the brain: a survey of interdisciplinary approaches. Journal of the Royal Society Interface, 2023, 20, .	3.4	6
1746	Action viewing and language in adolescents with autism spectrum disorder. Experimental Brain Research, 2023, 241, 559-570.	1.5	2
1747	Cocaine use disorder is associated with widespread surface-based alterations of the basal ganglia. Journal of Psychiatric Research, 2023, 158, 95-103.	3.1	3
1748	Functional alteration due to structural damage is network dependent: insight from multiple sclerosis. Cerebral Cortex, 2023, 33, 6090-6102.	2.9	1
1749	Cognitive trajectories during the menopausal transition. , 0, 2, .		1
1750	Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis. Molecular Psychiatry, 2023, 28, 1770-1782.	7.9	10
1751	Evaluation of transorbital sonography measures of optic nerve diameter in the context of global and regional brain volume in multiple sclerosis. Scientific Reports, 2023, 13, .	3.3	1
1752	The Spatio-temporal Relationship Between Concurrent Lesion and Brain Atrophy Changes in Early Multiple Sclerosis: A Post-hoc Analysis of the REFLEXION Study. NeuroImage: Clinical, 2023, , 103397.	2.7	0
1753	A multivariate brain signature for reward. NeuroImage, 2023, 271, 119990.	4.2	4
1754	High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial. EClinicalMedicine, 2023, 59, 101957.	7.1	6
1755	Impaired Brain Growth in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Acute Disseminated Encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	6.0	4

#	Article	IF	CITATIONS
1756	Impaired oxygen extraction and adaptation of intracellular energy metabolism in cerebral small vessel disease. Cerebral Circulation - Cognition and Behavior, 2023, 4, 100162.	0.9	1
1758	Home alone: A population neuroscience investigation of brain morphology substrates. NeuroImage, 2023, 269, 119936.	4.2	0
1759	High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. European Journal of Neurology, 2023, 30, 1389-1399.	3.3	3
1760	An open-source tool for longitudinal whole-brain and white matter lesion segmentation. NeuroImage: Clinical, 2023, 38, 103354.	2.7	4
1761	Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis. Multiple Sclerosis Journal, 2023, 29, 540-548.	3.0	4
1762	Volumetric measurements of brain in multiple sclerosis: comparison of segmentation methods in simulated MRI data. , 2023, , .		0
1763	Therapy effect on Al-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study. Multiple Sclerosis and Related Disorders, 2023, 74, 104708.	2.0	1
1764	Arterial spin labelling reveals multi-regional cerebral hypoperfusion in patients with transient ischemic attack that are unrelated to ischemia location: A proof-of-concept study. Cerebral Circulation - Cognition and Behavior, 2023, 4, 100164.	0.9	0
1765	Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis. Journal of Neurology, 0, , .	3.6	1
1767	Functional connectivity in older adults – the effect of cerebral small vessel disease. Brain Communications, 0, , .	3.3	1
1768	Assessing the Equivalence of Brain-Derived Measures from Two 3D T1-Weighted Acquisitions: One Covering the Brain and One Covering the Brain and Spinal Cord. American Journal of Neuroradiology, 0, , .	2.4	0
1769	Growing importance of brain morphometry analysis in the clinical routine: The hidden impact of MR sequence parameters. Journal of Neuroradiology, 2024, 51, 5-9.	1.1	0
1770	Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging. Multiple Sclerosis Journal, 2023, 29, 741-747.	3.0	4
1772	Tremor suppression following treatment with MRgFUS: skull density ratio consistency and degree of posterior dentatorubrothalamic tract lesioning predicts long-term clinical outcomes in essential tremor. Frontiers in Neurology, 0, 14, .	2.4	1
1773	Longitudinal stability of progressionâ€related microglial activity during teriflunomide treatment in patients with multiple sclerosis. European Journal of Neurology, 0, , .	3.3	0
1774	Is it all in the baseline? Trajectories of chair stand performance over 4 years and their association with grey matter structure in older adults. Human Brain Mapping, 2023, 44, 4299-4309.	3.6	2
1776	Visit-to-visit HbA1c variability, dementia, and hippocampal atrophy among adults without diabetes. Experimental Gerontology, 2023, 178, 112225.	2.8	2
1777	Cardiovascular risk factors in secondary progressive multiple sclerosis: A crossâ€sectional analysis from the <scp>MSâ€STAT2</scp> randomized controlled trial. European Journal of Neurology, 2023, 30, 2769-2780.	3.3	1

#	Article	IF	CITATIONS
1778	Association of brain tissue cerebrospinal fluid fraction with age in healthy cognitively normal adults. Frontiers in Aging Neuroscience, 0, 15, .	3.4	4
1780	Learning from pseudo-labels: deep networks improve consistency in longitudinal brain volume estimation. Frontiers in Neuroscience, 0, 17, .	2.8	1
1781	Subcortical brain anatomy as a potential biomarker of persistent pain after total knee replacement in osteoarthritis. Pain, 2023, 164, 2306-2315.	4.2	2
1782	Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine. Journal of Neurology, 0, , .	3.6	1
1784	Shortâ€ŧerm brain atrophy evolution after initiation of immunotherapy in a realâ€world multiple sclerosis cohort. Journal of Neuroimaging, 0, , .	2.0	0
1785	Menopausal transition in multiple sclerosis: relationship with disease activity and brain volume measurements. Frontiers in Neurology, 0, 14, .	2.4	3
1787	Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis. Journal of Neurology, 0, , .	3.6	0
1788	Reliability of brain atrophy measurements in multiple sclerosis using MRI: an assessment of six freely available software packages for cross-sectional analyses. Neuroradiology, 2023, 65, 1459-1472.	2.2	1
1789	A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis. Npj Digital Medicine, 2023, 6, .	10.9	5
1790	The thalamus and basal ganglia are smaller in children with epilepsy after perinatal stroke. Frontiers in Neurology, 0, 14, .	2.4	0
1791	Psychological factors and brain magnetic resonance imaging metrics associated with fatigue in persons with multiple sclerosis. Journal of the Neurological Sciences, 2023, 454, 120833.	0.6	1
1792	A Fully Automatic Method to Segment Choroid Plexuses in Multiple Sclerosis Using Conventional MRI Sequences. Journal of Magnetic Resonance Imaging, 0, , .	3.4	5
1793	Prevalence of 2-year "No evidence of disease activity―(NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study. Multiple Sclerosis and Related Disorders, 2023, 79, 105015.	2.0	0
1794	Relationships of Residential Distance to Major Traffic Roads with Dementia Incidence and Brain Structure Measures: Mediation Role of Air Pollution. Health Data Science, 2023, 3, .	2.3	0
1795	A Genetic Risk Variant for Multiple Sclerosis Severity is Associated with Brain Atrophy. Annals of Neurology, 2023, 94, 1080-1085.	5.3	0
1796	Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments. Journal of Magnetic Resonance Imaging, 0, , .	3.4	1
1797	Volumetric magnetic resonance imaging differences between complex febrile seizure and recurrent simple febrile seizure. Brain and Development, 2023, , .	1.1	0
1798	Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis. European Journal of Neurology, 2024, 31, .	3.3	2

#	Article	IF	CITATIONS
1800	Predictors of transition from relapsing‑remitting multiple sclerosis to secondary progressive. Medical Alphabet, 2023, , 40-44.	0.2	0
1801	Changes in Cortical Microstructure of the Human Brain Resulting from Long-Term Motor Learning. Journal of Neuroscience, 2023, 43, 8637-8648.	3.6	1
1802	NeuropsychBrainAge: A biomarker for conversion from mild cognitive impairment to Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
1803	Changes in brain perfusion with training-related visuomotor improvement in MS. Frontiers in Molecular Neuroscience, 0, 16, .	2.9	0
1804	Neurovascular coupling in early stage dementia – A case-control study. Journal of Cerebral Blood Flow and Metabolism, 0, , .	4.3	0
1805	Different types of screen time, physical activity, and incident dementia, Parkinson's disease, depression and multimorbidity status. International Journal of Behavioral Nutrition and Physical Activity, 2023, 20, .	4.6	0
1806	Brain volume increase after discontinuing natalizumab therapy: Evidence for reversible pseudoatrophy. Multiple Sclerosis and Related Disorders, 2024, 81, 105123.	2.0	0
1807	Phenotypes associated with genetic determinants of type I interferon regulation in the UK Biobank: a protocol. Wellcome Open Research, 0, 8, 550.	1.8	0
1808	The relationship of small vessel disease burden on cerebral and regional brain atrophy rates and cognitive performance over one year of follow-up after transient ischemic attack. Frontiers in Neurology, 0, 14, .	2.4	0
1809	Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes. Multiple Sclerosis Journal, 0, , .	3.0	0
1810	Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study. Journal of Neurology, Neurosurgery and Psychiatry, 0, , jnnp-2023-332573.	1.9	0
1811	Interactions of optic radiation lesions with retinal and brain atrophy in early multiple sclerosis. Annals of Clinical and Translational Neurology, 2024, 11, 45-56.	3.7	0
1812	Automatic estimation of brain parenchymal fraction in patients with multple sclerosis: a comparison between synthetic MRI and an established automated brain segmentation software based on FSL. Neuroradiology, 0, , .	2.2	0
1813	Validation of a semi-automated method to quantify lesion volume changes in multiple sclerosis on 2D proton-density-weighted scans based on image subtraction. NeuroImage Reports, 2024, 4, 100194.	1.0	0
1814	Structural and Functional Changes in Mild Cognitive Impairment in Parkinson's Disease. Medicina (Lithuania), 2024, 60, 33.	2.0	1
1815	Exploring Spoken Discourse and Its Neural Correlates in Women With Alzheimer's Disease With Low Levels of Education and Socioeconomic Status. American Journal of Speech-Language Pathology, 2024, 33, 893-911.	1.8	0
1816	Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2024, 11, 729-743.	3.7	0
1817	Longitudinal fibre-specific white matter damage predicts cognitive decline in multiple sclerosis. Brain Communications, 2023, 6, .	3.3	Ο

#	Article	IF	CITATIONS
1818	lsolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time. Journal of Neurology, 2024, 271, 2159-2168.	3.6	0
1819	Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study. Journal of Women's Health, 2024, 33, 480-490.	3.3	0
1820	Spatial correspondence among regional gene expressions and gray matter volume loss in multiple sclerosis. Molecular Psychiatry, 0, , .	7.9	0
1823	Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years. Multiple Sclerosis Journal, 2024, 30, 535-545.	3.0	0
1824	Effects of power training in older patients with multiple sclerosis on neurodegeneration, neuromuscular function, and physical function. A study protocol for the "power training in older multiple sclerosis patients (PoTOMS) randomized control trial. Contemporary Clinical Trials Communications, 2024, 38, 101279.	1.1	0
1826	Volumetric brain MRI signatures of heart failure with preserved ejection fraction in the setting of dementia. Magnetic Resonance Imaging, 2024, 109, 49-55.	1.8	0
1827	Evaluation of a self-administered iPad®-based processing speed assessment for people with multiple sclerosis in a clinical routine setting. Journal of Neurology, 0, , .	3.6	0
1828	Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis. CNS Drugs, 2024, 38, 267-279.	5.9	Ο